gemcitabine has been researched along with carboplatin in 879 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 21 (2.39) | 18.2507 |
| 2000's | 382 (43.46) | 29.6817 |
| 2010's | 404 (45.96) | 24.3611 |
| 2020's | 72 (8.19) | 2.80 |
| Authors | Studies |
|---|---|
| Allerheiligen, S; Carmichael, J; Walling, J | 1 |
| Brandt, A; Palmer, AJ | 1 |
| Natale, RB | 2 |
| Pedersen, AG | 1 |
| Devriendt, D; Klastersky, J | 1 |
| Ozols, RF | 2 |
| Athanassiades, A; Bacoyiannis, C; Briassoulis, E; Fountzilas, G; Kalogera-Fountzila, A; Kosmidis, P; Pavlidis, N; Samantas, E; Skarlos, D | 1 |
| Calvert, P; Langer, CJ; Ozols, RF | 1 |
| Daenen, M; Demedts, M; Nackaerts, K; Van Bleyenbergh, P; Vandevelde, A; Vansteenkiste, J | 1 |
| Caponigro, F; Costagliola, G; De Marino, V; Dimitri, P; Facchini, G; Ferrante, G; Ferraro, A; Gentile, M; Gravina, A; Iaffaioli, RV; Illiano, A; Marzano, N; Tortoriello, A | 1 |
| Burris, HA; Erland, JB; Greco, FA; Hainsworth, JD; Hon, JK; Kalman, LA; Meluch, AA; Morrissey, LH; Scullin, DC; Smith, SW | 1 |
| Calvert, P; Edelman, MJ; Gandara, DR; Langer, CJ; Ozols, RF | 1 |
| Bunn, PA | 2 |
| Chakravarthy, A; Choy, H; Johnson, D | 1 |
| Antoniou, F; Aspropotamitis, A; Athanassiou, A; Batzios, S; Halikia, A; Kalantaridou, A; Karvounis, N; Pectasides, D; Visvikis, A | 1 |
| Balaña, C; Martin, C; Rosell, R | 1 |
| Nervi, AM; Ornstein, DL; Rigas, JR | 1 |
| Einhorn, LH; Ng, EW; Robinson, L; Sandler, AB | 1 |
| Dimitriadis, K; Dimopoulos, A; Fountzilas, G; Kalophonos, C; Kosmidis, P; Mylonakis, N; Pavlidis, N; Samantas, E; Skarlos, D; Tsavdaridis, D | 1 |
| Burris, HA; Erland, JB; Greco, FA; Hainsworth, JD; Hon, JK; Kalman, LA; Morrissey, LH; Scullin, DC; Smith, SW | 1 |
| Goldwasser, F; Gross, M; Hiesse, C; Kriaa, F | 1 |
| Carles, J; Domènech, M; Guasch, I; Ibeas, R; Nogué, M; Pérez, C; Saigí, E; Villadiego, K | 1 |
| Cappuzzo, F; Green, MR; Rocha Lima, CM; Sherman, CA | 1 |
| Edelman, MJ; Gandara, DR; Lara, PN; Lau, DH | 1 |
| Burris, HA; Greco, FA; Hainsworth, JD | 1 |
| Kosmidis, P | 1 |
| Sandler, A | 1 |
| Bunn, PA; Kelly, K; Mikhaeel-Kamel, N; Murphy, J; Pan, Z; Prindiville, S | 1 |
| Barbieri, F; Bearz, A; Ceresoli, GL; Favaretto, A; Frustaci, S; Ghiotto, C; Oniga, F; Paccagnella, A; Schiavon, S; Villa, E | 1 |
| Bartus, RT; Dean, RL; Emerich, DF; Lafreniere, D; Marsh, J; Pink, M; Snodgrass, P | 1 |
| Hojo, K; Maekawa, R; Maki, H; Matsumoto, M; Nishitani, Y; Takeda, Y; Wada, T; Yoshioka, T | 1 |
| Bonomi, P; Shirazi, W | 1 |
| Belani, CP; Calvo, AR | 1 |
| Gajra, A; Graziano, SL; Kirshner, J; Mehdi, SA; Newman, N | 1 |
| Du, W; Hussain, M; Redman, B; Smith, DC; Vaishampayan, U | 1 |
| Malkowicz, SB; Vaughn, DJ | 1 |
| Edelman, MJ; Gandara, DR; Lara, P; Lau, DH; Lauder, IJ; Tracy, D | 1 |
| Hansen, SW | 2 |
| Bookman, MA | 4 |
| Murren, JR | 1 |
| Casado, V; Castillo, M; Dómine, M; Estévez, LG; León, A; Lobo, F; Martin, JI; Rubio, G | 1 |
| Barroso, A; Conde, S; Guimarães, T; Parente, B; Seada, J | 1 |
| Steele, JP | 1 |
| Carles, J; Nogué, M | 1 |
| Brooks, A; Crombie, C; Drummond, M; Gurney, H; Lau, H; Shannon, C | 1 |
| Rixe, O | 1 |
| Beryt, M; Felber, M; Hepp, H; Kahlert, S; Konecny, G; Langer, E; Lude, S; Pegram, M; Slamon, D; Untch, M | 1 |
| Edelman, MJ; Mullins, B; Quam, H | 1 |
| Coudray, AM; Faivre, S; Gespach, C; Louvet, C; Raymond, E | 1 |
| Blohmer, JU; du Bois, A; Kimmig, R; Lück, HJ; Moebus, V; Pfisterer, J; Quaas, J; Schroeder, W | 1 |
| Albanell, J; Baselga, J; Bellmunt, J; de Wit, R | 1 |
| du Bois, A | 1 |
| Boccieri, MG; Bruschi, G; Lo Re, G; Saracchini, S; Toffoli, G; Tumolo, S | 1 |
| Caffo, O | 1 |
| de Wit, R | 1 |
| Arcangeli, V; Drudi, G; Fochessati, F; Gianni, L; Mianulli, AM; Oliverio, G; Panzini, I; Pasini, G; Pasquini, E; Ravaioli, A; Sartori, S; Tassinari, D | 1 |
| Kindler, HL; van Meerbeeck, JP | 1 |
| Thigpen, T | 3 |
| Chen, YM; Lee, CS; Lee, YC; Perng, RP; Shih, JF; Tsai, CM; Whang-Peng, J | 1 |
| Gentile, A; Masotti, A; Morandini, G; Zannini, G | 1 |
| Stadler, WM | 1 |
| Hussain, M; Smith, DC; Vaishampayan, U | 1 |
| Misset, JL | 1 |
| Barton, JH; Bradof, JE; Burris, HA; Erland, JB; Greco, FA; Hainsworth, JD; Litchy, S; Morrissey, LH; Richards, P; Scullin, DC | 1 |
| Morere, JF | 1 |
| Hisada, T; Ito, T; Masuda, S; Mochida, A; Morinari, H; Nakahara, K; Nishi, K; Saito, K; Sasaki, S; Tahara, M; Yakumaru, K | 1 |
| Ferri-Dessens, RM; Gouva, S; Kleisbauer, JP; Léna, H; Robinet, G; Thomas, P; Vernejoux, JM | 1 |
| Bernardo, A; Bernardo, G; Brunetti, G; Cuzzoni, Q; Jedrychowska, I; Palumbo, R; Pozzi, U; Strada, MR | 1 |
| Cappuzzo, F; Crinò, L | 1 |
| Corlan, E; Draghici, IN; Grigorescu, AC; Gutulescu, N; Nitipir, C | 1 |
| Cortés-Funes, H | 1 |
| Gray, JR; Greco, FA; Hainsworth, JD; Hon, JK; Kalman, LA; Morrissey, LH | 1 |
| Culine, S | 1 |
| Sederholm, C | 1 |
| Takigawa, N | 1 |
| Watanabe, H | 1 |
| Okamoto, H; Watanabe, K | 1 |
| Caness, P; Pensa, F; Pronzato, P; Sinaccio, G; Tognoni, A; Vaira, F; Vigani, A | 1 |
| Cognetti, F; Felici, A; Gelibter, A; Nardoni, C; Serrone, L | 1 |
| Colantuoni, G; Gridelli, C; Maione, P; Rossi, A | 1 |
| Casado, E; De Castro, J; Feliu, J; González Barón, M; Ordoñez, A | 1 |
| Barton, JH; Burris, HA; Butts, JA; Erland, JB; Gray, JR; Greco, FA; Hainsworth, JD; Houston, GA; Litchy, S; Scott, C; Thompson, DS; Webb, C | 1 |
| Cox, K; Faul, MM; Keyes, K; Mann, L; Shih, C; Teicher, BA; Treadway, P | 1 |
| Joppert, MG; Rocha Lima, CM | 1 |
| Curran, MP; Plosker, GL | 1 |
| Duan, EY; Liu, AH; Wang, XS; Wu, YX; Zhou, Y | 1 |
| Adamo, V; Altavilla, G; Boni, C; Ceribelli, A; Clerici, M; Crinò, L; De Marinis, F; Di Costanzo, F; Failla, G; Frontini, L; Gridelli, C; Marangolo, M; Matano, E; Ricci, S; Rinaldi, M; Scagliotti, GV; Tonato, M | 1 |
| Petruzelka, L; Zatloukal, P | 1 |
| Edelman, MJ | 1 |
| Depierre, A; Jacoulet, P; Westeel, V | 1 |
| Gerinière, L; Souquet, PJ | 1 |
| Crinò, L | 1 |
| Arcangeli, V; Fochessati, F; Panzini, I; Ravaioli, A; Sartori, S; Tassinari, D | 1 |
| Smit, EF | 1 |
| Fournel, P | 1 |
| Aglione, S; Bajetta, E; Bidoli, P; Cortinovis, D; De Candis, D; Formisano, B; Mariani, L; Stani, SC; Zaffaroni, N; Zilembo, N | 1 |
| Senzer, N | 1 |
| Castro, M | 1 |
| Akman, Y; Alper, M; Cam, K; Kavak, A | 1 |
| Colowick, AB; Fleishman, A; Glaspy, JA; Jadeja, JS; Justice, G; Rossi, G | 1 |
| Butzbach, D; Cairdella, M; Capanna, T; DiPaola, RS; Dvorzhinski, D; Eid, J; Goodin, S; Rubin, E; Shih, JW; Todd, MB; Toppmeyer, D | 1 |
| Bunn, PA; Lilenbaum, R | 1 |
| Albrecht, P; Elmer, A; Kortsik, C | 1 |
| Colangelo, D; Mahboobi, H; Osella, D; Viarengo, A | 1 |
| Alonso, L; Arrivi, A; Carles, J; Font, A; Garrido, P; Juan, O; Mellado, B; Nogué-Aliguer, M; Sáenz, A | 1 |
| Arai, Y; Endo, M; Hagisawa, S; Hiramatu, M; Hoshi, S; Ohyama, C; Satoh, M; Watanabe, R | 1 |
| Goh, BC; Lee, HS; Lee, SC; Lehnert, M; Lim, HL; Millward, MJ; Soo, RA; Tok, LT; Wang, LZ | 1 |
| Aversa, SM; Bortolotti, L; Favaretto, AG; Loreggian, L; Manzini, Vde P; Monfardini, S; Oniga, F; Paccagnella, A; Palmisano, V; Rea, F; Stefani, M | 1 |
| Clowse, ME; Wigley, FM | 1 |
| Bepler, G; Boni, C; Cooc, J; Crinò, L; Danenberg, KD; De Marinis, F; Di Costanzo, F; Gozzelino, F; Lord, RV; Marangolo, M; Novello, S; Rinaldi, M; Rosell, R; Salonga, D; Sánchez, JJ; Scagliotti, G; Stephens, C; Taron, M; Tonato, M | 1 |
| Berghe, KV; Berkenblit, A; Cannistra, SA; Feyler, H; Kim, Y; Niloff, J; Tung, N | 1 |
| Flaherty, KT; Hahn, SM; O'Dwyer, PJ; Redlinger, M; Stevenson, JP | 1 |
| Battelli, T; Bonsignori, M; Buzzi, F; Catanzani, S; De Signoribus, G; Di Lullo, L; Lippe, P; Massacesi, C; Mattioli, R; Mazzanti, P; Morale, D; Pilone, A; Rocchi, MB; Rossi, G; Sturba, F; Trivisonne, R; Tuveri, G | 1 |
| Anderson, H; Ashcroft, L; Beresford, C; Burt, PA; Clemons, M; Danson, S; Dowd, I; Fairve-Finn, C; Hassan, J; Middleton, MR; O'Byrne, KJ; Ranson, M; Stout, R; Thatcher, N | 1 |
| Harper, P | 1 |
| Bookman, M; Copeland, LJ; Trimble, E | 1 |
| Mutch, DG | 1 |
| Fojtů, H; Grygárková, I; Havel, L; Horenková, E; Kolek, V; Kůta, M; Nováková, L; Pesek, M; Petruzelka, L; Průsa, P; Roubec, J; Sixtová, D; Skácel, T; Skricková, J; Zatloukal, P; Zemanová, M | 1 |
| Hanibuchi, M; Hirano, H; Ito, M; Maeda, H; Nakagawa, M; Okumura, Y; Sawabata, Y; Takeda, S; Uematsu, K | 1 |
| Dowlati, A; Levitan, N | 1 |
| Boni, C; Zanelli, F | 1 |
| Berkowitz, R; Campos, S; Colella, T; Duska, L; Fuller, A; Gore, S; Lee, H; Matulonis, U; Roche, M; Seiden, MV | 1 |
| Bremer, M; Dörk, T; Gross, M; Karstens, JH; Morlot, S; Schindler, D | 1 |
| Degen, JW; Lonser, RR; Oldfield, EH; Vortmeyer, AO; Walbridge, S | 1 |
| Albert, A; Bosch, C; Camps, C; Giner, V; Gómez, J; Gómez-Aldaraví, L; Llorca, C; Maestu, I; Oltra, A; Torregrosa, MD | 1 |
| Cable, CT; Mott, FE; Sharma, N | 1 |
| Bookman, MA; Herzog, TJ; Look, KY; Rocereto, T; Schol, J; Vinters, J | 1 |
| Aravantinos, G; Briassoulis, E; Dimopoulos, MA; Fountzilas, G; Gika, D; Kalofonos, C; Moulopoulos, LA; Papadimitriou, CA | 1 |
| Brown, J; Martin, MC; Ramondetta, LM; Smith, JA; Wolf, JK | 1 |
| Li, M; Rinehart, JJ; Wang, H; Zhang, R | 2 |
| Perez, EA | 1 |
| Belani, CP; Ramalingam, S | 2 |
| Pfisterer, J | 1 |
| Blohmer, J; Kaubitzsch, S; Lichtenegger, W; Oskay, G; Sehouli, J; Stengel, D | 1 |
| Barlow, C; Fennell, D; Gallagher, C; Ismay, J; Nystrom, M; Oesterling, C | 1 |
| Arai, Y; Hoshi, S; Itoh, A; Ohyama, C; Okada, Y; Ono, K; Saito, S; Satoh, M; Sohma, F; Takeda, A; Yamashita, S; Yamato, T | 1 |
| Beryt, M; Konecny, GE; O'Callaghan, C; Pegram, MD; Pietras, R; Slamon, DJ | 1 |
| Le Cesne, A; Le Guen, Y | 1 |
| Arai, Y; Habuchi, T; Horikawa, Y; Hoshi, S; Inoue, T; Kato, T; Matsuura, S; Ohyama, C; Saito, S; Sato, K; Satoh, S; Togashi, H; Tsuchiya, N | 1 |
| Bold, RJ; Mortenson, MM; Schlieman, MG; Virudachalam, S | 1 |
| A'Hern, R; Cole, C; Everard, M; Gibbens, I; Gore, M; Hall, G; Harries, M; Jenkins, A; Kaye, S; Moss, C; Perren, T; Pizzada, O; Shah, R | 1 |
| Helke, C; Hoschke, B; May, M; Seehafer, M | 1 |
| Chahine, GY; Dagher, JE; Farhat, FS; Ghosn, MG; Kattan, JG; Mokaddem, WT; Nasr, FL; Tueni, EA | 1 |
| Argiris, A; Kies, MS; LaCombe, M; Liptay, M; Marymont, M; Masters, G; Sundaresan, S | 1 |
| Bachem, MG; Berberat, P; Büchler, MW; di Mola, FF; Esposito, I; Friess, H; Giese, NA; Giese, T; Köninger, J | 1 |
| Dafni, U; Dimopoulos, MA; Dimopoulou, I; Efstathiou, E; Kastritis, E; Lyberopoulos, P; Moulopoulos, LA; Papadimitriou, C; Roussos, C; Samakovli, A | 1 |
| Ho, ES; Hung, MJ; Hwang, SF; Ke, YM; Liu, FS; Lu, CH | 1 |
| Albain, K; Bhoopalam, N; Chansky, K; Clark, JI; Crowley, J; Edelman, MJ; Gandara, DR; Giguere, JK; Kelly, K; Weiss, GR | 1 |
| Birk, CL; Brown, JV; Goldstein, BH; Graham, C; Mattison, J; Micha, JP; Rettenmaier, MA | 1 |
| Anagnostopoulos, A; Aravantinos, G; Athanasios Dimopoulos, M; Bafaloukos, D; Bamias, A; Deliveliotis, C; Efstathiou, E; Kalofonos, C; Linardou, H | 1 |
| deVere White, RW; Ellison, LM; Gandour-Edwards, R; Goldberg, Z; Karpman, E; Saffarian, A | 1 |
| Hermant, P; Jouveshomme, S; Patte, D | 1 |
| Asmar, L; Heaven, R; Ilegbodu, D; Neubauer, M; Olivares, J; Otsuka, A; Paschold, E; Sirridge, C; Tuttle, T | 1 |
| Reddy, KG | 1 |
| Burris, HA; Erland, JB; Greco, FA; Hainsworth, JD; Hermann, R; Litchy, S; Morrissey, LH; Rodriguez, GI; Shaffer, DW; Yardley, DA | 1 |
| Herzog, TJ | 1 |
| Driscoll, DL; Lele, S; Marchetti, D; Odunsi, K; Rodabaugh, K; Villella, J | 1 |
| Bader, K; Brown, JV; Goldstein, BH; Graham, C; Markman, M; Mattison, JA; Micha, JP; Rettenmaier, MA | 1 |
| Chen, CS; Chidiac, T; Lane, SR; Lilenbaum, RC; Schwarzenberger, PO; Thant, M; Versola, M | 1 |
| Chen, YT; Hong, GB; Jiang, RJ; Luo, JH; Xu, LF; Xu, LY; Zhou, JX | 1 |
| Arceci, RJ; Loeb, DM; Mack, AK; Small, D; Spevak, M; Strouse, JJ | 1 |
| Aristides, M; Brown, A; Crino, L; Danson, S; Fitzgerald, P; Gridelli, C; Le Chevalier, T; Manegold, C; Natale, R; Pujol, JL; Rosell, R; Rudd, RM; Scagliotti, G; Schiller, JH; Stahel, R; Thatcher, N; Thomas, P; van Meerbeeck, JP; van Zandwijk, N; Vansteenkiste, J | 1 |
| Foo, KF; Leong, SS; Lim, WT; Tan, EH; Tan, SB; Tan, T; Tay, MH; Thng, CH; Toh, CK; Wee, J | 1 |
| Eisen, TG; Gower, NH; Gregory, WM; Harper, PG; Hatton, M; James, LE; Johnson, PW; Lee, SM; Littler, JA; Martin, WM; Qian, W; Rankin, EM; Rudd, RM; Spiro, SG | 1 |
| Beslija, S; Fitzthum, E; Hayden, A; Kose, MF; Krejcy, K; Melemed, A; Minarik, T; Saip, P; Sufliarsky, J; Tulunay, G | 1 |
| Belau, A; Burges, A; du Bois, A; Elser, G; Jackisch, C; Lueck, HJ; Olbricht, S; Pfisterer, J; Richter, B; Schmalfeldt, B; Schroeder, W; Staehle, A; Wagner, U | 1 |
| Bamias, A; Bozas, G; Dimopoulos, MA; Efstathiou, E; Gika, D; Hamilos, G; Kakoyiannis, C; Kastritis, E; Moulopoulos, LA; Papadimitriou, C; Zorzou, MP | 1 |
| Li, HC; Russell, CA | 1 |
| Konecny, GE; Pegram, MD | 1 |
| Belani, CP; Eckardt, J | 1 |
| Cantore, M; Caudana, R; Ceravolo, C; Comella, G; Del Freo, A; Fiorentini, G; Luppi, G; Mambrini, A; Marangolo, M; Miserocchi, L; Piazza, E; Rabbi, C; Rosati, G; Zamagni, D | 1 |
| Dumontet, C; Sève, P | 1 |
| Funazaki, T; Nagasaki, N; Naitoh, N; Shiba, M; Watanabe, S | 1 |
| Bafaloukos, D; Bamias, A; Economopoulos, T; Efstathiou, E; Gogas, H; Kalofonos, H; Kastritis, E; Kosmidis, P; Onyenadum, A; Papacostas, P; Samantas, E; Samelis, G; Skarlos, D; Xiros, N | 1 |
| Felip, E; Maestre, J; Majo, J; Mendez, P; Queralt, C; Ronco, MS; Rosell, R; Sanchez, JJ; Sanchez, JM; Taron, M | 1 |
| Bearden, JD; Greco, FA; Hainsworth, JD; Litchy, S; Meluch, AA; Schnell, FM; Yost, K | 1 |
| Crinò, L; De Marinis, F; Foggi, P; Kielhorn, A; Maestri, A; Migliorino, AM; Novello, S; Rinaldi, M; Scagliotti, GV; Selvaggi, G; Stynes, G; Tilden, D; Tonato, M | 1 |
| Chen, YM; Perng, RP; Shih, JF; Tsai, CM; Whang-Peng, J | 1 |
| Lopes, G; Rocha Lima, CM | 1 |
| Antonia, S; Bepler, G; Chiappori, A; Haura, E; Rocha-Lima, C; Simon, G; Wagner, H; Williams, C | 1 |
| Abratt, R; Bertetto, O; Burillon, JP; Gatzemeier, U; Hui, R; Krzakowski, M; Macha, HN; Mattson, K; Parlier, Y; Pawel, JV; Pouget, JC; Reiterer, P; Szczesna, A; Tan, EH; Wernli, M | 1 |
| Esteban-Gonzalez, E; Fernández, Y; Fra, J; Lacave, AJ; Mareque, B; Muñiz, I; Palacio, I; Uña, E; Vieitez, JM; Villanueva, N | 1 |
| Arnaud, I; Blandin, S; Geriniere, L; Guibert, B; Mulsant, P; Perrot, E; Roy, P; Souquet, PJ | 1 |
| Bedor, M; Bisaccia, S; Doyle, LA; Edelman, MJ; Hausner, P; Kalra, K; Kendall, J; Smith, R | 1 |
| Berghmans, T; Sculier, JP | 1 |
| Brom, R; Candelaria, M; Cantu, D; Cetina, L; Chanona, J; de la Garza, J; Dolores, R; Duenas-Gonzalez, A; Gonzalez, A; Lopez-Graniel, C; Uribe, J | 1 |
| Duska, L; He, X; Klein, A; Mallett, A; Roche, M; Seiden, MV; Supko, JG | 1 |
| Brown, ER; Shepherd, FA | 1 |
| An, CH; Bang, SM; Cho, EK; Jeong, SH; Kyung, SY; Lee, JH; Lee, SP; Lim, YH; Park, JW; Park, SH; Shin, DB | 1 |
| De Petris, L; Friesland, S; Lax, I; Sirzén, F | 1 |
| Govindan, R | 1 |
| Grénman, SE; Jalkanen, JT; Kuoppala, TA; Leminen, AO; Mäenpää, JU; Puistola, US; Vuolo-Merilä, PM; Yliskoski, MH | 1 |
| Leow, CH; Liam, CK | 1 |
| Bordonaro, R; Castorina, S; Giannitto, GC; Giuffrida, D; La Venia, G; Marletta, F; Pappalardo, A; Potenza, E; Russo, A; Saita, S; Vincenzi, B | 1 |
| Cullen, M | 1 |
| Dufmats, M; Gawande, SR; Hillerdal, G; Kölbeck, K; Lamberg, K; Sederholm, C; Westberg, R | 1 |
| Blumenschein, G; Fossella, FV; Herbst, RS; Needle, M; Robert, F; Saleh, MN; Tseng, J | 1 |
| Berard, H; Bombaron, P; Fournel, P; Gouva, S; Kleisbauer, JP; Le Caer, H; Léna, H; Perol, M; Robinet, G; Thomas, P; Vergnenegre, A | 1 |
| Bavieri, M; Bigiani, N; Brambilla, E; Casali, C; Cavazza, A; Fabbri, LM; Facciolongo, N; Longo, L; Maiorana, A; Marchioni, A; Migaldi, M; Morandi, U; Rossi, G; Sartori, G; Schirosi, L | 1 |
| Addeo, A; Barone, C; Berruti, A; Bertetto, O; Buffoni, L; Dongiovanni, D; Dongiovanni, V; Fissore, C; Grillo, R | 1 |
| Aravantinos, G; Bamias, A; Dimopoulos, MA; Fountzilas, G; Gika, D; Kalofonos, HP; Kastritis, E; Koutras, A; Linardou, H; Moulopoulos, LA; Pectasides, D; Skarlos, D | 1 |
| Bloss, LP; Curiel, RE; Monberg, MJ; Obasaju, CK; Ye, Z | 1 |
| Alvero, AB; Brown, D; Chen, W; Garg, M; Kelly, G; Mor, G; O'Malley, D; Rutherford, T | 1 |
| Atkinson, R; Coleman, R; Kaye, S; Lewsley, L; Osborne, R; Parkin, D; Paul, J; Reed, NS; Rustin, GJ; Symonds, R; Vasey, PA | 1 |
| Amaya, H; Aotake, T; Hirai, S; Ihaya, A; Ikeda, T; Kawabe, M; Sasaki, H; Sasaki, M; Tanaka, K; Uchinami, M; Yoshida, M | 1 |
| Rudd, R; Saha, A | 1 |
| Barbieri, F; Bearz, A; Belloni, P; Biason, R; Ceresoli, G; Chella, A; Clerici, M; Favaretto, A; Ghi, MG; Nicoletto, MO; Oniga, F; Paccagnella, A; Riccardi, A; Ridolfi, R; Tirelli, U; Tumolo, S; Veglia, F | 1 |
| Barlesi, F; Daurès, JP; Pujol, JL | 1 |
| Julka, PK; Puri, T; Rath, GK | 1 |
| Aghajanian, C; Chi, DS; Correa, DD; Dupont, J; Hensley, ML; Sabbatini, P; Spriggs, D; Thaler, H; Venkatraman, E; Wilton, A | 1 |
| Kose, MF; Meydanli, MM; Tulunay, G | 1 |
| Bitran, JD; Edelman, MJ; Irwin, D; John, WJ; Lilenbaum, R; Makalinao, A; Peterson, P; Ritch, P; Rudin, CM | 1 |
| Alexandre, J; Chapron, C; Chopin, N; Goldwasser, F; Moachon, L | 1 |
| Belani, CP | 1 |
| Bao, HY; Chen, J; Fang, WJ; Huang, S; Mou, HB; Shen, P; Shi, GM; Xu, N; Yu, LF; Zhang, XC | 1 |
| Fukuchi, Y; Ito, J; Kajiyama, Y; Miura, K; Miyamoto, H; Nagashima, O; Sato, K; Shimanuki, Y; Suzuki, T; Tajima, K; Takahashi, K; Uekusa, T | 1 |
| Cantore, M; Capelli, P; Fiorentini, G; Iacono, C; Lombardi, M; Mambrini, A; Pacetti, P; Pagani, M; Pederzoli, P; Pulica, C; Serio, G; Torri, T | 1 |
| Cheong, KA; Chrystal, K; Galani, E; Gallagher, C; Harper, PG; Lofts, F; Marx, GM; Steer, CB; Strickland, AH; Thomas, H; Yip, D | 1 |
| Bhalla, S; Guerreiro, M; Laranjeira, L; Pimentel, FL | 1 |
| Beale, P; Boyer, M; Goh, BC; Lee, HS; Lee, SC; Liang, S; Lim, HL; Millward, M; Soo, RA; Tham, LS; Wang, LZ; Yong, WP | 1 |
| Ash, R; Passaperuma, K; Rodrigues, G; Venkatesan, V; Winquist, E | 1 |
| Ledermann, JA; Pfisterer, J | 1 |
| Economopoulos, T; Pectasides, D; Pectasides, M; Psyrri, A | 1 |
| Aitini, E; Cantore, M; Caudana, R; Ceravolo, C; Comella, G; Del Freo, A; Fiorentini, G; Luppi, G; Mambrini, A; Marangolo, M; Miserocchi, L; Piazza, E; Rosati, G; Zamagni, D | 1 |
| Doi, M; Fukuhara, K; Kuwabara, M; Maeda, H; Miyamoto, S; Sumiyoshi, H; Yamasaki, M | 1 |
| Aisner, J; Guensch, L; Joyce, M; Lutzker, S; Schwartz, S; Sovak, MA; Wu, Y; Zheng, L | 1 |
| Fukuoka, M; Kashii, T; Kato, T; Matsui, K; Nakagawa, K; Nakanishi, Y; Negoro, S; Sugiura, T; Takada, M; Takada, Y; Uejima, H; Yamamoto, N | 1 |
| Campos, S; Duska, LR; Falke, R; Krasner, CN; Lee, H; Matulonis, UA; Penson, RT; Roche, M; Seiden, MV; Smith, LM | 1 |
| Albiol, S; Bellmunt, J; de Olano, AR; Maroto, P; Pujadas, J | 1 |
| Akel, A; Bachmann, C; Dreischer, P; Eisele, K; Gulbins, E; Huober, J; Kempe, DS; Klarl, BA; Lang, F; Lang, PA; Niemoeller, OM; Sobiesiak, M; Wieder, T | 1 |
| Mountzios, G; Soria, JC | 1 |
| Huang, HB; Lin, PL; Lin, ZC; Liu, T; Zhong, JT | 1 |
| Bepler, G; Cantor, A; Gautam, A; Kusmartseva, I; Sharma, A; Sharma, S; Simon, G | 1 |
| Bentley, J; du Bois, A; Eisenhauer, E; Emerich, J; Hirte, H; Jackisch, C; Kimmig, R; Kuhn, W; Lacave, AJ; Le, T; Lück, HJ; Olbricht, S; Pfisterer, J; Plante, M; Rochon, J; Stähle, A; Stuart, G; Vergote, I; Wagner, U; Zimmermann, AH | 1 |
| Griep, C; Lelie, B; Pinson, PJ; Sanders, WH | 1 |
| Lehoczky, O; Pulay, T | 1 |
| Aoki, H; Arai, Y; Endoh, M; Ishidoya, S; Ito, A; Shimazui, T | 1 |
| Fangusaro, J; Finlay, J; Rook, J; Rosser, T | 1 |
| Helke, C; Hoschke, B; May, M | 1 |
| Blankenburg, T; Chemaissani, A; Guetz, S; Laier-Groeneveld, G; Reck, M; Schneider, CP; Schuette, W; Virchow, JC; von Weikersthal, LF | 1 |
| Ariyoshi, Y; Fukuoka, M; Kubota, K; Nakagawa, K; Negoro, S; Nishiwaki, Y; Ohashi, Y; Ohe, Y; Saijo, N; Tamura, T | 1 |
| Ilanchadran, A; Tan, TY; Tay, SK | 1 |
| Boswell, JS; Flam, MS; Tashjian, DN; Tschang, TP | 1 |
| Karapetis, CS; Keefe, DM; Koczwara, B; Kotasek, D; Moldovan, S; Olver, IN; Parnis, FX; Patterson, WK; Pittman, KB; Price, TJ; Yeend, SJ | 1 |
| Aleknavicius, E; Asadauskiene, J; Jankevicius, F; Zelviene, TP | 1 |
| Aitini, E; Bajetta, E; Bidoli, P; Cortinovis, D; Cullurà, D; Formisano, B; Isa, L; Mancin, M; Mariani, L; Nova, P; Pari, F; Zilembo, N | 1 |
| Cai, J; Huang, M; Liu, J; Wang, L; Wu, X; Xu, N | 1 |
| Becht, C; Culine, S; de Champfleur, NM; Pouessel, D; Vieillot, S | 1 |
| Hoshi, S; Kobayashi, T; Muto, A; Ono, K; Sasaki, M; Saso, S; Sugano, O; Suzuki, K; Tukigi, M | 1 |
| Bajorin, DF; Boyle, MG; Galsky, MD; Iasonos, A; Mironov, S; Scattergood, J | 1 |
| Amadori, D; Bertetto, O; Bono, A; Cartenì, G; Dogliotti, L; Marini, L; Martoni, A; Onat, H; Siena, S | 1 |
| Imamura, F; Uchida, J; Ueno, K; Yoshimura, M | 1 |
| Buettner, H; Kaur, H; Marks, RS; Salomao, DR | 1 |
| d'Amato, TA; Huang, W; Landreneau, RJ; Luketich, JD; Mechetner, E; Parker, R; Ricketts, W; Yu, IR | 1 |
| Johnson, DH; Langer, C; Li, S; Rapoport, BL; Schiller, J; Tester, W | 1 |
| Banerjee, S; Chiritescu, G; Dahrouge, S; Stewart, DJ; Tomiak, EM | 1 |
| Araya, T; Fujimura, M; Kasahara, K; Nakao, S; Sone, T; Tambo, Y; Tamori, S | 1 |
| Antonia, S; Chiappori, A; de Lima Lopes, G; Haura, E; Langevin, M; Lush, R; Rocha-Lima, CM; Simon, G; Sullivan, D | 1 |
| De Grève, J; De Mey, J; Fontaine, C; Meysman, M; Neyns, B; Schallier, D; Steene, JV | 1 |
| Altug, S; Chu, DT; Damyanov, D; Kim, SW; Krishnamurthy, S; Kuo, HP; Ozacar, R; Reece, WH; Salajka, F; Wang, L | 1 |
| Brown, JV; Goldstein, BH; Graham, C; Hu, JC; Markman, M; Micha, JP; Rettenmaier, MA | 1 |
| Bortolotti, L; Breda, C; Favaretto, AG; Loreggian, L; Marulli, G; Rea, F; Sartori, F | 1 |
| Mandrekar, SJ; Sargent, DJ | 1 |
| Argiris, AE; Beck, JT; Bloss, LP; Curiel, RE; Hahn, EA; Masters, GA; Monberg, MJ; Obasaju, CK; Rausch, PG; Ye, Z | 1 |
| Abratt, RP; Boyer, M; Brnabic, AJ; Han, JY; Kim, SW; Lee, JS; Lehnert, M; Mok, T; Reece, WH; Tsai, CM | 1 |
| Erridge, S; Jackson, S; Law, A; Rae, P | 1 |
| Aerts, JG; Hoogsteden, HC; Senan, S; Surmont, V; Tan, KY; van Klaveren, RJ; van Meerbeeck, JP; van Wijhe, G; Verhoeven, GT; Vernhout, R | 1 |
| Dowlati, A; Johnson, D; Langer, C; Li, S; Madajewicz, S; Masters, GA; Schiller, J | 1 |
| Aravantinos, G; Bacoyiannis, C; Bafaloukos, D; Boukovinas, I; Dimopoulos, MA; Fountzilas, G; Kalofonos, HP; Kosmidis, PA; Nicolaides, C; Pectasides, D; Syrigos, K | 1 |
| Arakelyan, N; Banu, A; Banu, E; Culine, S; Duclos, B; Escudier, B; Fournier, L; Medioni, J; Oudard, S; Priou, F; Rolland, F; Vieillefond, A | 1 |
| Ariganello, O; Belli, R; Cipri, A; Condò, S; de Marinis, F; De Santis, S; Di Molfetta, M; Migliorino, MR; Tedesco, B; Treggiari, S | 1 |
| Bartolini, S; Cancellieri, A; Cappuzzo, F; Crino, L; Finocchiaro, G; Hirsch, FR; Ligorio, C; Magrini, E; Paioli, D; Rossi, E; Toschi, L; Trisolini, R; Varella-Garcia, M | 1 |
| Vaughn, DJ | 1 |
| Chatta, GS; Chen, H; Dunn, RL; Glode, LM; Hussain, MH; Lara, PN; MacVicar, GR; Nanus, DM; Petrylak, DP; Smith, DC; Trump, DL; Vaishampayan, U | 1 |
| Huang, MZ; Wang, LR; Wu, XH; Xu, N; Zhang, GB | 1 |
| Fang, WJ; Qian, J; Xiong, JP; Xu, N; Yu, LF; Zhang, L; Zhang, XC | 1 |
| Hariharan, S; Welsh, CH | 1 |
| Branscheid, D; Droemann, D; Goldmann, T; Lang, DS; Martin, C; Ressmeyer, AR; Schultz, H; Vollmer, E; Zabel, P | 1 |
| El-Rayes, B; Griffith, KA; Kalemkerian, GP; Muler, JH; Philip, PA; Schneider, BJ; Zalupski, MM | 1 |
| Aasebø, U; Bailey, A; Bremnes, RM; Brunsvig, PF; Garpestad, OK; Helbekkmo, N; Hjelde, HH; Sundstrøm, SH; von Plessen, C | 1 |
| Jones, DV; Klementich, FJ; Ravindranathan, M | 1 |
| Iwata, H; Yamashita, T | 1 |
| Inui, K; Ito, N; Jiko, M; Kamoto, T; Masuda, S; Motohashi, H; Nakamura, E; Ogawa, O; Okuda, M; Sato, E; Segawa, T; Takahashi, K; Yano, I | 1 |
| Huang, MZ; Wang, LR; Zhang, GB | 1 |
| Besse, B; Vignot, S | 1 |
| Seto, T | 1 |
| Havrilesky, LJ; Kulasingam, S; Myers, E; Secord, AA | 1 |
| Faerber, GJ; Weizer, AZ; Wolf, JS | 1 |
| Ayoub, JP; Charpentier, D; Del Vecchio, P; Duclos, M; Faria, S; Gruber, J; Hirsh, V; Ofiara, L; Portelance, L; Souhami, L; Soulieres, D | 1 |
| Guan, ZZ; Huang, PY; Peng, PJ; Xu, F; Zhang, L; Zhang, Y | 1 |
| Aravantinos, G; Economopoulos, T; Gaglia, A; Gouveris, P; Koumarianou, A; Papaxoinis, G; Pectasides, D; Pectasides, E; Psyrri, A; Sykiotis, C; Xiros, N | 1 |
| Dudek, AZ; Keshtgarpour, M; Kumar, P; Larson, T | 1 |
| Aoki, H; Iijima, H; Imai, H; Inoue, T; Ishida, E; Ishihara, S; Iwasaki, Y; Kawashima, O; Kobayashi, G; Mori, M; Saito, R; Sato, K; Tomizawa, Y; Watanabe, S; Yamada, H; Yatomi, M | 1 |
| Burris, HA; Gandhi, JG; Gray, JR; Greco, FA; Hainsworth, JD; Kuzur, ME; Pati, A; Shipley, D; Spigel, DR; Thompson, DS; Webb, CD; Yardley, DA | 1 |
| Bafaloukos, D; Bakogiannis, C; Bamias, A; Boukovinas, I; Christodoulou, C; Dimopoulos, MA; Fountzilas, G; Kalofonos, HP; Kosmidis, PA; Makatsoris, T; Nicolaides, C; Samantas, E; Skarlos, D; Syrigos, K; Xiros, N | 1 |
| Aldaz, A; Aramendía, JM; Aristu, J; Centeno, C; Hernández, M; Moreno, M; Nieto, Y; Pérez-Calvo, J; Rifón, J; Sayar, O; Viteri, S; Viúdez, A; Zafra, A; Zufia, L | 1 |
| El Karak, F; Flechon, A | 1 |
| Blackhall, F; Califano, R; Nagel, S; Thatcher, N | 1 |
| Fujiwara, S; Ino, K; Kajiyama, H; Kato, S; Kikkawa, F; Nakamura, S; Nawa, A; Shibata, K; Suzuki, K | 1 |
| Detterbeck, FC; Edelman, MJ; Govindan, R; Gralla, RJ; Jahan, TM; Limentani, SA; Loesch, DM; Monberg, MJ; Obasaju, CK; Socinski, MA; Ye, Z; Zaman, MB | 1 |
| Bold, R; Davies, AM; Gandara, DR; Gumerlock, PH; Lara, PN; Lau, DH; Lenz, HJ; Ruel, C; Schenkein, DP; Shibata, S | 1 |
| Rödel, C; Sauer, R; Weiss, C | 1 |
| Davies, AM; Gandara, DR; Sangha, R | 1 |
| Hagisawa, S; Hatakeyama, S; Imai, A; Ishimura, D; Iwabuchi, I; Koie, T; Mori, K; Ohyama, C; Okamoto, A; Yamato, T; Yoneyama, T | 1 |
| Bedor, M; Brahmer, J; Bridges, BB; Doyle, LA; Edelman, MJ; Hausner, PF; Smith, R; Thomas, L | 1 |
| Charpidou, A; Dilana, K; Karapanagiotou, EM; Kosmas, E; Kotteas, E; Provata, A; Syrigos, K; Tourkantonis, I; Tzannou, I | 1 |
| Huang, F; Liang, ZY; Xiong, ZP; Zhang, YD | 1 |
| Drömann, D; Goldmann, T; Lang, DS; Marwitz, S; Radtke, J; Schultz, H; Vollmer, E | 1 |
| Bedor, M; Edelman, MJ; Gajra, A; Green, MJ; Hodgson, L; Jewell, S; Kratzke, RA; Masters, GA; Mauer, AM; Morrison, C; Vokes, EE; Wang, X; Watson, D | 1 |
| Goh, BC; Holford, NH; Lee, HS; Lee, SC; Soo, RA; Tham, LS; Wang, LZ | 1 |
| Kameda, A; Minami, K; Miyahara, E; Noso, Y; Suzuki, T; Tsutani, Y | 1 |
| Chereddy, S; Dudek, AZ; Maddaus, M; Nguyen, S; Wagner, JE | 1 |
| De Grève, J; De Mey, J; Decoster, L; Everaert, H; Meysman, M; Neyns, B; Nieboer, K; Schallier, D | 1 |
| Aasebø, U; Bremnes, RM; Brunsvig, PF; Helbekkmo, N; Sundstrøm, SH; von Plessen, C | 1 |
| Alexandrova, EN; Istomin, YP; Petrovich, SV; Sergeyeva, OP; Zhavrid, EA | 1 |
| Choi, SH; Han, SS; Kang, SB; Kim, JW; Lee, HP; Lee, YK; Park, NH; Song, YS | 1 |
| Gillani, JA; Iqbal, M; Khan, A; Nasreen, S; Samad, A | 1 |
| Aydiner, A; Derin, D; Guney, N; Tas, F; Topuz, E | 1 |
| Alivizatos, G; Antoniou, N; Bamias, A; Chrisofos, M; Dimopoulos, MA; Karayiotis, E; Kastritis, E; Koureas, A; Lainakis, G; Skolarikos, A | 1 |
| Aravantinos, G; Bafaloukos, D; Briasoulis, E; Christodoulou, C; Dafni, U; Dimopoulos, MA; Fountzilas, G; Gogas, H; Kalofonos, HP; Kalogera-Fountzila, A; Karina, M; Kosmidis, P; Koutras, A; Maniadakis, N; Matsiakou, F; Papadimitriou, C; Papakostas, P; Pectasides, D; Samantas, E; Skarlos, D | 1 |
| Blackstock, AW; Bogart, JA; Green, M; Gu, L; Masters, GA; Miller, AA; Munley, M; Rosenman, J; Sleeper, A; Socinski, MA; Ungaro, P; Vokes, EE; Wang, X | 1 |
| Benekli, M; Buyukberber, S; Coskun, U; Dikilitas, M; Kaya, AO; Ozkan, S; Ozturk, B; Uner, A; Yamac, D; Yaman, E; Yildiz, R | 1 |
| Hasegawa, Y; Hida, T; Horio, Y; Osada, H; Sekido, Y; Shimizu, J; Shimokata, K; Takahashi, T; Yatabe, Y | 1 |
| Cloud, G; Davidson, S; deShazo, M; Kuo, KL; Leggas, M; Li, M; Rinehart, J; Robert, F; Wang, H; Zhang, R | 1 |
| Deray, G; Isnard-Bagnis, C; Janus, N; Karie, S; Launay-Vacher, V | 1 |
| Fasching, PA; Heinemann, V; Kalischefski, B; Kolbl, H; Laessig, D; Maubach, P; Meerpohl, H; Melchert, F; Morack, G; Scharl, A; Stauch, M; Stemmler, HJ; Vehling-Kaiser, U; Weber, B | 1 |
| Goh, BC; Holford, NH; Lee, HS; Lee, SC; Soo, RA; Tham, LS; Wang, L; Yong, WP | 1 |
| Hee, SW; Leong, SS; Lim, WT; Poon, D; Rajan, S; Tan, EH; Tay, MH; Toh, CK; Wee, J | 1 |
| Asmar, L; Boehm, KA; Doane, L; Loesch, D; McIntyre, K; Monticelli, M; O'Shaughnessy, JA; Orlando, M; Paul, D; Vaughn, LG; Vukelja, S; Zhan, F | 1 |
| Kamiyama, Y; Kodama, T; Kondoh, T; Mori, K | 1 |
| Furuiye, M; Inase, N; Ishiwata, N; Jin, Y; Miyake, S; Miyashita, Y; Takano, S; Yoshizawa, M; Yoshizawa, Y | 1 |
| Cheng, T | 1 |
| Andriani, F; Bajetta, E; Bidoli, P; Cortinovis, DL; Fabbri, A; Livio, A; Marcomini, B; Mariani, L; Perrone, F; Pilotti, S; Roz, L; Sozzi, G | 1 |
| Hokkoku, K; Kiba, T; Mizuno, T; Mori, M; Nakagawa, T; Nakai, M; Oikawa, M; Sakuma, H; Shintaku, K; Ueda, H; Watanabe, Y; Yoshimitsu, Y | 1 |
| Choi, H; Choi, JH; Han, JH; Hwang, SC; Jeong, SH; Jung, YM; Kang, SY; Kim, JH; Lee, HW; Lim, HY; Oh, YJ; Oh, YT; Park, KJ; Sheen, SS | 1 |
| Eisen, T; Ferry, DR; Gilligan, D; Gower, NH; Harper, PG; Hocking, M; James, LE; Lee, SM; Prendiville, J; Qian, W; Rudd, RM; Spiro, S | 1 |
| Azim, H; Azim, HA; Elattar, I; Ganti, AK; Loberiza, FR; Mok, T | 1 |
| Backes, FJ; Cohn, DE; Copeland, LJ; Fowler, JM; O'Malley, DM; Richardson, DL; Seamon, LG; Zanagnolo, V | 1 |
| Dafni, U; Fountzilas, G; Fragkoulidi, A; Fragoulakis, V; Galani, E; Grimani, I; Maniadakis, N | 1 |
| Becker, M; Fichtner, I; Hammer, S; Hoffmann, J; Merk, J; Rolff, J; Sommer, A; Soong, R | 1 |
| Beekman, K; Dunn, RL; Hussain, M; Lee, CT; Mackler, NJ; Montie, JE; Petrylak, DP; Quinn, DI; Sanda, M; Smith, DC; Vaishampayan, U; Wood, D | 1 |
| Barton, JH; Burris, HA; Drosick, D; Greco, FA; Hainsworth, JD; Shipley, D; Simons, L; Spigel, DR; Yardley, DA | 1 |
| Blitzer, J; Evans, S; Flam, M; Hager, S; Link, J; Lyons, W; Nagourney, RA; Sommers, BL | 1 |
| Habuchi, T; Horikawa, Y; Inoue, T; Kumazawa, T; Narita, S; Obara, T; Saito, M; Satoh, S; Tsuchiya, N; Yuasa, T | 1 |
| Hillerdal, G; Hjerpe, A; Riska, H; Sorensen, JB; Sundström, S; Vikström, A | 1 |
| Babineaux, S; Buesching, D; Earle, C; Faries, D; Lang, K; Marciniak, MD; Morissette, N; Stokes, M; Thompson, D; Treat, J | 1 |
| Boersma, L; Bootsma, G; Borger, J; De Ruysscher, D; Dehing, C; Dekker, A; Dingemans, AM; Geraedts, W; Hochstenbag, M; Lambin, P; Ollers, M; Pitz, C; Simons, J; Wanders, R; Yu, S | 1 |
| Fujita, Y; Fukushima, M; Furuse, K; Kawahara, M; Komuta, K; Kubota, K; Minato, K; Nishiwaki, Y; Ogawara, M; Teramukai, S | 1 |
| El-Baradie, M; Ismail, HM; Khorshid, O; Moneer, M; Touny, A | 1 |
| Arnold, A; Crabb, SJ; Ellis, PM; Goss, G; Laurie, SA; Leighl, NB; Patsios, D; Powers, J; Sauerbrei, E; Seymour, L; Shepherd, FA | 1 |
| Al-Batran, SE; Aldaoud, A; Bernhard, H; Burkart, C; Folprecht, G; Hoffmann, M; Huebner, G; Jahn, A; Kaiser, U; Kohne, CH; Kretzschmar, A; Kullmann, F; Link, H; Menges, M; Otremba, B; Schoffski, P; Stahl, M; Steinbach, S | 1 |
| Bromund, JL; Chen, R; Dakhil, SR; Fidias, PM; Gill, J; Hristova-Kazmierski, M; Loesch, DM; Lyss, AP; Marciniak, M; Obasaju, CK; Schiller, JH; Treat, J; Waterhouse, DM | 1 |
| Choy, H; Curran, W; Demas, WF; Ettinger, DS; Jain, AK; Moughan, J; Whipple, G | 1 |
| Albain, KS; Chansky, K; Crowley, J; Davies, AM; Gandara, DR; Gumerlock, PH; Lara, PN; Vogel, SJ | 1 |
| Folkerts, G; Grootenboers, M; Pasterkamp, G; Schramel, F; van Boven, WJ; van Oosterhout, M; van Putte, BP | 1 |
| Fukui, T; Hatooka, S; Ishiguro, F; Kobayashi, R; Mitsudomi, T; Mori, S; Ogawa, S; Okuda, K; Shinoda, M | 1 |
| Agelaki, S; Androulakis, N; Bozionelou, V; Georgoulias, V; Kalbakis, K; Kalykaki, A; Mavroudis, D; Vamvakas, L | 1 |
| Ansari, RH; Detterbeck, FC; Edelman, MJ; Gralla, RJ; Jahan, TM; Luketich, JD; Monberg, M; Moore, DT; Obasaju, CK; Peng, G; Rivera, MP; Socinski, MA | 1 |
| Hoskins, PJ | 1 |
| Accario-Winslow, C; Alberts, DS; Argenta, PA; Bookman, MA; Brady, MF; Burger, RA; Colombo, N; De Geest, K; Fowler, JM; Friedlander, M; Harper, PG; McGuire, WP; Mutch, DG; Roth, LM; Swart, AM; Trimble, EL | 1 |
| Belderbos, J; Borst, GR; Burgers, S; Lebesque, J; Sonke, JJ | 1 |
| Bhatt, A; Farooq, MU; Kassab, M; Majid, A | 1 |
| Aasebø, U; Bremnes, RM; Helbekkmo, N; Strøm, HH; Sundstrøm, SH; Von Plessen, C | 1 |
| Fujimoto, T; Koshiji, M; Nambu, Y; Yamamoto, N | 1 |
| Altman, RB; Brunak, S; Hansen, NT | 1 |
| Crawford, ED; deVere White, RW; Goldman, B; Hussain, MH; Lara, PN; Smith, DC; Tangen, CM; Wood, DP | 1 |
| Choong, NW; Connor, TB; George, B; Wirostko, WJ | 1 |
| Brown, JV; Goldstein, BH; John, CR; Markman, M; Micha, JP; Rettenmaier, MA | 1 |
| Bral, S; De Grève, J; De Mey, J; Decoster, L; Fontaine, C; Ilsen, B; Meysman, M; Neyns, B; Schallier, D | 1 |
| Davies, AM; Gandara, DR; Gautschi, O; Jablons, DM; Mack, PC; Rosell, R | 1 |
| Chekerov, R; Fotopoulou, C; Karavas, A; Lichtenegger, W; Sehouli, J; Trappe, R | 1 |
| Cao, Y; Chen, B; Cheng, H; Cheng, L; Feng, J; Ji, J; Li, F; Lu, Z; Ma, J; Qin, S; Sun, N; Sun, X; Zhou, Y | 1 |
| Aasebø, U; Amundsen, T; Bremnes, RM; Brunsvig, PF; Fløtten, O; Grønberg, BH; Hjelde, HH; Kaasa, S; Stornes, F; Sundstrøm, S; Tollåli, T; von Plessen, C; Wammer, F | 1 |
| Chovanec, J; Dorr, A; Habetinek, V; Helpianska, L; Horvathova, D; Jancokova, I; Koza, I; Kroslakova, D; Lalabova, R; Laluha, A; Magdin, D; Malec, V; Minarik, T; Packan, T; Rakicka, G; Sevcik, L; Spacek, J; Stresko, M; Sufliarsky, J; Svetlovska, D; Tkacova, V | 1 |
| Bonomi, P; Langer, C; Lilenbaum, R; O'Brien, M; O'Byrne, K; Oldham, FB; Ross, HJ; Sandilac, L; Singer, JW; Socinski, M; Villaflor, VM | 1 |
| Arrieta, O; Astorga-Ramos, AM; de la Garza, J; Gallardo-Rincón, D; Martínez-Barrera, L; Michel, RM; Villarreal-Garza, C | 1 |
| Takahashi, T; Tanaka, A | 1 |
| Goto, K; Kim, YH; Kubota, K; Niho, S; Nishiwaki, Y; Ohmatsu, H; Saijo, N; Yoh, K | 1 |
| Alexandrescu, DT; Dasanu, CA; Herzog, TJ | 1 |
| Choo, SP; Leong, SS; Li, HH; Lim, WT; Tan, EH; Tan, SH; Tham, CK; Toh, CK | 1 |
| Dragnev, K; Dudek, AZ; Gupta, V; Isaksson, R; Kratzke, RA; Larson, T; Lesniewski-Kmak, K; Maddaus, MA | 1 |
| Bakshandeh-Bath, A; Homann, N; Peters, SO; Stölting, S; Stoltz, AS; Wagner, T | 1 |
| Holm, B; Mellemgaard, A; Skov, BG; Skov, T | 1 |
| Chan, D; Chuah, B; Goh, BC; Lee, SC; Lim, SE; Soo, R; Tan, SH; Tiemsim Cordero, M; Wong, CI; Yeo, WL | 1 |
| Boyer, MJ; Chen, YM; Chua-Tan, M; Chui, W; Ignacio, J; Jin, K; Johnston, M; Lee, JS; Liao, M; Mok, TS; Srimuninnimit, V; Sriuranpong, V; Sudoyo, AW; Wu, YL; Yu, CJ; Zhang, L; Zhou, C | 1 |
| Alamara, C; Chatzidarellis, E; Georgiadis, E; Giza, L; Makrilia, N; Syrigos, KN | 1 |
| Gilligan, D; Gower, N; Hackshaw, A; Jitlal, M; Lee, SM; Ottensmeier, C; Price, A; Rudd, R; Spiro, S; Woll, PJ | 1 |
| Bellmunt, J; De Santis, M; de Wit, R; Kerst, JM; Leahy, M; Maroto, P; Marreaud, S; Mead, G; Skoneczna, I; Sylvester, R | 1 |
| Alvarez, RD; Gallion, HH; García, AA; Kilgore, LC; Lucci, J; Mannel, R; Numnum, TM; Orlando, M; Tai, DF; Zou, SX | 1 |
| Ansari, R; Belani, CP; Catalano, RB; Comis, RL; Edelman, MJ; Gillenwater, HH; Gonin, R; Marinucci, DM; Obasaju, CK; Rowland, KM; Socinski, MA; Treat, JA | 1 |
| Amour, E; Beckendorf, V; Bossard, N; Douillard, JY; Girard, N; Grunenwald, D; Milleron, B; Mornex, F; Quoix, E | 1 |
| Asmar, L; Bepler, G; Boehm, KA; Boulware, D; Bromund, J; Caton, JR; Demarco, LC; Li, X; Monberg, MJ; O'Rourke, MA; Obasaju, C; Peng, G; Reynolds, C; Schell, MJ; Shaw Wright, G; Zheng, Z | 1 |
| Cormier, JN; Du, XL; Hardy, D; Liu, CC; Xia, R; Xing, Y | 1 |
| Hudson, E; Lester, JF | 1 |
| Dempoya, J; Hayashi, A; Mikuniya, M; Morimoto, T; Nakamura, K; Okudera, K; Okumura, K; Takanashi, S | 1 |
| Auner, V; Horvat, R; Oskay-Oezcelik, G; Sehouli, J; Speiser, P; Zeillinger, R | 1 |
| Harnett, EL; Laurie, SA; Maksymiuk, A; Parulekar, WR; Siu, LL; Tu, D; Walsh, W; Winquist, E | 1 |
| Adachi, S; Kimura, M; Matsumoto, R; Matsuoka, T; Nakao, T; Okada, K; Tanaka, Y; Usami, E; Yasuda, T; Yoshimura, T | 1 |
| Crinò, L; De Marinis, F; Gridelli, C; Liepa, AM; Peterson, P; Ricci, S; Rinaldi, M; Scagliotti, GV; Tonato, M; Zhao, YD | 1 |
| Ansari, RH; Belani, CP; Chen, R; Edelman, MJ; Monberg, MJ; Obasaju, CK; Socinski, MA; Treat, J | 1 |
| Favaretto, AG; Magro, C; Pasello, G | 1 |
| Arrieta, O; Astorga, A; Flores-Estrada, D; Martinez-Barrera, L; Michel Ortega, RM; Pachuca, D; Villarreal-Garza, C | 1 |
| Gupta, S; Mallik, S; Munshi, A | 1 |
| Hirai, T; Ichikawa, Y; Kishikawa, H; Kobayashi, Y; Nishimura, K; Soda, T; Yamanaka, K | 1 |
| Chen, ZH; Cheng, H; Dong, S; Guo, AL; Huang, Y; Wang, Z; Wu, YL; Xie, Z; Yan, HH; Zhang, XC | 1 |
| Komori, E; Nogami, H; Ogino, A; Sawada, S; Segawa, Y; Shinkai, T; Suehiro, H; Yamashita, M | 1 |
| Arima, K; Kise, H; Soga, N; Sugimura, Y | 1 |
| Belani, CP; Chen, R; Edelman, MJ; Monberg, MJ; Obasaju, CK; Socinski, MA; Treat, J | 1 |
| Gu, CP; Hong, D; Li, T; Lou, GY; Zhang, YP | 1 |
| Agarwal, R; Carty, K; Gabra, H; Gore, ME; Gourley, C; Kaye, SB; Parkin, DE; Paul, J; Perren, TJ; Reed, N; Rustin, GJ | 1 |
| Athanasas, G; Economopoulos, T; Koumarianou, A; Macheras, A; Papaxoinis, G; Pectasides, D; Pectasides, E; Pliarchopoulou, K; Psyrri, A; Xiros, N | 1 |
| Ansari, RH; Belani, CP; Catalano, RB; Chen, R; Comis, RL; Edelman, MJ; Gonin, R; Marinucci, DM; Monberg, MJ; Obasaju, CK; Socinski, MA; Treat, J | 1 |
| Chaudhary, RT; Kleynberg, RL; Sofi, AA | 1 |
| Bonfill Abella, T; Dalmau Pórtulas, E; Gallardo-Díaz, E; Moya-Horno, I; Pericay Pijaume, C; Querol Niñerola, R; Saigí Grau, E | 1 |
| Amundsen, T; Bremnes, RM; Fløtten, O; Grønberg, BH; Hjelde, HH; Jordhøy, M; Kaasa, S; Plessen, Cv; Sundstrøm, S | 1 |
| Lv, M; Ren, S; Xu, J; Zhang, J; Zhang, L; Zhou, C; Zhou, S | 1 |
| Bagust, A; Boland, A; Davis, H; Dickson, R; Dundar, Y; Fleeman, N; Green, J; Greenhalgh, J; McLeod, C; Pearson, M; Tudur Smith, C | 1 |
| Aerts, JG; Hoogsteden, HC; Legrand, C; Schmitz, PI; Surmont, V; Tan, KY; Tournoy, K; van Klaveren, RJ; van Meerbeeck, JP; Vernhout, RM | 1 |
| Choi, YH; Jung, JW; Kim, HS; Lee, HJ; Lee, JC; Nam, SB; Park, KY | 1 |
| Andersson, K; Hillerdal, G; Sederholm, C | 1 |
| Daniels, JT; Garrison, MA; Gjerset, GF; Gooley, TA; Gopal, AK; Lonergan, M; Murphy, AE; Pagel, JM; Petersdorf, SH; Press, OW; Shustov, AR; Smith, JC | 1 |
| Ansari, RH; Catalano, RB; Chen, R; Comis, RL; Liles, DK; Marinucci, DM; Monberg, MJ; Obasaju, CK; Ribeiro, MJ; Socinski, MA; Treat, J | 1 |
| Bear, MD; Kulp, SK; London, CA; McMahon, MB; Pennell, ML | 1 |
| Ashley, S; Brunetto, AT; Carden, CP; Faria, AL; Myerson, J; O'Brien, ME; Popat, S | 1 |
| Leaw, SJ; Luo, J; Xu, Y; Zheng, D | 1 |
| Fournier, CC; James, JS; Picus, J; Suresh, R; Tan, BR; Trinkhaus, K; Williams, KJ | 1 |
| Chen, H; Li, C; Pan, Y; Sun, Y; Wang, Q; Yang, S | 1 |
| Hasegawa, Y; Imaizumi, K; Kondo, M; Shimokata, K; Shindo, J; Suzuki, R; Taniguchi, H; Usami, N; Yamamoto, M; Yokoi, K | 1 |
| Gabra, H; Hartley, JA; James, LE; Jayson, GC; Jitlal, M; Ledermann, JA; Rustin, GJ; Spanswick, VJ | 1 |
| Avall-Lundqvist, E; Burges, A; du Bois, A; Gropp, M; Hardy-Bessard, AC; Harter, P; Herrstedt, J; Huober, J; Jackisch, C; Jelic, S; Joly, F; Kristensen, G; Kurzeder, C; Müller, HH; Pfisterer, J; Pujade-Lauraine, E; Sehouli, J; Staehle, A; Weber, B; Wimberger, P | 1 |
| Brigulová, K; Cervinka, M; Sedláková, I; Tošner, J | 1 |
| Burkhard, FC; Gautschi, O; Ghadjar, P; Studer, UE; Thalmann, GN | 1 |
| Ebina, A; Imai, T; Kishimoto, K; Nakamura, Y; Sato, N | 1 |
| Berthillot, C; Gaertner, S; Miréa, C; Stephan, D; Welsch, M | 1 |
| Billaud, EM; Bobin-Dubigeon, C; Boisdron-Celle, M; Boyer, JC; Chatelut, E; Concordet, D; Durdux, C; Etienne-Grimaldi, MC; Evrard, A; Floquet, A; Gladieff, L; Laffont, CM; Lafont, T; Lansiaux, A; Le Guellec, C; Mazières, J; Mousseau, M; Ollivier, F; Pinguet, F; Schmitt, A | 1 |
| Clément-Duchêne, C; Colevas, AD; Ganjoo, K; Krupitskaya, Y; Kumar, A; Lavori, P; McMillan, A; Padda, S; Pedro-Salcedo, MS; Wakelee, HA; Zhao, G; Zhou, L | 1 |
| Der, CJ; Roberts, PJ; Socinski, MA; Stinchcombe, TE | 1 |
| Grendys, EC; Holloway, RW; Lefebvre, P; McMeekin, S; Vekeman, F | 1 |
| Besse, B; Ferrand, FR; Le Floch, H; Mairovitz, A; Margery, J; Planchard, D; Rivière, F; Ruffié, P; Vaylet, F | 1 |
| Friedman, GK; Hilliard, LM; Kelly, DR; Vaid, YN; Walsh, A | 1 |
| de Vere White, R; Henderson, P; Lara, PN; Malfatti, M; Pan, CX; Turteltaub, K; Wang, S; Zhang, H | 1 |
| Alvarez, PJ; Aranega, A; Burgos, M; Hita, F; Melguizo, C; Ortiz, R; Prados, J; Rama, AR; Ramos, JL; Rodríguez-Serrano, F | 1 |
| Fujita, S; Fukuhara, A; Hata, A; Hatachi, Y; Kaji, R; Katakami, N; Kim, YH; Masago, K; Mio, T; Mishima, M | 1 |
| Cheng, L; Evans, C; Pan, CX; Wang, S; Zhang, H | 1 |
| Inoue, M; Nagashima, A; Nakanishi, K; Nakanishi, R; Osaki, T; Sakata, H; Uchiyama, A; Uramoto, H; Yasumoto, K; Yoshimatsu, T | 1 |
| Huang, XE; Jiang, Y; Li, Y; Xiang, J; Yan, PW | 1 |
| Airoldi, M; Amoroso, D; Ardizzoia, A; Aurilio, G; Bajetta, E; Ballardini, P; Balzelloni, ML; Banna, GL; Barbieri, F; Barletta, E; Basso, U; Bernardini, I; Boni, C; Bordin, V; Bretti, S; Bria, E; Bronte, G; Brunetti, C; Buti, S; Capanna, L; Collovà, E; Colombo, A; Condemi, G; Cortinovis, D; Dambrosio, M; Di Fonzo, C; Di Lucca, G; Di Maio, M; Dima, G; Falzetta, A; Favaretto, A; Ferraù, F; Follador, A; Garetto, L; Gebbia, V; Genestreti, G; Gentile, AL; Giovanardi, F; Labianca, R; Lorusso, V; Mantovani, G; Martelli, O; Massari, F; Mazzoli, M; Menis, J; Michetti, G; Mordenti, P; Mucciarini, C; Munao, S; Nacci, A; Novello, S; Pogliani, C; Procopio, G; Riccardi, F; Rizzato, S; Rossi, A; Rosti, G; Russo, P; Saladino, T; Salesi, N; Santangelo, D; Sava, T; Savarino, A; Spinnato, F; Tiseo, M; Tomassi, O; Tondulli, L; Tonini, G; Turano, S; Valerio, MR; Verderame, F; Zanelli, F; Zanon, E | 1 |
| Baak, JP; Guo, H; Liu, JX; Madebo, T; Xu, L | 1 |
| Choi, YJ; Chung, JH; Kim, CH; Kim, HR; Lee, CT; Lee, JC; Lee, JS; Rho, JK; Xu, X; Yoon, HI | 1 |
| Hilpert, F; Jonat, W; Kuemper, C; Mundhenke, C; Schaefer, F; Strauss, A | 1 |
| Asmar, L; Kobina, S; Neubauer, MA; Pritchard, S; Reynolds, CH; Weissman, CH | 1 |
| Bradley, C; Koo, IC; O'Shaughnessy, J; Osborne, C; Patt, D; Pippen, JE; Rocha, C; Sherman, BM; Yoffe, M | 1 |
| Wang, XY; Zhao, YL | 1 |
| Biesma, B; Dalesio, O; Groen, HJM; Slaets, JPJ; Smit, EF; Smit, HJM; Stigt, JA; van Felius, CL; van Putten, JWG; Vincent, A; Wymenga, ANM | 1 |
| Bepler, G; Chen, DT; Chiappori, A; Dilling, TJ; Greenberg, H; Haura, E; Hazelton, T; Simon, G; Stevens, C; Tanvetyanon, T; Wagner, H; Walsh, F; Williams, C | 1 |
| Ando, M; Fukuoka, M; Iwamoto, Y; Katakami, N; Kurata, T; Maeda, M; Nakagawa, K; Nakano, T; Saito, H; Takeda, K | 1 |
| Bonanno, L; Carli, P; Favaretto, A; Jirillo, A; Magro, C; Marulli, G; Nicotra, S; Pasello, G; Rea, F | 1 |
| Baldi, A; Bazzano, S; D'Anna, S; Orlando, F; Palmieri, A; Tenaglia, S; Valentinis, L | 1 |
| Baracos, VE; Chu, QS; Mazurak, VC; Mourtzakis, M; Murphy, RA; Reiman, T | 1 |
| Bharadwaj, RR; Chen, EX; Jarvi, A; Kamel-Reid, S; Le Tourneau, C; Mann, V; Perez-Ordonez, B; Siu, LL; Wang, L; You, B | 1 |
| Hamamoto, Y; Kamimura, M; Takano, N; Yamada, K | 1 |
| Ducoloné, A; Fraisse, P; Mennecier, B; Quoix, E | 1 |
| Akino, H; Aoki, Y; Ito, H; Miwa, Y; Oyama, N; Yokoyama, O | 1 |
| Habuchi, T; Horikawa, Y; Inoue, T; Maita, S; Narita, S; Numakura, K; Obara, T; Saito, M; Satoh, S; Tsuchiya, N; Tsuruta, H | 1 |
| Al-Barrak, J; Gilks, CB; Hoskins, P; Lau, H; Santos, JL; Swenerton, KD; Tinker, A | 1 |
| Chung, HC; Del Giglio, A; Feng, J; Jiang, Z; Kim, SB; Malzyner, A; Pen, DL; Shen, LJ; Xu, B; Yu, S | 1 |
| Blackstock, AW; Bogart, JA; Crawford, JC; Gu, L; Morano, K; Salama, JK; Socinski, MA; Stinchcombe, TE; Vokes, EE; Wang, X | 1 |
| Azzarello, D; Bottari, M; Maisano, M; Maisano, R; Nardi, M; Raffaele, M; Zavettieri, M | 1 |
| Cleves, A; Mason, M; Shelley, M; Wilt, TJ | 1 |
| Ambrosone, CB; Bookman, M; Darcy, KM; Deloia, JA; Gallion, H; Krivak, TC; Tian, C | 1 |
| Eller, J; Furák, J; Hideghéty, K; Kahán, Z; Maráz, A; Molnár, J; Pálföldi, R; Szántó, E; Thurzó, L; Tiszlavicz, L | 1 |
| Agelaki, S; Ardavanis, A; Chandrinos, V; Christophyllakis, C; Georgoulias, V; Giassas, S; Karachaliou, N; Kotsakis, A; Pallis, AG; Polyzos, A; Samonis, G; Saridaki, Z; Syrigos, K; Vamvakas, L; Vardakis, N; Varthalitis, I | 1 |
| Liu, T; Zhang, JQ; Zhang, L | 1 |
| Adamo, V; Alabiso, O; Ardizzoni, A; Barbera, S; Barni, S; Buscarino, C; Caprioli, A; Crinò, L; De Marinis, F; Filippelli, G; Gebbia, V; Gridelli, C; Lorusso, V; Maione, P; Marangolo, M; Morena, R; Pela, R; Piazza, E; Venturino, P; Zilembo, N | 1 |
| Bang, YJ; Bergethon, K; Camidge, DR; Christensen, J; Clark, JW; Dy, J; Iafrate, AJ; Kim, DW; Kwak, EL; Maki, RG; Ou, SH; Salgia, R; Siwak-Tapp, C; Solomon, BJ; Tan, W; Wilner, KD | 1 |
| Li, X; Lv, M; Ren, S; Wu, F; Xu, J; Zhang, J; Zhang, L; Zhou, C; Zhou, S | 1 |
| Cortesi, E; Frati, L; Gandini, O; Gazzaniga, P; Gradilone, A; Naso, G; Nicolazzo, C; Palazzo, A; Petracca, A; Raimondi, C | 1 |
| Armstrong, DK; Bristow, RE; Diaz-Montes, TP; Giuntoli, RL | 1 |
| Rexer, H | 1 |
| Chen, G; Chen, L; Feng, J; Hu, C; Huang, J; Liu, XQ; Lu, S; Luo, Y; Ma, J; Ren, S; Wang, C; Wang, J; Wu, YL; Xiu, Q; Ye, M; You, C; Zhang, L; Zhang, S; Zhang, Y; Zhi, X; Zhou, C; Zhou, S | 2 |
| Barraclough, H; Pavlakis, N; Standfield, L; Van Kooten, M; Weston, AR | 1 |
| Cetto, GL; Cingarlini, S; Frizziero, M; Genestreti, G; Giovannini, N; Maglie, M; Molino, AM; Piciucchi, S; Sanna, S; Santo, A | 1 |
| Baudrin, L; Bennouna, J; Bigay-Game, L; Dansin, E; Dauba, J; Debieuvre, D; Ducoloné, A; Herman, D; Laporte, S; Lavolé, A; Lebitasy, MP; Milleron, B; Molinier, O; Moro-Sibilot, D; Oster, JP; Pichon, E; Poudenx, M; Quoix, E; Souquet, PJ; Tredaniel, J; Vaylet, F; Westeel, V; Zalcman, G | 1 |
| Reckamp, KL | 1 |
| Ando, M; Hasegawa, Y; Isa, S; Kawaguchi, T; Kubo, A; Nakagawa, K; Ou, SH; Shiraishi, J; Takada, M; Tsuji, T; Tsujino, K | 1 |
| Fukushima, M; Furuse, K; Kawahara, M; Kubota, K; Origasa, H; Shinkai, T; Tada, H; Teramukai, S; Tokoro, A | 1 |
| Chen, ZW; Cheng, BJ; Jian, H; Lu, S; Xu, YH; Ye, XY; Zhou, Z | 1 |
| Lagerstedt, E; Mäenpää, J; Seppänen, J; Staff, S | 1 |
| Burris, HA; Ervin, TJ; Greco, FA; Hainsworth, JD; Kohler, PC; Lubiner, ET; Peyton, JD; Shipley, DL; Spigel, DR; Waterhouse, DM | 1 |
| Horai, T; Ikeda, N; Imamura, F; Inoue, A; Kimura, Y; Nishino, K; Nishio, M; Noro, R; Ohsaki, Y; Tsuboi, M; Uchida, J | 1 |
| Culine, S; Demery, ME; Pouessel, D; Thézenas, S | 1 |
| Chen, CP; Jablons, DM; Jahan, TM; Weinberg, VK; Yom, SS | 1 |
| Christenson, R; Edelman, MJ; Hodgson, L; Jewell, S; Kratzke, R; Vokes, E; Wang, X | 1 |
| Burkholder, TL; Chen, MD; Gill, JF; Gordon, AN; Hines, J; Homesley, HD; Janicek, MF; Lim, PC; McMeekin, S; Obasaju, CK; Orlando, M; Tai, DF; Teneriello, M; Vaccarello, L; Wang, Y; Zhao, L | 1 |
| Barbera, S; Barletta, E; Ceribelli, A; De Maio, E; Di Maio, M; Favaretto, A; Filipazzi, V; Gallo, C; Gamucci, T; Gridelli, C; Iaffaioli, RV; Isa, L; Maione, P; Morabito, A; Perrone, F; Piccirillo, MC; Rocco, G; Rossi, A; Signoriello, S; Vecchione, A | 1 |
| Baas, P; Bard, MP; Beijnen, JH; Burgers, SA; Doodeman, VD; Haitjema, TJ; Huitema, AD; Joerger, M; Schellens, JH; Smit, EF; Smits, PH; Vincent, A | 1 |
| Brekken, RA; Gazdar, AF; Girard, L; Greer, RM; Harran, P; Larsen, JE; Minna, JD; Peyton, M; Wang, L; Wang, X; Xie, Y | 1 |
| Fukunaga, K; Hirata, Y; Iida, H; Kakuno, A; Morita, M; Murata, S; Nishigami, T; Tamura, M; Tani, S; Yamanaka, N | 1 |
| Bahleda, R; Bosq, J; Hartl, DM; Hollebecque, A; Massard, C; Soria, JC | 1 |
| Ambrosone, CB; Armstrong, DK; Bookman, MA; Darcy, KM; Davis, W; DeLoia, JA; Gallion, H; Krivak, TC; Moysich, K; Tian, C; Zhao, H | 1 |
| Bellmunt, J; Collette, S; Daugaard, G; De Santis, M; de Wit, R; Gil, T; Kerst, JM; Leahy, M; Lorent, J; Maroto, P; Marreaud, S; Mead, G; Skoneczna, I; Sylvester, R | 1 |
| Jiang, G; Li, J; Li, X; Li, Y; Liu, J; Wang, J; Yang, F; Zhao, H | 1 |
| Orlova, RV; Protasova, AE | 1 |
| Cormier, Y; Gitlitz, B; Gleave, ME; Hao, D; Laskin, JJ; Lee, C; Murray, N; Nemunaitis, J; Nicholas, G; Nugent, F; Pressnail, B; Sanborn, R; Stephenson, J; Ung, Y; Vincent, M | 1 |
| Hashimoto, Y; Hatakeyama, S; Imanishi, K; Kamimura, N; Koie, T; Ohyama, C; Okamoto, A; Okamoto, T; Tokui, N; Yoneyama, T | 1 |
| Fan, Y; Huang, Z; Lin, N; Luo, L; Miao, L; Yu, H | 1 |
| Altavilla, G; Artal, A; Baize, N; Bearz, A; Bernabe, R; Bombaron, P; Bover, I; Carcereny, E; Cobo, M; Corre, R; Cortesi, E; Dansin, E; de Aguirre, I; de Castro, J; De Marinis, F; Domine, M; Drozdowskyj, A; Felip, E; Ferrera-Delgado, L; Garcia-Campelo, R; Garcia-Gomez, R; Garrido, P; Gebbia, V; Gervais, R; Illiano, A; Insa, A; Isla, D; Jimenez, U; Longo, F; Lopez-Vivanco, G; Massuti, B; Mazieres, J; Milella, M; Molina, MA; Molinier, O; Moran, T; Moreno, MA; Muñoz-Langa, J; Pallares, C; Palmero, R; Paz-Ares, L; Porta, R; Provencio, M; Queralt, C; Ramirez, JL; Reguart, N; Robinet, G; Rodriguez-Abreu, D; Rolfo, C; Rosell, R; Sanchez, JJ; Sanchez, JM; Sanchez-Ronco, M; Taron, M; Terrasa, J; Valdivia, J; Vergnenegre, A | 1 |
| Chen, J; Li, J; Li, MW; Shentu, JZ; Wang, LR; Wang, Y; Xu, N; Zhang, GB | 1 |
| Aoki, T; Fukuoka, M; Hirashima, T; Ikeda, N; Ishiguro, T; Iwamoto, Y; Kawaguchi, T; Kotani, Y; Kurata, T; Nakagawa, K; Sawa, T; Tsuboi, M | 1 |
| Burt, AD; Dasari, BV; Kelly, PJ; Loughrey, MB; Spence, R; Taylor, M | 1 |
| Gao, Q; Wang, FY; Yu, H | 1 |
| Jafari, M; Kislukhin, G; Long, AD; Murphy, ML | 1 |
| Chilelli, M; D'Auria, G; Fabbri, MA; Frittelli, P; Massari, A; Moscetti, L; Natoli, G; Nelli, F; Ruggeri, EM | 1 |
| Brown, NJ; Jitlal, M; Lee, SM; Tin, AW; Woll, PJ; Young, RJ | 1 |
| Engehausen, DG; Giedl, J; Goebell, PJ; Hartmann, A; Keck, B; Kunath, F; Wullich, B | 1 |
| Au-Yeung, G; Davis, ID; Liew, MS | 1 |
| Fu, L; Gao, Y; Hong, D; Hong, W; Hu, L; Kou, JY; Su, D; Xie, FJ; Zhang, YP; Zhao, P | 1 |
| Kamiyama, Y; Kasai, H; Kodama, T; Mori, K | 1 |
| Antoine, M; Beau-Faller, M; Bergot, E; Brambilla, E; Braun, D; Creveuil, C; de Fraipont, F; Debieuvre, D; Favrot, MC; Hainaut, P; Levallet, G; Milleron, B; Morin, F; Moro-Sibilot, D; Mounawar, M; Quoix, E; Richard, N; Rouquette, I; Westeel, V; Zalcman, G | 1 |
| Arbea, L; Aristu, J; Gil-Bazo, I; Moreno-Jimenez, M; Perez-Gracia, JL; Rodríguez-Ruiz, ME; San Miguel, I | 1 |
| Iyoda, A; Jiang, SX; Kageyama, T; Masuda, N; Matsumoto, T; Nagashio, R; Ryuge, S; Saegusa, M; Sato, Y; Satoh, Y | 1 |
| Behrens, C; Correa, AM; Erasmus, JJ; Kalhor, N; Kim, ES; Lee, JJ; Pataer, A; Raso, MG; Roth, JA; Stewart, DJ; Swisher, SG; Vaporciyan, AA; Wistuba, II | 1 |
| Bouchardy, C; Dehler, S; Ess, S; Frick, H; Joerger, M; Konzelmann, I; Savidan, A; Thürlimann, B | 1 |
| Guo, Z; Li, J | 1 |
| Hirano, T; Iseki, K; Itagaki, S; Kobayashi, M; Sugawara, M; Takahashi, N; Takekuma, Y | 1 |
| Chida, K; Inui, N; Karayama, M; Kuroishi, S; Kusagaya, H; Masuda, M; Nakamura, Y; Shirai, T; Suda, T; Toyoshima, M; Yamada, T; Yasuda, K; Yokomura, K | 1 |
| Hoshina, A; Onishi, T; Sasaki, T | 1 |
| Aasebø, U; Amundsen, T; Bremnes, R; Fløtten, Ø; Grønberg, BH; Hornslien, K; Rolke, H; Sundstrøm, S; von Plessen, C; Wentzel-Larsen, T | 1 |
| Baudrin, L; Cadranel, J; Coëtmeur, D; Duruisseaux, M; Monnet, I; Morère, JF; Morin, F; Moro-Sibilot, D; Mourlanette, P; Quoix, E; Soria, JC; Westeel, V; Wislez, M | 1 |
| De Pas, T; Giovannetti, E; Peters, GJ; Toffalorio, F | 1 |
| Chew, DJ; de Brito Galvao, JF; Inpanbutr, N; Kisseberth, WC; Murahari, S; Sutayatram, S | 1 |
| Chu, Z; Huang, R; Jiang, J; Liang, X; Zhan, Q; Zhou, X | 1 |
| Abotouk, N; Halim, A | 1 |
| Hu, LM; Hu, ZB; Huang, MD; Shen, HB; Shu, YQ; Wang, ZW; Xu, JL; Yin, ZQ | 1 |
| Arcand, SL; Caceres, KY; Cyr, L; de Ladurantaye, M; Delvoye, N; Létourneau, IJ; Mes-Masson, AM; Meunier, L; Portelance, L; Provencher, DM; Quinn, MC; Shen, Z; Tonin, PN; Wang, LL | 1 |
| Azuma, K; Fukumoto, T; Kikugawa, T; Miura, N; Miyauchi, Y; Shimamoto, K; Shirato, A; Tanji, N; Yanagihara, Y; Yokoyama, M | 1 |
| Alken, S; Breathnach, OS; El-Helali, A; Greene, J; Grogan, L; Korpanty, G; Smyth, L | 1 |
| Hashimoto, Y; Hatakeyama, S; Kamimura, N; Koie, T; Ohyama, C; Yamamoto, H; Yoneyama, T | 1 |
| Bussink, J; Soetekouw, PM; Timmer-Bonte, JN; Tjan-Heijnen, VC; van der Drift, MA; van Die, L; van Leeuwen, F; Wagenaar, M | 1 |
| Cao, Q; Dudek, AZ; H Thaw, SS; Kumar, P; Larson, T; Pawloski, P | 1 |
| Hirose, T; Ishida, H; Kusumoto, S; Murata, Y; Nakashima, M; Ohmori, T; Ohnishi, T; Oki, Y; Okuda, K; Shirai, T; Sugiyama, T; Yamaoka, T | 1 |
| Adjei, AA; Ansari, RH; Dy, GK; Lyss, AP; Mandrekar, SJ; Meyers, JP; Molina, JR; Nelson, GD; Ross, HJ; Schild, SE; Stella, PJ | 1 |
| Fujioka, T; Iwasaki, K; Kato, Y; Obara, W; Takata, R; Tanji, S | 1 |
| Hirashima, T; Imamura, F; Kawase, I; Kijima, T; Komuta, K; Minami, S; Nakatani, T; Namba, Y; Ogata, Y; Okafuji, K; Osaki, T; Otsuka, T; Shiroyama, T; Tachibana, I; Uchida, J; Yamamoto, S | 1 |
| Apolo, AB; Bajorin, DF; Balar, AV; Gallagher, DJ; Garcia-Grossman, IR; Iasonos, A; Milowsky, MI; Mironov, S; Ostrovnaya, I; Regazzi, AM; Trout, A | 1 |
| Chua, M; Coleman, A; Collins, M; Corry, J; D'Costa, I; Hicks, RJ; Lim, AM; Peters, L; Rischin, D; Solomon, B | 1 |
| Cruickshank, S; Delmore, JE; diZerega, GS; Drummond, L; Peterson, KJ; Pham, H; Reed, E; Rodgers, KE; Schwartz, BM | 1 |
| Cheon, J; Choi, IK; Kang, SG; Kang, SH; Kim, HS; Kim, JS; Kim, ST; Kim, YH; Ko, YH; Lee, SW; Oh, SC; Park, JH; Park, KH; Park, YJ; Seo, JH; Sung, DJ | 1 |
| Fahmy, ES; Habib, EE | 1 |
| Kawakita, M; Matsumoto, K; Muguruma, K; Segawa, T; Sumiyoshi, T; Utsunomiya, N | 1 |
| Budman, DR; Calabro, A; Lesser, M; Rosen, L | 1 |
| Arnold, S; Baeker, T; Brooks, M; Carloss, H; Croley, J; Kloecker, G; Kvale, E; Leggas, M; Lim, A; Maheshwari, JG; Rinehart, J; Shelton, B; Slone, S; Zaydan, MA | 1 |
| du Bois, A; Harter, P; Heitz, F; Kurzeder, C; Lubbe, D; Pfisterer, J; Plante, M; Vergote, I | 1 |
| Dohrmann, T; Izbicki, JR; Jaenicke, F; Kutup, A; Mahner, S; Müller, V; Vashist, YK | 1 |
| Banna, GL; Basile, A; Fraggetta, F; Ippolito, M; Lipari, H; Marletta, F; Nicolosi, M; Saita, S; Terminella, A; Urso, OE; Vaglica, M | 1 |
| Fang, J; Li, S; Lv, C; Ma, Y; Sun, Y; Wu, N; Yan, S; Yang, Y; Zheng, Q | 1 |
| Li, J; Lu, Q; Ouyang, L; Peng, L; Tan, C; Wang, S; Zeng, X | 1 |
| Cheng, J; Gao, J; Liu, X; Wang, J; Wang, L; Xiong, L | 1 |
| Han, JC; Li, HB; Li, XD; Wu, XY; Zhang, YJ | 1 |
| Amadori, D; Bauknecht, T; Carrasco, E; Desaiah, D; Labianca, R; Martin, M; Moreau, V; Roesel, S; Soldatenkova, V; Uziely, B | 1 |
| Chan, KS; Lim, KH; Lim, WT; Lynette, O; Montoya, J; Ng, QS; Sakktee Krisna, S; Takano, A; Tan, DS; Tan, EH | 1 |
| Chen, AB; Johnson, BE; Schrag, D; Sharma, DB; Weeks, JC; Zhu, J | 1 |
| Borzási, E; Együd, Z; Fodor, E; Furák, J; Hideghéty, K; Kahán, Z; Maráz, A; Pálföldi, R; Tiszlavicz, L; Varga, Z | 1 |
| Abonyi-Tóth, Z; Katona, L; Kovács, G; Moldvay, J; Rokszin, G | 1 |
| Anile, M; Ciccone, AM; D'Andrilli, A; Ibrahim, M; Maurizi, G; Rendina, EA; Venuta, F | 1 |
| Akewanlop, C; Ithimakin, S; O-Charoenrat, P; Prasarttong-Osoth, P; Ratanawichitrasin, A; Rojananin, S; Soparattanapaisarn, N; Srimuninnimit, V; Veerasarn, V | 1 |
| Dahlberg, SE; Hoang, T; Johnson, DH; Schiller, JH | 1 |
| Andreu, F; Arellano, A; Arnaiz, Mdel M; Calvo, F; Cardenal, F; Cobo, M; Delgado, R; Dómine, M; García-Gómez, R; Garrido, P; Isla, D; Massutí, B; Morán, T; Morera, R; Perez-Casas, A; Ramos, A; Rosell, R; Valencia, J; Zamora, J | 1 |
| Lv, M; Ren, JC; Sun, J; Wang, B; Wang, X; Zhang, L; Zhang, T | 1 |
| Abou-Elela, E; Darwish, D; Ibrahim, N | 1 |
| Beijnen, JH; Huitema, AD; Leijen, S; Schellens, JH; van Werkhoven, E; Veltkamp, SA | 1 |
| Cho, YJ; Hwang, YS; Jeong, YY; Kim, HC; Kim, IS; Kim, MJ; Kim, SH; Lee, GW; Lee, JD; Lee, S; Ling, H; Oh, SY | 1 |
| Antonia, S; Bepler, G; Brahmer, J; Chen, W; Chiappori, A; Fischer, JR; Gadgeel, S; Gray, J; Haura, E; Pinder-Schenck, M; Schell, MJ; Schreiber, F; Simon, G; Tanvetyanon, T; Williams, C; Zhao, X; Zheng, Z | 1 |
| Alva, A; Daignault-Newton, S; Grivas, PD; Hafez, K; Hollenbeck, B; Hussain, M; Lee, CT; Montgomery, JS; Montie, JE; Smith, DC; Weizer, A; Wood, D | 1 |
| Adam, J; Pinilla-Dominguez, P; Richardson, J; Robertson, J | 1 |
| Gschwend, JE; Horn, T; Kübler, HR; Ladwein, B; Maurer, T; Redlin, J; Retz, M; Seitz, AK | 1 |
| Khunnarong, J; Manusirivithaya, S; Pataradool, K; Pitakkarnkul, S; Prutthiphongsit, W; Srijaipracharoen, S; Tangjitgamol, S; Thavaramara, T | 1 |
| Bigay-Game, L; Braun, D; David, P; Debieuvre, D; Depierre, A; Douillard, JY; Laporte, S; Lavolé, A; Lebeau, B; Lemarié, E; Milleron, B; Molinier, O; Morin, F; Ozenne, G; Poudenx, M; Pujol, JL; Puyraveau, M; Quoix, E; Rivière, A; Westeel, V; Zalcman, G | 1 |
| Darwiche, K; Freitag, L; Goldberg, EP; Huang, H; Li, Q; Petridis, D; Ritzoulis, C; Spyratos, D; Yarmus, L; Zarogoulidis, K; Zarogoulidis, P | 1 |
| Bara, I; Chang, GC; Chen, YM; Cheng, A; Fuerte, F; Ho, J; Jin, K; Kurnianda, J; Ladrera, G; Lee, JS; Lee, V; Liao, M; Liu, HE; Margono, B; Mok, T; Pan, H; Qian, X; Sandoval-Tan, J; Seetalarom, K; Srimuninnimit, V; Sriuranpong, V; Sun, Y; Syahruddin, E; Thongprasert, S; Truman, M; Wang, J; Wu, YL; Yu, CJ; Zhang, L; Zhou, C; Zhu, Y | 1 |
| Ball, D; Collins, M; Francis, H; Franco, M; Kofoed, S; Mileshkin, L; Paramanathan, A; Solomon, B | 1 |
| Dobra, K; Hjerpe, A; Mundt, F; Nilsonne, G; Souri, P; Szulkin, A; Wasik, AM | 1 |
| Shi, X; Yu, XM; Zhang, YP; Zhao, J | 1 |
| Butthongkomvong, K; Jhankumpha, S; Kumdang, S; Sirachainan, E; Sukhontharot, OU | 1 |
| da Silva, EM; de Castria, TB; Gois, AF; Riera, R | 1 |
| Kolek, V | 1 |
| Campbell, L; Eakin, RL; Hanna, GG; Hussain, A; Khan, K; McAleese, J; Scullin, P | 1 |
| Stinchcombe, TE | 1 |
| Ichioka, D; Inai, H; Kawai, K; Miyazaki, J; Nishiyama, H | 1 |
| Hatakeyama, S; Koie, T; Ohyama, C; Yoneyama, T | 1 |
| Chen, M; Zhang, J; Zhou, CC; Zhu, J | 1 |
| Cai, QC; Guan, HH; Lin, ZX; Wu, ZY; Yang, HK; Zhou, L | 1 |
| Jamil, K; Naidu Madireddy, UR; Natukula, K; Pingali, UR; Suresh Attili, VS | 1 |
| Bonetti, A; Durante, E; Furini, L; Giuliani, J; Greco, F; Mercanti, A; Moratello, G; Piacentini, P; Tognetto, M; Trolese, AR | 1 |
| Azad, A; Bolton, D; Davis, ID; Eapen, R; Liew, MS; Sengupta, S; Tafreshi, A | 1 |
| Chen, JH; Ma, GY; Meng, L; Wang, L; Wang, XW | 1 |
| Asna, N; Grisaru, D; Inbar, M; Matcejevsky, D; Safra, T; Shpigel, S; Veizman, A | 1 |
| Momeni, M; Veras, L; Zakashansky, K | 1 |
| Albiges, L; Allory, Y; Bigot, F; Escudier, B; Gachet, J; Massard, C; Méjean, A; Oudard, S; Pécuchet, N; Teghom, C | 1 |
| Aljumaily, R; Gay, HA; Parent, T; Russo, S; Walker, PR; Zhang, J | 1 |
| Fujisawa, M; Inoue, T; Miyake, H; Miyazaki, A; Tanaka, H; Terakawa, T; Yokoyama, N | 1 |
| Alva, A; Daignault, S; Hussain, M; Smith, DC | 1 |
| Lee, HY; Lim, KH; Song, SY | 1 |
| Jiang, Y; Yang, L; Yuan, Z; Zhang, Y; Zhao, Q | 1 |
| Alexandre, J; Coronado, C; Dios, JL; Faivre, S; Fernández-García, EM; Goldwasser, F; Kahatt, CM; Miguel-Lillo, B; Paramio, PG; Raymond, E | 1 |
| Sinha, G | 1 |
| Avan, A; Giovannetti, E; Orsini, V; Peters, GJ; Ruiz, MG; Smit, EF | 1 |
| Brustugun, OT; Grønberg, BH; Lund-Iversen, M; Scott, H; Strøm, EH | 1 |
| Aghajanian, C; Blank, S; Goff, B; Husain, A; Nycum, LR; Wang, Y | 1 |
| Chen, X; Gao, G; He, Y; Li, W; Li, X; Ren, S; Zhang, L; Zhou, C; Zhou, F | 1 |
| Chen, X; Dai, H; Qian, Z; Wang, Y; Xu, X; Zhao, Y | 1 |
| Altimari, A; Di Tullio, P; Fiorentino, M; Giunchi, F; Gruppioni, E; Martorana, G; Pinto, C | 1 |
| Arce-Lara, C; Kelley, MJ; Santana-Davila, R; Szabo, A; Whittle, J; Williams, CD | 1 |
| Hashimoto, Y; Hatakeyama, S; Imai, A; Koie, T; Ohyama, C; Tobisawa, Y; Yamamoto, H; Yoneyama, T | 3 |
| Bootsma, G; Brans, B; Das, M; de Ruysscher, D; Dingemans, AM; Hochstenbag, M; Houben, R; Lambin, P; Reymen, B; van Baardwijk, A; van Belle, A; Wanders, R | 1 |
| Chi, Y; Song, Y; Wang, J; Yang, L; Zhou, A | 1 |
| Archer, V; Burdaeva, O; Delmar, P; Gorbunova, V; Hilton, M; Juhasz, E; Mok, T; Orlov, S; Pallaud, C; Reck, M; Szima, B; Yu, CJ | 1 |
| Hasegawa, Y; Kitamura, C; Kobayashi, K; Miura, D; Sato, N; Suzuki, T | 1 |
| Callahan, MJ; Cobb, B; Cohn, DE; Copeland, LJ; Eisenhauer, EL; Fowler, JM; O'Malley, DM; Salani, R; Sutton, G; Zanagnolo, V | 1 |
| Booth, CM; Mackillop, WJ; Peng, Y; Siemens, DR; Tannock, IF | 1 |
| Brana, I; Calles, A; Calvo, E; de Boer, CJ; LoRusso, PM; Puchalski, TA; Seetharam, S; Tabernero, J; Yee, LK; Zhong, B | 1 |
| Arai, Y; Ito, A; Kaiho, Y; Mitsuzuka, K; Nakagawa, H; Namiki, S; Saito, H; Sato, K; Yamada, S; Yamashita, S | 1 |
| Boku, N; Furuse, J; Ishido, K; Kasuga, A; Machida, N; Morizane, C; Nishina, T; Okusaka, T; Sudo, K; Takahashi, H; Tobimatsu, K; Yamaguchi, T | 1 |
| Aghajanian, C; DeLair, D; Grisham, RN; Hyman, DM; Iasonos, A; Iyer, G; Sala, E; Zhou, Q | 1 |
| Inoue, K; Sonoda, T; Tsubamoto, H | 1 |
| Benson, MC; Danzig, MR; Decastro, GJ; Deibert, CM; Ghandour, RA; McKiernan, JM; Stevenson, SM | 1 |
| Galsky, MD; Gimpel-Tetra, K; Godbold, J; Holcombe, RF; Lee, KM; Lowe, N; Misiukiewicz, K; Oh, WK; Posner, M; Soto, R; Tsao, CK | 1 |
| Al-Massarani, G; Alali, A; Alammar, M; Almalla, N; Altahan, M; Bachour, M; Najjar, F | 1 |
| Attygalle, A; Barton, S; Chau, I; Chua, S; Cunningham, D; Dearden, C; Ethell, M; Gleeson, M; Hawkes, EA; Horwich, A; Peckitt, C; Potter, M; Wotherspoon, A | 1 |
| Cao, J; Huang, XE; Qian, ZY; Shi, L; Wu, XY; Xu, X | 1 |
| Bai, C; Chen, H; Gao, Z; Han, B; Jin, L; Li, Q; Li, X; Lu, D; Qian, J; Shao, M; Song, X; Wang, J; Wang, S; Wu, J; Zhao, X | 1 |
| Beohou, E; Bonnetain, F; Borg, C; Cleau, D; Demarchi, M; Dobi, E; Fein, F; Fiteni, F; Fratté, S; Jary, M; Kim, S; Monnien, F; Nerich, V; Nguyen, T; Pivot, X | 1 |
| Ak, G; Akcay, M; Bayman, E; Etiz, D | 1 |
| Chen, X; Li, W; Li, X; Liu, L; Ren, S; Zhou, C; Zhou, F | 1 |
| Blokzijl, E; Driever, EM; Groen, HJ; Hiltermann, TJ; Kerner, GS; Liesker, JJ; Mertens, MJ; Pieterman, RM; Renkema, TE; van Dullemen, LF; van Putten, JW; Widder, J; Wiegman, EM | 1 |
| Allory, Y; Bouquot, M; Comperat, E; de la Taille, A; Masson-Lecomte, A; Rouprêt, M; Sibony, M; Xylinas, E; Zerbib, M | 1 |
| Amundsen, T; Grønberg, BH; Helbostad, JL; Hjelde, H; Kaasa, S; Stene, GB; Sørhaug, S | 1 |
| King, EG; Kislukhin, G; Long, AD; Walters, KN | 1 |
| Chen, GY; Cheng, Y; Huang, C; Song, Y; Wu, YL; Yan, HH; Yang, JJ; Zhou, Q | 1 |
| Chen, XS; Garfield, DH; Huang, O; Shen, KW; Wu, JY; Yuan, Y | 1 |
| Azim, HA; de Azambuja, E; Piccart, M; Sonnenblick, A | 1 |
| Carlson, RW; Charpentier, E; Danso, MA; Finn, RS; Garcia-Ribas, I; Hellerstedt, B; Miller, KD; Neubauer, M; O'Shaughnessy, J; Richards, P; Robert, N; Rugo, HS; Saleh, M; Schwartzberg, L; Specht, JM; Winer, EP; Yardley, DA | 1 |
| Ai, Z; Lu, B; Sun, L; Xu, J; Yan, X | 1 |
| de Lima, VA; Sørensen, JB | 1 |
| Babacan, NA; Deveci, K; Kacan, T; Sancakdar, E; Seker, A; Seker, MM; Turesin, AK; Yilmaz, A | 1 |
| Mahdi, H; Rizzo, A; Rose, PG | 1 |
| Abali, H; Köse, F; Mertsoylu, H; Muallaoğlu, S; Ozyilkan, O; Sezer, A; Sümbül, AT | 1 |
| Branden, E; Hillerdal, G; Kolbeck, K; Koyi, H | 1 |
| Deng, QH; He, JX; He, YW; Yang, XY; Zeng, J; Zhao, ML | 1 |
| Matsumoto, K; Onda, T; Yaegashi, N | 1 |
| Bergqvist, M; Bergström, S; Brandén, E; Ekman, S; Harmenberg, J; Holgersson, G; Jerling, M; Klockare, M; Koyi, H; Larsson, O; Lundström, KL; Ringbom, M | 1 |
| Bai, C; Cao, S; Chen, H; Chen, J; Dai, J; Han, B; Hu, Z; Jin, G; Li, Q; Lu, D; Ma, H; Shen, H; Shu, Y; Song, X; Sun, C; Tang, S; Wang, C; Wang, S; Wu, J; Xu, L; Yin, R | 1 |
| Ang, MK; Cheah, SL; Fong, KW; Lim, WT; Ng, QS; Ong, WS; Quah, D; Soo, KC; Soong, YL; Tan, D; Tan, SH; Tan, T; Wee, J; Yip, C | 1 |
| Abkevich, V; Carlson, RW; Chang, PJ; Dakhil, SR; Flaherty, PJ; Ford, JM; Goldstein, LJ; Haley, B; Hartman, AR; Head, B; Jensen, KC; Kurian, AW; Lipson, JA; Manola, J; Reid, JE; Schackmann, EA; Sparano, JA; Telli, ML; Timms, K; Vinayak, S; Wapnir, IL | 1 |
| Belderbos, J; De Ruysscher, D; Deasy, JO; Din, S; Dingemans, AM; Houben, R; Lambin, P; Oberije, C; Rimner, A; Uyterlinde, W; van de Heuvel, M | 1 |
| Jamil, K; Jayaraman, A; Subhani, S | 1 |
| Ali-El-Dein, B; Babjuk, M; Burger, M; Chang, SS; Clayman, RH; Daneshmand, S; Efstathiou, JA; Fritsche, HM; Gakis, G; Galland, S; Hrbacek, J; Keegan, KA; Mischinger, J; Morgan, TM; Olugbade, K; Rink, M; Schubert, T; Stenzl, A; Thalmann, GN; Todenhöfer, T; Zaid, HB | 1 |
| Hisada, T; Imai, H; Ishihara, S; Kaira, K; Kuwako, T; Masuda, T; Minato, K; Miura, Y; Mogi, A; Saito, R; Shimizu, K; Sunaga, N; Takise, A; Tomizawa, Y; Yamada, M; Yoshino, R | 1 |
| Abesada-Terk, G; Alemany, C; Brown, RH; Cartwright, TH; Faig, D; Fulp, WJ; Jacobsen, PB; Kim, GP; Lee, JH; Levine, RM; Malafa, M; Markham, MJ; Schreiber, F; Sharp, PV; Tanvetyanon, T | 1 |
| Ahn, H; Hong, B; Hong, JH; Jeong, IG; Kim, YR; Lee, JL; Song, C; You, D | 1 |
| Chen, J; He, LJ; Li, Y; Li, YY; Lou, Y; Wang, LR; Wang, Y; Zhang, GB | 1 |
| Hashimoto, Y; Hatakeyama, S; Imai, A; Koie, T; Ohyama, C; Yoneyama, T | 1 |
| Bai, C; Gao, Z; Han, B; Li, H; Li, Q; Li, X; Liu, W; Lu, D; Ma, K; Qian, J; Wang, H; Wang, J; Wang, S; Wang, X; Wu, J; Wu, W; Zhao, X | 1 |
| Artal, A; Barneto, I; De Castro, J; Esteban, E; Gascó, P; Gasent, JM; Montalar, J; Muñoz-Langa, J; Sanchez, A; Vidal, S | 1 |
| Ichioka, D; Inoue, T; Kageyama, S; Kikuchi, E; Kinoshita, H; Matsui, Y; Mitsuzuka, K; Miyazaki, J; Nishiyama, H; Nomoto, T; Shiraishi, Y; Sugimoto, M; Wakeda, H | 1 |
| Chen, L; Cheng, Y; Fernando, MCL; Han, B; How, SH; Huang, C; Jiang, G; Li, E; Liam, CK; Liang, H; Liu, X; Lu, S; Pan, H; Qin, S; Wu, G; Wu, YL; Xia, F; Zhang, Y; Zhong, Z; Zhou, C; Zhu, Y; Zuo, Y | 1 |
| Al-Massarani, G; Alammar, M; Banat, I; Najjar, F | 1 |
| Berlin, S; Campos, S; Horowitz, N; Krasner, C; Lee, H; Liu, J; Matulonis, U; Obermayer, E; Penson, R; Whalen, C | 1 |
| Ikuta, S; Inoue, K; Sonoda, T; Tani, S; Tsubamoto, H; Yamanaka, N | 1 |
| Han, BH; Jin, B; Lou, YQ; Ren, ZH; Xu, JL; Yang, QZ; Zhou, ZR | 1 |
| Asami, Y; Iiba, M; Kitagawa, R; Kondo, K; Sato, N; Sugita, M; Tadauchi, K; Tsunoda, H; Uenoyama, A | 1 |
| Bassett, R; Champlin, R; Gulbis, AM; Holmberg, L; Jones, RB; Kingham, A; Ledesma, C; Margolin, K; Nieto, Y; Pagliaro, L; Tannir, N; Tu, SM | 1 |
| Arriaga, Y; Courtney, K; Krabbe, LM; Lotan, Y; Margulis, V; Raj, GV; Sagalowsky, AI; Westerman, ME | 1 |
| Aghajanian, C; Blank, SV; Goff, B; Husain, A; Nycum, LR; Wang, YV | 1 |
| Besse, B; Blackhall, F; Brandén, E; de Petris, L; Edsgärd, D; Gréen, H; Hasmats, J; Koyi, H; Kupershmidt, I; Lewensohn, R; Lindgren, A; Lundeberg, J; Peterson, C; Vikingsson, S | 1 |
| Bradley, WH; Eng, KH; Hanlon, BM; Szender, JB | 1 |
| Bokemeyer, C; Oechsle, K; Oing, C; Rink, M; Seidel, C; von Amsberg, G | 1 |
| Feng, YH; Huang, KH; Li, CF; Lin, KL; Shen, KH; Tzeng, WS | 1 |
| Hur, GY; Kang, EJ; Kang, KH; Kim, JS; Lee, SY; Min, KH; Oh, SC; Seo, JH; Shim, JJ | 1 |
| Ceresoli, GL; Zucali, PA | 1 |
| Ahn, SJ; Ban, HJ; Chung, WK; Jeong, JU; Kim, KS; Kim, YC; Kim, YH; Nam, TK; Oh, IJ; Song, JY; Yoon, MS | 1 |
| Apolo, AB; Bajorin, DF; Furberg, HF; Ostrovnaya, I; Regazzi, AM; Rosenberg, JE; Tully, CM; Zabor, EC | 1 |
| An, G; Ma, Y; Wang, J; Wang, Q; Xu, F; Yang, L | 1 |
| Albiges, L; Bellmunt, J; Culine, S; De Santis, M; Flechon, A; Lin, CC; Loidl, WC; Lucas, C; Mourey, L; Necchi, A; Retz, MM; Senkus-Konefka, E; Su, WC; Vaissière, N; Wiechno, PJ | 1 |
| Barton, D; Beck, RM; Brufsky, A; Coleman, RE; Conte, PF; Cortes, J; Glück, S; Harbeck, N; Ko, A; Nabholtz, JM; O'Shaughnessy, J; Renschler, MF; Yardley, DA | 1 |
| Debus, J; Hoffmann, H; Huber, PE; Nicolay, NH; Roeder, F; Safi, S; Sterzing, F; Thieke, C | 1 |
| Adam, J; Bastien, B; Beck, JT; Chouaid, C; Debieuvre, D; Felip, E; Forget, F; Gervais, R; Halluard, C; Kazarnowicz, A; Lacoste, G; Lena, H; Limacher, JM; Losonczy, G; Madroszyk, A; Ottensmeier, C; Palanché, T; Papai, Z; Quoix, E; Szczesna, A; Tavernaro, A; Westeel, V | 1 |
| Chekerov, R; Ismaeel, F; Richter, R; Roots, I; Sehouli, J; Siepmann, T; Woopen, H | 1 |
| Chain, P; Cimino, G; de Vere White, R; Gleasner, C; Henderson, PT; Hu, B; Lin, TY; Malfatti, M; Mcmurry, K; Pan, AW; Pan, CX; Scharadin, TM; Turteltaub, K; Vinall, R; Vuyisich, M; Wang, S; Zhang, H; Zimmermann, M | 1 |
| du Bois, A; Grabowski, JP; Harter, P; Heitz, F; Heitz, J; Kristensen, G; Pfisterer, J; Pujade-Lauraine, E; Ray-Coquard, I; Reuss, A; Traut, A | 1 |
| Fujiwara, K; Hanaoka, T; Hasegawa, K; Iwasa, N; Kurosaki, A; Nagao, S; Nishikawa, T | 1 |
| Cho, BC; Heo, SJ; Jeong, J; Jung, I; Kim, HR; Kim, JH; Lee, CK; Lim, SM; Moon, YW; Shim, HS | 1 |
| Audigier-Valette, C; Auliac, JB; Baize, N; Bérard, H; Bota, S; Chouaïd, C; Corre, R; Dansin, E; Daurès, JP; Decroisette, C; Descourt, R; Dujon, C; Falchero, L; Greillier, L; Lamy, R; Le Caër, H; Léna, H; Marcq, M; Massuti, B; Monnet, I; Pérol, M; Plassot, C; Vergnenègre, A | 1 |
| Brody, JR; Daum, GS; DuHadaway, JB; Dunton, CJ; Furuuchi, N; Huang, YH; Jimbo, M; Leiby, BE; Peng, W; Pirritano, A; Sawicki, JA | 1 |
| Hou, W; Lin, HS; Liu, J; Wang, XQ | 1 |
| Chen, N; Fang, W; Hu, Z; Huang, J; Quan, R; Zhan, J; Zhang, H; Zhang, L; Zhou, T | 1 |
| Aglietta, M; Calogero, R; De Simone, M; Di Renzo, MF; Erriquez, J; Katsaros, D; Mittica, G; Olivero, M; Ponzone, R; Scalzo, MS; Vaira, M; Valabrega, G | 1 |
| Abramian, A; Arden, JM; Ayub, TH; Doeser, A; Hecking, T; Hoeller, T; Kaiser, C; Keyver-Paik, MD; Kuhn, W; Lüders, C; Thiesler, T | 1 |
| Enas, NH; Friberg, LE; Gueorguieva, I; Zecchin, C | 1 |
| Bellmunt, J; Galsky, MD; Giannatempo, P; Grivas, P; Necchi, A; Pond, GR; Raggi, D; Sonpavde, G; Vogelzang, NJ | 1 |
| Anota, A; Bigay-Game, L; Bonnetain, F; Dansin, E; Dauba, J; Debieuvre, D; Fiteni, F; Milleron, B; Molinier, O; Morin, F; Oster, JP; Pichon, E; Poudenx, M; Quoix, E; Souquet, PJ; Westeel, V; Wislez, M; Zalcman, G | 1 |
| Daniel, BR; Eakle, JF; Hainsworth, JD; Lamar, RE; Lane, CM; Ward, PJ; Yardley, DA | 1 |
| Apolo, AB; De Santis, M; Galsky, MD; Leibovich, BC; Milowsky, MI; Pham, MN; Pisters, LL; Siefker-Radtke, AO; Sonpavde, G; Steinberg, GD; Sternberg, CN; Tagawa, ST; Weizer, AZ; Woods, ME | 1 |
| Fan, Y; Lin, NM; Tong, YH; Wang, LL; Weng, X; Yan, YY; Zeng, JM | 1 |
| Gakis, G | 1 |
| Antonia, S; Borghaei, H; Brahmer, JR; Chen, AC; Chow, LQ; Gerber, DE; Gettinger, S; Goldman, JW; Harbison, CT; Hellmann, MD; Juergens, RA; Laurie, SA; Nathan, FE; Rizvi, NA; Shen, Y; Shepherd, FA | 1 |
| Amitani, H; Inui, T; Kubo, K; Kuchiike, D; Mette, M; Nishikata, T; Uto, Y | 1 |
| Anamalai, M; Julka, PK; Kumaran, D; Nambirajan, A; Velu, U | 1 |
| Hashimoto, Y; Hatakeyama, S; Imai, A; Iwabuchi, I; Kawaguchi, T; Koie, T; Murasawa, H; Ogasawara, M; Ohyama, C; Yamamoto, H; Yoneyama, T | 1 |
| Allory, Y; Bastuji-Garin, S; Beuzeboc, P; Chevreau, C; Culine, S; Houédé, N; Le Thuaut, A; Loriot, Y; Pouessel, D; Sevin, E; Taille, A; Vordos, D | 1 |
| Chen, J; Liu, JY; Liu, ZQ; Qian, CY; Wang, Y; Yin, JY; Zheng, Y; Zhou, HH | 1 |
| Chisaki, Y; Terada, T; Yano, Y | 1 |
| Cheah, SL; Chua, ML; Fong, KW; Kusumawidjaja, G; Shwe, MT; Soong, YL; Tan, SH; Tan, TW; Wee, JT | 1 |
| Arpino, G; De Placido, S; Giuliano, M; Schettini, F | 1 |
| Chan, C; Duan, X; Han, W; Lin, W; Poon, C | 1 |
| Penel, N | 1 |
| Bastuji-Garin, S; Brureau, L; Canoui-Poitrine, F; Carvahlo-Verlinde, M; Culine, S; Demery, ME; Fléchon, A; Laurent, M; Paillaud, E; Thuaut, AL | 1 |
| Fujiwara, Y; Goto, K; Horinouchi, H; Hozumi, H; Kanda, S; Kitazono, S; Kubo, E; Mizugaki, H; Nokihara, H; Shiraishi, H; Sunami, K; Tamura, T; Tanaka, A; Utsumi, H; Yamamoto, N | 1 |
| Belau, AK; Bover-Barcelo, I; Canzler, U; Chekerov, R; Gonzalez-Martin, A; Hanker, LC; Harter, P; Hilpert, F; Keil, E; Klare, P; Kurzeder, C; Mahner, S; Meier, W; Petru, E; Reinthaller, A; Richter, R; Sehouli, J; Wimberger, P; Woopen, H; Zeimet, A | 1 |
| Areepium, N; Kumpiro, S; Sriuranpong, V | 1 |
| Juszczak, M; Paschke, L; Slupski, M | 1 |
| Airhart, S; Chamie, K; Cimino, GD; de Vere White, R; Drakaki, A; Haack, K; Henderson, PT; Lin, TY; Malfatti, M; Ognibene, T; Pan, CX; Tepper, CG; Turteltaub, KW; Wang, SS; Yang, H; Zhang, H; Zimmermann, M | 1 |
| Fukushi, K; Hashimoto, Y; Hatakeyama, S; Imai, A; Koie, T; Matsumoto, T; Narita, T; Ohyama, C; Soma, O; Tobisawa, Y; Yamamoto, H; Yoneyama, T | 1 |
| Chang, CL; Chen, JH; Chen, TM; Lai, MT; Lee, FP; Lin, KC; Wu, CC; Wu, SY; Yen, YC; Yuan, KS | 1 |
| Du, X; Li, X; Liu, N; Sheng, X; Wang, F; Yu, H | 1 |
| Chen, Y; Gao, L; Hong, C; Hong, Y; Jin, Y; Lu, L; Mao, G; Qin, Z; Su, D; Wei, Y; Wu, G; Ye, X; Yuan, G; Zhao, T; Zhou, H; Zhou, Y | 1 |
| Chisaki, Y; Nakamura, N; Yano, Y | 1 |
| Arenare, L; Bergamini, A; Cecere, SC; Della Pepa, C; Di Napoli, M; Facchini, G; Gargiulo, P; Mangili, G; Pignata, S; Pisano, C; Rossetti, S; Tambaro, R | 1 |
| Booth, CM; Mackillop, WJ; Robinson, AG; Vera-Badillo, FE; Wei, X | 1 |
| Amundsen, T; Grønberg, BH; Hjelde, HH; Kaasa, S; Kristensen, A; Solheim, TS; Sørhaug, S | 1 |
| Bhosale, P; Dalton, HJ; Fleming, ND; Gershenson, DM; Schmeler, KM; Sun, CC | 1 |
| Guan, X; Song, W; Tang, L; Wang, S; Xie, H; Xu, J; Xu, Y; Zhang, W | 1 |
| Alanee, SR; Bajorin, DF; Garcia-Grossman, IR; Littman, J; Offit, K; Ostrovnaya, I; Pendse, DV; Regazzi, AM; Shah, S; Vijai, J; Zabor, EC | 1 |
| Albrecht, T; Michalik, K; Nolte-Ernsting, C; Pereira, PL; Pützler, M; Schicho, A; Stroszczynski, C; Wiggermann, P | 1 |
| Abrahams, L; Ahmad, GT; Ajakaiye, AM; Alatsatianos, M; AlHumaidi, AS; Ashmore-Harris, C; Bahsoun, B; Baines, AJ; Blackburn, E; Cinatl, J; Clark, I; Dura, UK; Fixmer, CN; Garrett, MD; Gourlay, CW; Griffin, DK; Gullick, WJ; Hargreaves, E; Hogwood, CE; Howard, MJ; Ike-Morris, C; Lithgow, PE; Lloyd, DR; Mato Prado, M; Mccullough, D; Michaelis, M; Mishra, S; Rossman, JS; Rothweiler, F; Rowe, M; Saintas, E; Schöler, KM; Smales, CM; Timur, H; Tsaousis, AD; von der Haar, T; Wass, MN; Williamson, MD; Yiangou, L; Zehner, R | 1 |
| Fukushi, K; Hashimoto, Y; Hatakeyama, S; Koie, T; Narita, T; Ohyama, C; Tobisawa, Y; Yamamoto, H; Yoneyama, T | 1 |
| Huang, J; Li, Z; Shen, X; Wang, Y; Zhi, Q; Zhou, J | 1 |
| An, X; Deng, YF; Jiang, WQ; Li, LR; Shao, C; Shi, YX; Sun, P; Thomas, R; Xue, C; Yang, W | 1 |
| Mahdi, H; Maurer, K; Michener, C; Rose, PG | 1 |
| Fong, KW; Hussain, A; Ong, WS; Sommat, K; Soong, YL; Tan, T; Wee, J | 1 |
| Anile, G; Banna, GL; Castaing, M; Conte, P; Dieci, MV; Guarneri, V; Lal, R; Marletta, F; Nicolosi, M; Parra, HJS; Strano, S | 1 |
| Fujita, N; Hamano, I; Hashimoto, Y; Hatakeyama, S; Hosogoe, S; Iwamura, H; Koie, T; Kusaka, A; Ohyama, C; Tobisawa, Y; Yamamoto, H; Yoneyama, T | 1 |
| Bai, C; Feng, J; Gao, B; Hua, D; Huang, J; Jian, H; Li, W; Lu, S; Ma, S; Ma, Z; Pan, H; Qin, S; Song, Y; Tao, M; Yu, Y; Zhu, H | 1 |
| Arenare, L; Bergamini, A; Bologna, A; Breda, E; Bryce, J; Cecere, SC; Cinieri, S; Cormio, G; Daniele, G; Di Napoli, M; Ferrandina, G; Gallo, C; Lorusso, D; Mangili, G; Murgia, V; Natale, D; Perrone, F; Piccirillo, MC; Pignata, S; Pisano, C; Raspagliesi, F; Sacco, C; Salutari, V; Scambia, G; Signoriello, S; Sorio, R; Vergote, IB; Wagner, U | 1 |
| Behera, UC; Modi, RR; Sheth, J; Singh, A | 1 |
| Kai, M; Kubo, M; Nakamura, M; Yamada, M; Yamamoto, H | 1 |
| Arkenau, HT; Blackhall, F; Califano, R; Dean, E; Dymond, AW; Ghiorghiu, D; Greystoke, A; Hossack, S; Lindsay, CR; Md Haris, N; Plummer, R; So, K; Steele, N; Summers, Y; Voskoboynik, M | 1 |
| Bonetti, A; Giuliani, J | 1 |
| Barone, C; Bassi, P; Cassano, A; Marandino, L; Monterisi, S; Nazzicone, G; Orlandi, A; Pierconti, F; Racioppi, M; Rossi, E; Schinzari, G | 1 |
| Abe, H; Kamai, T; Kobayashi, M; Mizuno, T; Nishihara, D; Nukui, A; Sakamoto, K; Suzuki, I; Takei, K; Tokura, Y; Uematsu, T; Yamaguchi, Y | 1 |
| Hisada, T; Kaira, K; Kawashima, O; Miura, Y; Saito, R; Sakurai, R; Sunaga, N; Tomizawa, Y; Tsurumaki, H; Yamada, M; Yoshii, A | 1 |
| Li, SY; Lin, XQ; Liu, YQ; Ouyang, M; Qin, YY; Xie, ZH; Zhang, DH; Zhang, JX; Zhou, CZ | 1 |
| Jensen, AB; Knoop, A; Langkjer, ST; Rosvig, LH | 1 |
| Aktas, B; Bangemann, N; Braun, M; Christgen, M; Clemens, M; Forstbauer, H; Gluz, O; Grischke, EM; Hackmann, J; Harbeck, N; Kates, R; Kohls, A; Kreipe, HH; Kuemmel, S; Liedtke, C; Lindner, C; Nitz, U; Potenberg, J; Schumacher, C; Schumacher, J; Staib, P; Uleer, C; von Schumann, R; Warm, M; Wuerstlein, R | 1 |
| Bell-McGuinn, K; Cristea, M; Fleming, GF; Gray, HJ; Luo, Y; Martin, LP; McKee, MD; Munasinghe, W; Sullivan, D; Xiong, H | 1 |
| Jiang, L; Lee, SC; Ng, TC | 1 |
| Borgmann, H; Cebulla, A; Dogan, S; Frank, T; Hennig, M; Hofbauer, SL; Klatte, T; Kramer, M; Merseburger, AS; Salem, J; Struck, JP | 1 |
| Brustugun, OT; Grønberg, BH; Lund-Iversen, M; Scott, H; Strøm, EH; Theiss, N | 1 |
| Chen, H; Cohen, HJ; Edelman, MJ; Feliciano, JL; Gajra, A; Hurria, A; Jatoi, A; Lafky, J; Le-Rademacher, JG; Lilenbaum, R; Maggiore, R; McMurray, RP; Muss, HB; Wong, ML; Zemla, TJ | 1 |
| Agócs, L; Döme, B; Fábián, K; Fillinger, J; Kajdácsi, Z; Moldvay, J; Pipek, O; Reiniger, L; Rojkó, L; Szállási, Z; Téglási, V; Tímár, J; Vágvölgyi, A | 1 |
| Kawamata, O; Murata, T; Uda, M | 1 |
| Chen, H; Cohen, HJ; Edelman, MJ; Feliciano, JL; Gajra, A; Hurria, A; Jatoi, A; Le-Rademacher, JG; Lilenbaum, R; McMurray, R; Muss, H; Zemla, T | 1 |
| Ali, H; Barton, D; Bengala, C; Brufsky, A; Coleman, R; Conte, P; Cortes, J; de la Cruz-Merino, L; Eakel, J; Glück, S; Harbeck, N; Li, H; Miller, J; O'Shaughnessy, J; Schneeweiss, A; Shtivelband, M; Wilks, S; Yardley, DA; Young, R | 1 |
| Bianchi, G; Capri, G; Cona, MS; de Braud, F; Ferrari, B; Huber, V; Maggi, C; Manoukian, S; Mariani, G; Mennitto, A; Milano, M; Prisciandaro, M; Rinaldi, L; Rivoltini, L; Vernieri, C | 1 |
| Hasanov, M; Hernandez, CMR; Konoplev, SN | 1 |
| Fløtten, Ø; Grønberg, BH; Kristensen, A; Solheim, TS | 1 |
| Deshpande, H; Donadio, A; Hurwitz, ME; Kelly, WK; Markowski, P; Mehnert, JM; Mortazavi, A; Patel, J; Petrylak, DP; Stein, MN; Yao, X | 1 |
| Kim, HS; Seo, HK | 1 |
| Berkowitz, RS; Bonventre, JV; Crum, CP; D'Andrea, AD; Decker, B; Do, KT; Feltmate, CM; Hill, SJ; Horowitz, NS; Kochupurakkal, BS; Konstantinopoulos, PA; Liu, JF; Matulonis, UA; Morizane, R; Muto, MG; Nguyen, H; Nucci, MR; Roberts, EA; Shapiro, GI; Swisher, EM; Worley, MJ; Yang, C | 1 |
| Apolo, AB; Chowdhury, S; Galsky, MD; Hahn, NM; Merseburger, AS; Milowsky, MI; Petrylak, D; Powles, T; Quinn, DI; Rosenberg, JE; Siefker-Radtke, A; Sonpavde, G; Sternberg, CN | 1 |
| Bahl, C; Behera, D; Sharma, S; Singh, N | 1 |
| Adamowicz, K; Janiszewska, J; Lichodziejewska-Niemierko, M | 1 |
| Hashimoto, A; Ichikawa, H; Inui, Y; Ito, M; Kakiuchi, S; Kawamoto, S; Kurata, K; Matsuoka, H; Minami, H; Miyata, Y; Mizutani, Y; Nagao, S; Okuni, M; Saito, Y; Sakai, R; Shinzato, I; Suto, H; Tanaka, Y; Uehara, K; Yakushijin, K; Yamamoto, K | 1 |
| Appius, A; Button, P; Hooper, G; Lee, V; Liam, CK; Lu, S; Mok, T; Palma, JF; Park, K; Schulze, K; Scudder, S; Shames, DS; Srimuninnimit, V; Wang, J; Wu, YL; Yin, AY; Zhang, G; Zhou, C | 1 |
| Cao, S; Han, B; Teng, J; Xu, J; Zhong, H | 1 |
| Aldrich, JD; Overman, MJ; Raghav, KPS; Varadhachary, GR; Wolff, RA | 1 |
| Galsky, MD; Gore, JL; Holt, SK; Ramos, JD; Schade, GR; Wright, JL; Yu, EY | 1 |
| Ben, XS; Chen, GY; Chen, HJ; Cheng, Y; Huang, C; Jiang, BY; Song, Y; Wang, BC; Wang, Z; Wu, YL; Xu, CR; Yan, HH; Yang, JJ; Zhou, Q | 1 |
| Burges, A; Colomban, O; Du Bois, A; Freyer, G; Hardy-Bessard, AC; Kurzeder, C; Leary, A; Lortholary, A; Péron, J; Pfisterer, J; Ray-Coquard, I; Tod, M; You, B | 1 |
| Bellmunt, J; Rodriguez-Vida, A | 1 |
| André, F; Cortés, J; Dent, R; Deurloo, R; Easton, V; Gonçalves, A; Kümmel, S; Martín, M; Pollex, E; Schmid, P; Schuetz, F; Swain, SM | 1 |
| Alba, E; Awada, A; Bonnefoi, H; Charpentier, E; Coudert, B; Diéras, V; Emmons, GT; Garcia-Ribas, I; Gligorov, J; Jager, A; Lindeman, GJ; Paridaens, R; Pivot, X; Verweij, J; Zambelli, S | 1 |
| Ahmad, M; Akhlaq, M; Danish, Z; Saeed, H; Saleem, Z; Sattar, S | 1 |
| Levy, BP; Parisi, M; Patterson-Lomba, O; Signorovitch, JE; Xiang, CQ; Yang, H | 1 |
| Batteson, R; de Wit, R; Grivas, P; Keefe, S; Li, H; Meng, Y; Patterson, K; Pellissier, J; Prabhu, V; Xu, R; Zarabi, N; Zhong, Y | 1 |
| Bracco, OL; Frenkl, T; Freshwater, T; Keefe, S; Li, H; Li, M; Perini, R; Valiathan, C | 1 |
| Hikita, K; Honda, M; Iwamoto, H; Kimura, Y; Morizane, S; Nishikawa, R; Takenaka, A; Teraoka, S; Yumioka, T | 1 |
| Arcieri, M; Ergasti, R; Fagotti, A; Marchetti, C; Palluzzi, E; Pietragalla, A; Rosati, A; Scaletta, G; Scambia, G | 1 |
| Guan, H; Liu, G; Sheng, Y; Shi, L; Xie, F | 1 |
| Apellániz-Ruiz, M; Björn, N; Brandén, E; de Petris, L; Gréen, H; Koyi, H; Lewensohn, R; Lundeberg, J; Pradhananga, S; Rodríguez-Antona, C; Sigurgeirsson, B; Svedberg, A | 2 |
| Bell, R; Bell-McGuinn, K; Buderath, P; Campbell, R; Farrington, DL; Fiorica, J; Golden, L; Hamilton, A; Heitz, F; Lee, CM; Moore, KN; Pitou, C; Powell, M; Sehouli, J; Teneriello, M; Vergote, I; Wenham, RM; Zhang, W | 1 |
| Alvarez Secord, A; Armstrong, DK; Azab, M; Banerjee, S; Basu, B; Birrer, MJ; Blagden, SP; Braly, P; Fleming, GF; Ghamande, S; Hall, GD; Hao, Y; Hirte, HW; Jueliger, S; Keer, H; Kristeleit, R; Markham, MJ; Matei, D; Matulonis, UA; McGuire, WP; Naim, S; Nemunaitis, J; Nephew, KP; Oganesian, A; Oza, AM; Provencher, DM; Roman, LD; Schwartz, B | 1 |
| Biasoni, D; Bisogno, G; Boldrini, R; Conte, M; Crocoli, A; D'Angelo, P; Dall'Igna, P; De Pasquale, MD; Inserra, A; Miele, E; Siracusa, F; Spreafico, F; Terenziani, M | 1 |
| Abdel Karim, N; Aljohani, HM; Bahassi, EM; Eldessouki, I; Gaber, O; Morris, J | 1 |
| Sridhar, SS | 1 |
| Bi, J; Chen, S; Diao, C; Dong, Y; Fan, H; Fan, W; Feng, Q; Geng, D; Han, X; Huang, G; Li, F; Li, G; Li, P; Li, Q; Li, T; Li, W; Li, Y; Liu, B; Meng, M; Meng, Q; Ni, Y; Ren, H; Sheng, L; Sun, D; Sun, L; Sun, W; Sun, Y; Tian, H; Wang, C; Wang, J; Wei, Z; Xu, X; Xu, Y; Xue, G; Yang, X; Ye, X; Yu, G; Zhang, B; Zhang, K; Zhang, L; Zheng, A; Zou, Z | 1 |
| Chen, J; Fan, Y; He, T; Li, W; Liu, Y; Wang, Q; Wang, Y; Wang, Z | 1 |
| Chen, H; Li, J; Liang, X; Pu, X; Shen, T; Song, Z; Wang, L; Wang, W; Xu, C; Yu, Z; Zhang, Y | 1 |
| Bun, S; Kato, MK; Kato, T; Miyasaka, N; Shimoi, T; Tamura, K; Yonemori, K; Yunokawa, M | 1 |
| Basch, E; Dueck, A; Johansen, C; Lindberg, H; Pappot, H; Taarnhøj, GA | 1 |
| Akamine, S; Ebi, N; Ichiki, M; Matsumoto, T; Nakanishi, Y; Takayama, K; Tokunaga, S; Uchino, J; Yamada, T | 1 |
| Fujiwara, Y; Goto, Y; Horinouchi, H; Kanda, S; Nokihara, H; Ohe, Y; Tamura, T; Yamamoto, N; Yamamoto, T | 1 |
| Abbasnezhad, A; Abd El-Ghafar, OA; Abhilash, L; Abouzid, KAM; Achberger, AM; Ackerman, S; Akhatayeva, Z; Akin, D; Al-Kaysi, RO; Alakhdar, AA; Alame, M; Aleksic Sabo, V; Alinezhadbalalami, N; Allen, JD; Alonso, JM; Alqatani, S; Alsayed, B; Álvarez Larraondo, M; Alvarez, M; Amini, SB; An, Z; Anasir, MI; Anderson, GH; Andremont, A; Andrés, S; Angel, S; Anigboro, AA; Anini, Y; Antonides, CFJ; Arafa, K; Arafa, RK; Aryal, UK; Asbaghi, O; Assefa, MK; Atyah, M; Avwioroko, OJ; Ayora-Talavera, G; Azpilikueta, A; Azyazov, VN; Ba, YF; Bachmann, KF; Badoual, J; Bae, SJ; Baek, SH; Bahrami, B; Bai, J; Baid-Agrawal, S; Bailey, MR; Baillie, JK; Balani, N; Balcar, VJ; Banica, T; Banks, L; Barb, J; Bardeen, CJ; Barrett, HE; Bartnikowski, N; Bashir, R; Battaglia, M; Bautista-Hernández, V; Becker, B; Beekman, FJ; Benidir, M; Benjelloun, M; Bentley, RF; Bergé, J; Berger, D; Bernsen, MR; Berraondo, P; Bhattacharya, R; Bhayani, SB; Bi, W; Bi, X; Bi, YL; Bi, Z; Bian, K; Biesecker, LG; Billadeau, DD; Blaszczyk, R; Blum, JL; Boachie, R; Boelte, K; Bogers, AJJC; Boileau, I; Bonduelle, C; Bonny, O; Bonsu, JM; Boos, LA; Borges-Argáez, R; Bouchard, PA; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, E; Boyle, AJ; Branigan, D; Briones, S; Broniowska, KA; Brossas, JY; Brown, WA; Brzezinska, J; Buitron, G; Burnier, M; Bursulaya, B; Burton, PR; Bush, AA; Busuttil, RW; Cabello-Aguilar, S; Cáceres-Farfán, M; Cacheux, V; Caffrey, PJ; Cai, B; Cai, Q; Cai, S; Cai, Y; Calders, P; Cammarota, G; Campbell, DA; Cancelli, C; Cao, Q; Cao, WH; Cao, X; Capet, M; Capoluongo, E; Carey, ME; Carnero, M; Carrasco, LI; Carreno, J; Carrillo-Reyes, J; Casini, I; Cassar, M; Catalan, G; Cattamanchi, A; Cazares-Granillo, M; Celie, B; Cen, YK; Cena, H; Cerbo, RM; Ceron, E; Cetina-Montejo, L; Chaâbane-Banaoues, R; Chabanet, C; Chace-Donahue, F; Chalfun-Júnior, A; Chan-Balan, R; Chang, CS; Chen, CS; Chen, D; Chen, J; Chen, L; Chen, PN; Chen, Q; Chen, S; Chen, W; Chen, WP; Chen, X; Chen, Z; Cheng, H; Cheng, J; Cheng, Q; Cheng, T; Chi, T; Chianelli, D; Chieppa, M; Child, CJ; Cho, JH; Cho, JY; Chogtu, B; Choi, GH; Choi, J; Choi, M; Choi, NG; Cholu, CO; Chow, ES; Chowdhury, AH; Chu, PC; Chu, Q; Chu, S; Chua, H; Chung, T; Chunyan, L; Church, JS; Civardi, E; Cobiella, J; Colinge, J; Collado, CJ; Collins, TJ; Cong, LM; Conkrite, KL; Cope, SJ; Corbett, JA; Cornet, M; Cornillot, E; Corvaisier, S; Costes-Martineau, V; Courtioux, B; Coussens, M; Covino, M; Criado, A; Cui, J; Cui, Y; Cunitz, BW; Curry, AE; Cussó, L; D'Urzo, AD; D'Urzo, KA; Dabbous, S; Dahlgren, RA; Dai, H; Dai, T; Dai, W; Dalinghaus, M; Dang, S; Davalos, RV; Davidson, H; de Andrea, CE; De Angelis, M; de Blois, E; de Carvalho, PA; De Clercq, E; De Giuseppe, R; de Jong, M; De Langhe, S; De Oliveira, L; de Souza Pinto Lemgruber, R; de Souza, LB; de Swart, J; De Wandele, I; de Woestijne, PCV; Delaney, S; Delorme, M; Delvenne, P; Deng, L; Deng, Z; Denkinger, CM; der Meulen, MHV; Deraeve, C; Desco, M; DeSilva, S; Destere, A; Dhali, A; Di Ciano, P; Dias-Santagata, D; Diskin, SJ; Djè, MK; Doddipatla, S; Doerr, AJ; Dokla, EME; Domiciano, D; Domingo, N; Dong, C; Dong, J; Dong, Q; Dong, S; Dong, X; Dong, Z; Douair, I; Douglas, TA; Doyle, SM; Drain, PK; Du, K; Du, L; Du, Q; Du, S; Duan, C; Duan, H; Duan, J; Duan, S; Duan, W; Dueluzeau, R; Dukic, L; Dunmire, BL; Duvauchelle, T; Dymek, B; Dzwonek, K; Earnest, A; Eckardt, KU; El Ghadraoui, L; El Massoudi, S; Elloumi, F; Elnour, IE; Embarak, S; Ende, M; England, K; Enikeev, D; Enyedy, I; Epple, R; Erickson, GE; Eriksson, J; Erndt-Marino, J; Errachidi, F; Etxeberria, I; Evan, AP; Fairlamb, AH; Falahi, E; Fan, CC; Fan, H; Fan, M; Fan, MZ; Fan, S; Fan, Y; Fang, CS; Fang, J; Fang, X; Fang, Z; Farmany, A; Farooqi, A; Farouk, HO; Fazelipour, S; Feng, D; Feng, J; Feng, JX; Feng, YL; Ferraz, SL; Ferreira, CR; Figenshau, RS; Finn, AV; Fiseha, T; Fleischer, AS; Fogleman, AD; Fontaine, O; Ford, CR; Fouladvand, F; Four, M; Fousteri, G; Francis, JR; Fraser, JF; Frazier, RP; Fu, H; Fu, P; Fu, YJ; Fujishima, A; Fuster, V; Gabilan, JC; Gagliani, N; Gai, QY; Galán-Arriola, C; Gale, P; Galimova, GR; Galkin, A; Gallo, A; Gallo, AA; Gang, DD; Ganschow, S; Gao, C; Gao, F; Gao, GP; Gao, H; Gao, K; Gao, M; Gao, MY; Gao, P; Gao, R; Gao, S; Gao, WJ; Gao, Y; Garbacz, P; García Ruiz, L; Garcia, EM; Garofoli, F; Gasbarrini, A; Gattinoni, L; Gaudig, M; Gbureck, U; Ge, X; Genko, N; Gentile, GL; George, MW; Gerety, GF; Gestwicki, JE; Geusens, PP; Ghassemi, M; Giardina, JD; Giebultowicz, JM; Gifford, CA; Gijsen, FJH; Gilfillan, R; Gilson, E; Gingl, K; Giuliano, C; Glybochko, P; Goessler, W; Gofflot, S; Golab, J; Goldstein, A; Golebiowski, A; Gómez, L; Gómez-Carballo, J; Gonçalves, PEO; Gonzales, R; Gonzalez-Cotto, M; González-Fernández, D; Gonzalez-Lopez de Turiso, F; Goodman, JM; Govinda Raju, S; Grimm, J; Gross, AJ; Gruenheid, S; Gu, C; Gu, FF; Gu, S; Gu, Z; Guest, RL; Gui, C; Gui, J; Guillem, A; Guo, G; Guo, L; Guo, Q; Guo, S; Guo, SW; Guo, W; Guo, Y; Guo, YG; Guo, Z; Guretzky, JA; Haenggi, M; Hahn, MS; Hakkola, J; Halim, AA; Hampel, D; Han, B; Han, BH; Han, D; Han, G; Han, J; Han, LZ; Han, R; Han, S; Han, X; Han, Z; Handley, MA; Hanke, I; Hannongbua, S; Hao, P; Happ, JT; Hara, M; Haraux, F; Hare, JL; Harper, JD; Hartley, AM; Harvey, E; Hashimoto, K; Hassan, HM; Hautajärvi, H; Hayton, TW; He, C; He, H; He, HJ; He, WP; He, Y; He, Z; Hedrick, V; Heffernan, JK; Hegrová, J; Heidarimoghadam, R; Helms, K; Hengphasatporn, K; Henry, D; Herrmann, TRW; Hesson, T; Himmelbauer, MK; Hindle, A; Hoffmann, R; Hogg, N; Hong, KB; Hong, SK; Honjol, Y; Hood, C; Hsi, RS; Hsu, JL; Hu, B; Hu, BC; Hu, D; Hu, H; Hu, J; Hu, K; Hu, M; Hu, MK; Hu, T; Hu, W; Hu, Y; Hu, Z; Hua, S; Huang, H; Huang, J; Huang, L; Huang, M; Huang, P; Huang, X; Huang, Y; Huang, Z; Hukkanen, J; Hung, MC; Huo, X; Hyötyläinen, T; Ianiro, G; Ibanez, B; Imran, M; Ireland, S; Irwin, MS; Ishiguro, H; Jackowski, K; Jackson, C; Jacob, SI; Jahromy, MH; Jakob, SM; Jang, J; Javvaji, PK; Jefferson, KK; Jena, P; Ji, H; Jiang, F; Jiang, GH; Jiang, H; Jiang, J; Jiang, X; Jiang, Z; Jiao, J; Jiménez, A; Jin, X; Jincai, W; Jintao, X; Jo, K; Jofra, T; Johari, Y; Johnson, ACM; Jones, JH; Josephine Fauci, A; Juhl, AK; Jun, S; Kaiser, RI; Kajioka, J; Kajiyama, H; Kalliyil, A; Kalthur, SG; Kamalanathan, M; Kamaldinov, T; Kanaani, L; Kang, D; Kang, J; Kang, S; Känsäkoski, P; Kaplan, DL; Karwan, M; Kasibhatla, S; Kaur, A; Kawazoe, Y; Ke, C; Keyser, J; Khalique, A; Khan, IT; Kharshoum, RM; Kher, R; Kherani, J; Ki, KK; Kikkawa, F; Kikkawa, R; Kim, BT; Kim, EH; Kim, GA; Kim, GD; Kim, HB; Kim, HG; Kim, JS; Kim, MJ; Kim, SI; Kim, SJ; Kim, Y; King, K; Kinyamu-Akunda, J; Kirkkala, T; Kjaer-Sorensen, K; Kleppinger, EL; Kloner, RA; Klopfenstein, TJ; Knappe, D; Knezevic, P; Kobos, LM; Kohli, M; Kolano, L; Kolodgie, FD; Kolte, AP; Koneru, B; Kong, D; Kong, F; Kong, X; Konggidinata, MI; Köpke, M; Koski, KG; Kotsis, F; Köttgen, A; Kouakou-Kouamé, CA; Kraemer, US; Krane, V; Krehbiel, CR; Krenning, BJ; Kretzschmar, D; Ku, KB; Kubota, Y; Kulich, P; Kumar, NG; Kupiec-Weglinski, JW; Lalani, SS; Lan, X; Landfeldt, E; Langenberg, E; Lapauw, B; Larkin, J; Lassoued, MA; Laukhtina, E; Laura Martinez, J; Laveillé, A; Lavela, P; Law, AD; Lazraq, A; Le Foll, B; Lee, BK; Lee, C; Lee, CS; Lee, EJ; Lee, EY; Lee, G; Lee, HY; Lee, JH; Lee, JJ; Lee, JO; Lee, JS; Lee, R; Lei, H; Lei, P; Lellouche, F; Lennerz, JK; Leong, W; Leslie, I; Lessem, E; Levin, M; Levinger, I; Li, C; Li, CW; Li, CX; Li, CY; Li, D; Li, H; Li, HM; Li, J; Li, L; Li, LM; Li, N; Li, S; Li, W; Li, X; Li, XX; Li, Y; Li, Z; Li, ZL; Li, ZX; Lian, Q; Liang, C; Liang, GH; Liang, H; Liang, J; Liang, X; Liao, CX; Liao, R; Ličbinský, R; Lim, YS; Lima, HK; Lin, JG; Lin, L; Lin, S; Lin, WP; Lin, Z; Liso, M; Liu, BX; Liu, C; Liu, H; Liu, J; Liu, M; Liu, Q; Liu, S; Liu, SF; Liu, SL; Liu, T; Liu, W; Liu, X; Liu, XB; Liu, Y; Liu, YY; Liu, Z; Liu, ZQ; Lobo, M; Loitzenbauer, M; López, F; Lopez, G; López, GJ; Lou, Z; Lu, IC; Lu, J; Lu, M; Lu, W; Lu, X; Lu, Y; Luhovyy, BL; Luna-Abanto, J; Luo, J; Luo, K; Luo, L; Luo, M; Luo, W; Luo, X; Luo, XM; Lv, Y; Lv, YQ; Lyu, HD; Lyu, J; Ma, C; Ma, G; Ma, L; Ma, Q; Ma, X; Ma, Y; Macha, SJ; MacLean, E; Mahalapbutr, P; Maina, T; Malfait, F; Malfertheiner, MV; Malzert-Fréon, A; Mansouri, E; Mao, C; Marcellin, E; Marchiori, PER; Marcotte, DJ; Maréchal, A; Maric, N; Maris, JM; Maron, L; Marti, CN; Martínez-Milla, J; Mateo, J; Mather, K; Mathison, CJN; Matthay, MA; Maxwell, CL; Mazier, D; Mazumder, D; Mazurkiewicz, M; Mazzucchelli, TG; McAuley, DF; Mccoy, K; McVicar, DW; Mebel, AM; Mech, A; Meester, EJ; Meiselbach, H; Melero, I; Ménard, G; Meng, X; Mengya, Y; Merle, G; Meunier, B; Mfarrej, B; Mi, K; Migueliz, I; Mikuška, P; Miladi, K; Miletich, R; Millar, JE; Mills, MR; Milne, R; Minute, L; Misiak, M; Mo, F; Modi, A; Mok, F; Molina, C; Mollen, CJ; Molteni, V; Montalto, M; Montet, D; Monti, MC; Moor, MB; Moravec, P; Morsiani, C; Murillo, E; Murugan, P; Muslem, R; Myers, RK; N'guessan, FK; Nabil, H; Nadal, J; Nadeem, M; Nafady, MM; Nafie, MS; Nair, HP; Nakano, R; Nance, J; Naren, N; Neil, CJ; Nelson, J; Nery, FC; Netsch, C; Nguyen, TH; Ni, L; Ni, YX; Nie, W; Nielsen, LK; Nigam, K; Nikolayev, AA; Nishiyama, M; Niu, LL; Niu, PP; Nock, BA; Noer, PR; Noll, G; Noll, S; Norenberg, JP; Nowicka, J; Nutho, B; O'Connor, M; Obonyo, NG; Ochiai, T; Ochoa, MC; Oh, BL; Oh, S; Olczak, J; Olivares, X; Ommurugan, B; Oosthuizen, MC; Operario, D; Orešič, M; Oshima, K; Otano, I; Ou, Y; Owen, TW; Oxvig, C; Pacey, V; Pai, M; Paik, H; Paiva, R; Palmieri, EM; Palpant, N; Pan, L; Pan, Q; Panahi, S; Pang, B; Pang, ZC; Pannecouque, C; Paris, L; Park, D; Park, DJ; Park, E; Park, EC; Park, IH; Park, JH; Park, JI; Park, S; Passmore, MR; Pattaranggoon, NC; Paun, M; Pedersen, S; Pedron, J; Peng, M; Peng, X; Penzhorn, BL; Pérez-Camargo, D; Perez-Maldonado, R; Pérez-Vicente, C; Pham, TD; Pickering, L; Pickersgill, NA; Pinault, E; Pinotsis, N; Plan, M; Pocino, K; Poh, CL; Pons, EDC; Popoff, MR; Porri, D; Pourmand, A; Pratviel, G; Prudente, DO; Qi, H; Qi, N; Qian, LY; Qiao, L; Qiao, Q; Qin, QP; Qiu, N; Qiu, SW; Qu, F; Quan, M; Quigg, A; Raee, E; Raibaud, P; Ramanitrahasimbola, D; Rapoport, L; Rasby, RJ; Rasoanirina, BNV; Raspini, B; Ratner, JR; Razafindrakoto, Z; Redd, MA; Ren, H; Ren, N; Rey, J; Reynolds, CP; Rich, PR; Richards, CJ; Rigol, M; Rimoldi, S; Robert, P; Rodrigues, AE; Roe, JH; Rohde, S; Rokita, JL; Roland, J; Rombaut, L; Ronkainen, J; Rothenberg, SM; Roy, SC; Ruan, Z; Rucker, PV; Rueda, D; Ruhwald, M; Rungrotmongkol, T; Rupert, AS; Rusjan, P; Ryabov, AD; Rysä, J; Saad, NES; Sabioni, P; Sadow, PM; Sahai, N; Salem, HF; Salinas, B; Salonurmi, T; Samé Guerra, D; Sánchez, J; Sanchez-González, J; Sanmamed, MF; Sansores-Peraza, P; Santoro, JC; Santschi, PH; Saritas, T; Sarkisova, Y; Savolainen, MJ; Scherberich, JE; Schlom, DG; Schmelz, EM; Schmid, MC; Schneider, MP; Schumacher, S; Schwartz, JC; Schwartzer, JJ; Schwehr, K; Schweitzer, DH; Scott, ME; Sedky, NK; See Hoe, L; Sejian, V; Selvaraju, S; Sen, SK; Seo, G; Šerý, O; Settles, JA; Sfar, S; Shaffer, J; Shan, GL; Shang, Q; Shannahan, JH; Shao, B; Shao, H; Shao, J; Shao, ZH; Shasha, Y; Shaw, K; Sheeba, V; Shekar, K; Shen, G; Shen, H; Shen, XD; Shen, Y; Sherrell, PC; Shete, PB; Shi, AX; Shi, J; Shi, JH; Shi, S; Shi, X; Shigeta, Y; Shimbo, A; Shin, E; Sikka, N; Silhavy, TJ; Simanon, N; Simard, S; Simon, J; Simon, M; Simpson, SD; Simundic, AM; Since, M; Singh, B; Singhroy, DN; Sinisterra, OT; Smith, EH; Sobreira, TJP; Solanes, N; Somasundar, Y; Sommerer, C; Sonei, A; Song, B; Song, E; Song, J; Song, M; Song, Y; Soo Lee, M; Sorensen, MD; Sournia-Saquet, A; Spaepen, E; Spirk, D; Srivastava, S; Stancill, JS; Stanczak, PS; Starenki, D; Starr, F; Step, DL; Steubl, D; Stigliani, JL; Stráská, J; Sträter, N; Su, ZZ; Sudano, I; Suen, JY; Suh, HJ; Sui, ZY; Suico, JG; Suleiman, K; Sumon, K; Sun, HB; Sun, J; Sun, L; Sun, LL; Sun, M; Sun, Q; Sun, W; Sun, X; Sun, XF; Sun, Y; Sun, YB; Sun, YH; Sun, YN; Sun, Z; Sunada, K; Suzuki, S; Sylvan, JB; Takala, J; Talla, D; Tamir, Z; Tan, SJ; Tanda, S; Tang, H; Tang, J; Tang, LF; Tang, SJ; Tang, Y; Tao, FB; Tappel, R; Taratkin, M; Teijeira, Á; Tellew, JE; Thomas, AM; Thomas, SG; Thomson, SR; Tian, J; Tie, Y; Tirado, JL; Tolonen, A; Tosato, G; Tronnet, A; Tsai, S; Turtoi, A; Turtoi, E; Tvrdoňová, M; Tyagi, A; Tzou, DT; Uddin Ahmad, Z; Urias, E; Usawachintachit, M; Ustriyana, P; Utsumi, F; Vacca, M; Vaculovič, T; Vaidya, SS; Valentin, A; Valgepea, K; van den Berg, P; van den Bergh, JP; van der Heiden, K; van Gaalen, K; Van Gemert, W; van Haard, PMM; van Hest, JCM; Vecchiarelli, E; Večeřa, Z; Venkatesh, R; Verhaeghe, P; Verhagen, HJ; Vetter, JM; Vieira, D; Vilchez-Tschischke, JP; Villena-Gutierrez, R; Villoslada Terrones, V; Vital-Jacome, M; Voelkl, J; Vogel, K; Vogrin, S; Volke, D; von Bahr, V; Vysloužil, J; Wade, TL; Wagner-Gillespie, M; Walsh, SW; Wan, LJ; Wan, SP; Wang, AL; Wang, B; Wang, BY; Wang, C; Wang, D; Wang, F; Wang, H; Wang, HR; Wang, HY; Wang, J; Wang, JY; Wang, K; Wang, L; Wang, LF; Wang, P; Wang, Q; Wang, R; Wang, SF; Wang, SP; Wang, SR; Wang, T; Wang, W; Wang, WP; Wang, X; Wang, XJ; Wang, Y; Wang, YL; Wang, YN; Wáng, YXJ; Wang, Z; Wang, ZF; Wang, ZY; Waning, B; Warner, JM; Washington, SL; Watson, AK; Wei, B; Wei, C; Wei, F; Wei, X; Wei, Y; Wemhoff, AP; Wen, Z; Weng, TT; Wesdemiotis, C; Wheeler, DA; Wildner, M; Wilson, BK; Wirth, LJ; Wissler, M; Wu, F; Wu, G; Wu, J; Wu, KH; Wu, MC; Wu, P; Wu, PK; Wu, S; Wu, W; Wu, X; Wu, XP; Wu, Y; Wyatt, E; Wyllie, S; Xia, Y; Xiao, BH; Xiao, SZ; Xiao, W; Xiao, X; Xiao, Z; Xie, D; Xie, K; Xie, X; Xie, Y; Xie, YF; Xin, S; Xin, Z; Xing, Q; Xing, WQ; Xiong, D; Xiong, X; Xu, C; Xu, D; Xu, F; Xu, G; Xu, H; Xu, J; Xu, JY; Xu, L; Xu, N; Xu, W; Xu, X; Xu, Y; Xu, YM; Xue, H; Xue, J; Xue, Z; Yan, R; Yan, SQ; Yan, W; Yan, X; Yan, Z; Yang, C; Yang, D; Yang, F; Yang, FC; Yang, G; Yang, J; Yang, M; Yang, P; Yang, Q; Yang, R; Yang, S; Yang, SJ; Yang, TWW; Yang, X; Yang, Y; Yang, Z; Yao, C; Yao, L; Yao, LP; Yao, M; Yao, T; Yao, W; Yao, Y; Yaseen, T; Yazdani, V; Ye, J; Ye, S; Yerys, BE; Yi, HWL; Yi, JL; Yin, F; Yin, J; Yin, Y; Yin, Z; Yong, ZP; Yongli, S; Yoo, JS; Yoshikawa, N; You, Q; Yu, B; Yu, CQ; Yu, H; Yu, HG; Yu, J; Yu, L; Yu, Q; Yu, X; Yu, Y; Yu, YK; Yu, Z; Yuan, Q; Yuan, R; Yuan, W; Yuan, X; Yuan, Y; Zager, RA; Zagozdzon, A; Zaller, N; Zang, YP; Zappi, ME; Zelikoff, JT; Zeman, T; Zhai, X; Zhan, P; Zhang, B; Zhang, C; Zhang, G; Zhang, H; Zhang, HB; Zhang, J; Zhang, JS; Zhang, L; Zhang, M; Zhang, Q; Zhang, RX; Zhang, S; Zhang, T; Zhang, W; Zhang, WH; Zhang, X; Zhang, XX; Zhang, Y; Zhang, YQ; Zhang, YW; Zhang, Z; Zhang, ZH; Zhao, D; Zhao, FL; Zhao, K; Zhao, L; Zhao, M; Zhao, R; Zhao, S; Zhao, W; Zhao, WG; Zhao, X; Zhao, Y; Zheng, G; Zheng, J; Zheng, S; Zheng, W; Zheng, Y; Zheng, YG; Zhong, Z; Zhou, C; Zhou, D; Zhou, H; Zhou, HY; Zhou, L; Zhou, Q; Zhou, X; Zhou, Y; Zhou, YL; Zhou, Z; Zhu, J; Zhu, L; Zhu, N; Zhu, X; Zhu, XF; Zhu, Y; Zhu, Z | 1 |
| Blasi, M; Bozorgmehr, F; Hommertgen, A; Kieser, M; Krisam, J; Kuon, J; Lasitschka, F; Maenz, M; Schneider, M; Stenzinger, A; Thomas, M | 1 |
| Birtle, A; Casbard, A; Chester, J; Crabb, S; Elliott, T; Evans, L; Griffiths, G; Huang, C; Huddart, R; Jagdev, S; Jones, R; Lester, J; Madden, TA | 1 |
| Fujita, M; Harada, T; Ichiki, M; Inoue, K; Shiraishi, Y; Sugio, K; Takayama, K; Takeshita, M; Tokunaga, S; Uchino, J; Wataya, H; Yamada, T | 1 |
| Björn, N; Gréen, H; Jakobsen, I; Lotfi, K | 1 |
| Andrade, CF; Figueiró, F; Filippi-Chiela, E; Gonzalez, EA; Klamt, F; Nunes, V; Pilar, ES; Solari, JIG | 1 |
| Borsellino, N; Cipolla, C; Galanti, D; Gebbia, V; Pardo, S; Serretta, V; Valerio, MR; Vecchia, M | 1 |
| Akie, K; Amano, T; Dosaka-Akita, H; Fujita, Y; Fuke, S; Fukumoto, SI; Harada, M; Harada, T; Isobe, H; Ito, K; Kinoshita, I; Nakano, K; Nishigaki, Y; Nishimura, M; Oizumi, S; Sakakibara-Konishi, J; Sukoh, N; Takamura, K | 1 |
| Brunn, M; Frost, N; Grohé, C; Klauschen, F; Ochsenreither, S; Raspe, M; Ruwwe-Glösenkamp, C; Suttorp, N; Temmesfeld-Wollbrück, B; von Laffert, M; Witzenrath, M; Zhamurashvili, T | 1 |
| Berjon, A; Brenes, J; Casado, G; Castelo, B; Espinosa, E; Feliu, J; Gallego, A; Hardisson, D; Hernandez, A; Mendiola, M; Ramon-Patino, J; Redondo, A | 1 |
| Badam, TVS; Björn, N; Brandén, E; De Petris, L; Gréen, H; Gustafsson, M; Koyi, H; Lewensohn, R; Lubovac-Pilav, Z; Lundeberg, J; Sahlén, P; Spalinskas, R | 1 |
| Fukami, N; Fukaya, K; Ichino, M; Kusaka, M; Nukaya, T; Sasaki, H; Shiroki, R; Sumitomo, M; Takahara, K; Takenaka, M; Zennami, K | 1 |
| Chen, F; Gou, S; Wang, X | 2 |
| Aoe, K; Atagi, S; Ebiana, V; Fukuhara, T; Han, SR; Hida, T; Horiike, A; Horinouchi, H; Hotta, K; Katakami, N; Kishi, K; Kurata, T; Nakagawa, K; Noguchi, K; Nosaki, K; Ohira, T; Okamoto, H; Okamoto, I; Saka, H; Sakai, H; Satouchi, M; Sekine, A; Sugawara, S; Takahashi, T; Umemura, S; Yamamoto, N | 1 |
| Aragon-Ching, JB; Bellmunt, J; Blake-Haskins, JA; Caserta, C; Costa, N; Davis, C; Demey, W; di Pietro, A; Fowst, C; Grivas, P; Gurney, H; Huang, B; Kalofonos, H; Kopyltsov, E; Laliberte, R; Loriot, Y; Park, SH; Petrylak, DP; Powles, T; Radulović, S; Sridhar, SS; Sternberg, CN; Tsuchiya, N; Ullén, A; Valderrama, BP; Voog, E; Wang, J | 1 |
| Beumer, JH; Christner, S; Chu, E; Guo, J; Holleran, JL; Ivy, SP; Joshi, A; Kiesel, B; Miller, BM; Parise, RA; Taylor, S; Venkataramanan, R | 1 |
| Andric, Z; Barrios, CH; de Marinis, F; Deng, Y; Enquist, I; Felip, E; Geater, S; Giaccone, G; Herbst, RS; Jassem, J; Komatsubara, K; Kuriki, H; McCleland, M; Mocci, S; Morise, M; Özgüroğlu, M; Reinmuth, N; Sandler, A; Spigel, DR; Vergnenegre, A; Wen, X; Zou, W | 1 |
| Atari, M; Imai, K; Matsuo, T; Minamiya, Y; Motoyama, S; Nakayama, K; Nomura, K; Sato, Y; Shibata, H; Takashima, S | 1 |
| Chung, H; Kim, HS; Kim, JW; Kim, SI; Lee, EJ; Lee, M; Park, NH; Song, YS | 1 |
| Björn, N; Gréen, H; Pellé, L; Schimek, V; Svedberg, A | 1 |
| Boras, B; Chen, W; D'Argenio, DZ; Hu, W; Spilker, ME; Sung, T | 1 |
| Alcaraz-Sanabria, A; Burgos, M; Corrales-Sanchez, V; Galan-Moya, EM; Martinez-Canales, S; Montero, JC; Nieto-Jimenez, C; Nuncia-Cantarero, M; Ocaña, A; Pandiella, A | 1 |
| Li, J; Liu, Z; Mi, M; Wang, Y; Zhang, C; Zhang, L | 1 |
| Dash, A; Diamontopoulos, LN; Gore, JL; Grivas, P; Holt, SK; Lin, DW; Nyame, YA; Psutka, SP; Schade, GR; Winters, BR; Wright, JL; Yu, EY | 1 |
| Slater, H | 1 |
| Dehghanian, A; Firouzabadi, D; Mahmoudi, L; Rezvani, A; Talei, A | 1 |
| Funakoshi, S; Hirose, S; Kouno, T; Machino, C; Oikawa, H; Sato, T | 1 |
| Aerts, JG; Baas, P; Biesma, B; Bootsma, GP; Buikhuisen, WA; Burgers, JA; Cornelissen, R; Dammeijer, F; de Gooijer, CJ; den Brekel, AJS; Groen, HJM; Lalezari, F; Soud, MY; Stigt, JA; van der Noort, V; van Heemst, RC; van Tinteren, H; van Walree, N | 1 |
| Bentsion, D; Bondarenko, I; Chen, CI; Cicin, I; Clingan, P; Gao, B; Gladkov, O; Gogishvili, M; Gullo, G; Gümüş, M; Kilickap, S; Lee, S; Li, S; Lowy, I; Makharadze, T; McGuire, K; Nechaeva, M; Özgüroğlu, M; Paydas, S; Rietschel, P; Rizvi, N; Seebach, F; Sezer, A; Sriuranpong, V; Turk, HM; Weinreich, DM; Yancopoulos, GD | 1 |
| Im, HS; Jeong, H; Kim, HD; Kim, JH; Lee, JL; Park, I; Yoon, SK | 1 |
| Bao, PT; Lin, H; Liu, XF; Mu, M; Pan, P; Tian, FF; Wang, Q; Zhang, R; Zhao, WG | 1 |
| Agopsowicz, K; Burlot, C; Cardinal, O; Craig, M; Crosley, P; Farkkila, A; Fu, Y; Heikinheimo, M; Hitt, MM; Jenner, AL; Pihlajoki, M; Potts, KG | 1 |
| Chovanec, M; Kalavska, K; Mardiak, J; Mego, M; Obertova, J; Palacka, P; Reckova, M; Rejlekova, K; Svetlovska, D; Sycova-Mila, Z | 1 |
| Burns, G; Greystoke, A; Iqbal, MS; Robinson, M; Rodriguez, CN | 1 |
| Bartos, P; Bartunkova, J; Chovanec, J; Cibula, D; Fucikova, J; Galluzzi, L; Hassan, HIB; Hein, A; Hraska, M; Hrnciarova, T; Kieszko, D; Klat, J; Knapp, P; Madry, R; Mallmann, P; Markowska, J; Melichar, B; Minar, L; Pecen, L; Pluta, M; Rob, L; Spacek, J; Spisek, R; Streb, J; Valha, P; Wimberger, P | 1 |
| Adelantado, EZ; Beck, JT; Campone, M; Chan, A; Couillebault, XM; De Laurentiis, M; Duhoux, FP; Fan, L; Greil, R; Guerreiro, N; Im, SA; Kim, SB; Kuemmel, S; Kuter, I; Kwong, A; Loirat, D; Lopez, RL; Lu, YS; Mataraza, J; Özgüroğlu, M; Sand-Dejmek, J; Scholz, CW; Singer, CF; Steger, GG; Tibau, A; Vega, E; Wimberger, P; Zamagni, C | 1 |
| Hikita, K; Honda, M; Iwamoto, H; Kawamoto, B; Morizane, S; Shimizu, R; Takenaka, A; Teraoka, S; Yamaguchi, N; Yumioka, T | 1 |
| Anai, S; Aoki, K; Fujimoto, K; Gotoh, D; Hori, S; Ichikawa, K; Kiba, K; Maesaka, F; Matsumura, Y; Miyake, M; Mizobuchi, S; Morizawa, Y; Nakai, Y; Nishimura, N; Oda, Y; Ohmori, C; Shimizu, T; Tachibana, A; Tanaka, N; Tomizawa, M; Torimoto, K; Yoshikawa, T | 1 |
| Katsuda, T; Matsukuma, K; Nasu, H; Nishio, S; Park, J; Tasaki, K; Terada, A; Tsuda, N; Ushijima, K; Yoshimitsu, T | 1 |
| Imada, K; Kaneko, H; Mizutani, C; Nagata, O; Naka, R; Tada, K; Tashima, M | 1 |
| Björn, N; Brandén, E; De Petris, L; Gréen, H; Jakobsen, I; Koyi, H; Lewensohn, R; Udagawa, C; Zembutsu, H | 1 |
| Basiri, A; Fattahi, MR; Ghajari, M; Houshyari, M; Jafari, A; Mofid, B; Razzaghdoust, A; Taghizadeh-Hesary, F | 1 |
| Chan, H; Chiu, M; Elinder-Camburn, A; Hague, S; Merriman, E | 1 |
| Anderson, B; Azaro, A; Benhadji, KA; Cassier, PA; Massard, C; Oakley, G; Pant, S; Yu, D; Yuen, E | 1 |
| Aftimos, P; Andrić, Z; Beelen, A; Goel, S; Malik, R; O'Shaughnessy, J; Rugo, HS; Tan, AR; Yi, JS; Zhang, J | 1 |
| Bao, Y; Cai, M; Chen, M; Chen, Z; Fu, C; Guo, J; Hu, H; Huang, J; Huang, Z; Jiang, S; Li, C; Su, R; Wang, Z; Wei, Q; Xue, W; Yuan, Y; Zheng, B | 1 |
| Aning, J; Barocas, DA; Bivalacqua, TJ; Black, AJ; Black, PC; Cookson, MS; Dall'Era, MA; Daneshmand, S; Dinney, CP; Einerhand, SMH; Fairey, AS; Garcia, JA; Grivas, P; Holzbeierlein, JM; Jacobson, NE; Kassouf, W; Krabbe, LM; Lotan, Y; McGrath, JS; Mertens, LS; Mir, MC; Montgomery, JS; Morgan, TM; North, S; Shah, JB; Shariat, SF; Spiess, PE; Sridhar, SS; Stephenson, AJ; Thorpe, AC; van Rhijn, BWG; Vasdev, N; Wright, JL; Xylinas, E; Yu, EY; Zargar, H; Zargar-Shoshtari, K | 1 |
| Boonsong, T; Chang, A; Khongthong, P; Nakwan, N; Ruklerd, T; Usaha, S | 1 |
| Akiyama, Y; Fukuhara, H; Kawai, T; Kinjo, M; Kishitani, K; Kume, H; Masuda, K; Miyakawa, J; Nakagawa, T; Nakamura, Y; Sato, Y; Sugimoto, K; Taguchi, S; Tambo, M; Yamada, D; Yamada, Y | 1 |
| Bianchi, GV; Cantarelli, B; Capri, G; de Braud, F; Depretto, C; Fucà, G; Leporati, R; Ligorio, F; Lobefaro, R; Manoukian, S; Mariani, L; Peverelli, G; Presti, D; Pruneri, G; Rametta, A; Scaperrotta, G; Vernieri, C; Vingiani, A; Zattarin, E | 1 |
| Ambrosio, AJ; Birrer, MJ; Bradley, C; Konstantinopoulos, PA; Krasner, CN; Matulonis, UA; Penson, RT; Whalen, CA | 1 |
| Alqaisi, H; Chan, CT; Côté, G; Jiang, DM; Kandel, C; Kitchlu, A; Pelletier, K; Sridhar, SS; Wald, R | 1 |
| Bayram, E; Guzel, AB; Khatib, G; Kuçukgoz-Gulec, U; Paydas, S; Vardar, MA | 1 |
| Ates, O; Buyukkor, M; Tay, F | 1 |
| Audenet, F; Bendjeddou, L; Calleris, G; Chevallier, T; Houédé, N; Masson-Lecomte, A; Neuzillet, Y; Rouprêt, M; Seisen, T; Thibault, C; Xylinas, E | 1 |
| Huntington, SF; Kshattry, S; Parker, TL | 1 |
| Arima, F | 1 |
127 review(s) available for gemcitabine and carboplatin
| Article | Year |
|---|---|
The cost-effectiveness of four cisplatin-containing chemotherapy regimens in the treatment of stages III B and IV non-small cell lung cancer: an Italian perspective.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Etoposide; Gemcitabine; Health Care Costs; Humans; Ifosfamide; Insurance, Health, Reimbursement; Italy; Lung Neoplasms; Mitomycin; Ribonucleotide Reductases; Vinblastine; Vinorelbine | 1996 |
Overview of current and future chemotherapeutic agents in non-small cell lung cancer.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Forecasting; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic | 1997 |
New cytostatic agents for the treatment of head and neck cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Head and Neck Neoplasms; Humans; Ifosfamide; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Taxoids | 1997 |
Future directions in the chemotherapy of ovarian cancer.
Topics: Administration, Oral; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Etoposide; Europe; Female; Forecasting; Gemcitabine; Humans; Injections, Intraperitoneal; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Time Factors; Topotecan; Vinblastine; Vinorelbine | 1997 |
Experience with new chemotherapeutic agents in non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Treatment Outcome | 1998 |
Gemcitabine and carboplatin in combination: phase I and phase II studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms | 1998 |
Hemolytic-uremic syndrome caused by gemcitabine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Fatal Outcome; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Lung Neoplasms; Male; Middle Aged; Vindesine | 1998 |
Gemcitabine and carboplatin in combination: an update of phase I and phase II studies in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms | 1999 |
Triplet chemotherapy with gemcitabine, a platinum, and a third agent in the treatment of advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel; Vinblastine; Vinorelbine | 1999 |
The role of radiation, with or without chemotherapy, in the management of NSCLC.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Radiation-Sensitizing Agents; Topotecan; Vinblastine; Vinorelbine | 1999 |
Ifosfamide in non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Etoposide; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel | 1999 |
Docetaxel (Taxotere) in combination chemotherapy and in association with thoracic radiotherapy for the treatment of non-small-cell lung cancer. Thoracic Oncology Program.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 1999 |
Advances in treatment of inoperable NSCLC: gemcitabine doublets--a promising alternative.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Remission Induction; Taxoids; Vinblastine; Vinorelbine | 2000 |
Gemcitabine/carboplatin combination regimens: importance of dose schedule.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms; Palliative Care; Randomized Controlled Trials as Topic; Thrombocytopenia | 2000 |
Chemotherapy in metastatic non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Mitomycin; Paclitaxel; Taxoids; Tirapazamine; Triazines; Vinblastine; Vinorelbine | 2000 |
Chemoradiation in locally advanced non-small cell lung cancer.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Forecasting; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Lung cancer: therapeutic options for stage IV and recurrent NSCLC.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Taxoids; Teniposide; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Recent developments in chemotherapy for bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bridged-Ring Compounds; Carboplatin; Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Paclitaxel; Taxoids; Urinary Bladder Neoplasms | 2001 |
Developmental chemotherapy in advanced ovarian cancer: incorporation of topoisomerase-I inhibitors and perspective of the Gynecologic Oncology Group.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; DNA Adducts; Female; Gemcitabine; Humans; Immunologic Factors; Liposomes; Ovarian Neoplasms; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis; Topoisomerase I Inhibitors; Topotecan | 2001 |
Rationale for non-platinum chemotherapy in advanced NSCLC.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Vinblastine; Vinorelbine | 2001 |
Gemcitabine and carboplatin for patients with advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms | 2001 |
Gemcitabine/carboplatin in advanced urothelial cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Urinary Bladder Neoplasms | 2001 |
[Preclinical studies of oxaliplatin in combination chemotherapy].
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Drug Interactions; Drug Screening Assays, Antitumor; Fluorouracil; Gemcitabine; Humans; Mice; Models, Biological; Organoplatinum Compounds; Oxaliplatin; Tumor Cells, Cultured | 2001 |
Treatment of advanced ovarian cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Liposomes; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Topotecan | 2001 |
Topoisomerase I inhibitors combination chemotherapy in non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Doxorubicin; Enzyme Inhibitors; Etoposide; Gemcitabine; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Topotecan; Vinblastine; Vinorelbine | 2001 |
Radiosensitization with chemotherapeutic agents.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Platinum Compounds; Radiation-Sensitizing Agents; Taxoids; Vinblastine; Vinorelbine | 2001 |
[New developments in chemotherapy for metastasized bladder cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclophosphamide; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Male; Methotrexate; Paclitaxel; Palliative Care; Randomized Controlled Trials as Topic; Urinary Bladder Neoplasms; Vinblastine | 2001 |
The role of gemcitabine in the treatment of malignant mesothelioma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Mesothelioma | 2002 |
The role of gemcitabine-based doublets in the management of ovarian carcinoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carboplatin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Topotecan; Vinblastine; Vinorelbine | 2002 |
Gemcitabine, platinum, and paclitaxel regimens in patients with advanced ovarian carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel | 2002 |
Developmental chemotherapy in advanced ovarian cancer: incorporation of newer cytotoxic agents in a phase III randomized trial of the Gynecologic Oncology Group (GOG-0182).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Topotecan | 2002 |
Gemcitabine doublets in advanced urothelial cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Doxorubicin; Forecasting; Gemcitabine; Humans; Methotrexate; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Prognosis; Renal Insufficiency; Survival Analysis; Trastuzumab; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2002 |
Novel gemcitabine-containing triplets in the management of urothelial cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Doxorubicin; Forecasting; Gemcitabine; Humans; Methotrexate; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2002 |
Brief communication: use of the multitargeted antifolate pemetrexed (Alimta) in genitourinary cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Folic Acid Antagonists; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pemetrexed; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Urogenital Neoplasms | 2002 |
Gemcitabine in non-small cell lung cancer.
Topics: Age Factors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms; Radiotherapy, Adjuvant | 2002 |
New treatment approaches for lung cancer and impact on survival.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Incidence; Lung Neoplasms; Paclitaxel; Survival Rate | 2002 |
Incorporation of pemetrexed (Alimta) into the treatment of non-small cell lung cancer (thoracic tumors).
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Folic Acid; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Mesothelioma; Pemetrexed; Pleural Neoplasms; Thymidylate Synthase; Vitamin B 12 | 2002 |
The present and future of combination chemotherapy in bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Gemcitabine; Glutamates; Guanine; Humans; Methotrexate; Paclitaxel; Pemetrexed; Taxoids; Urinary Bladder Neoplasms; Vinblastine | 2002 |
[Docetaxel].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Radiotherapy, Adjuvant; Taxoids | 2002 |
[Carboplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2002 |
[Chemotherapy for elderly patients with lung cancer].
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vincristine; Vinorelbine | 2002 |
Chemotherapy of non-small cell lung cancer in elderly patients.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Risk Factors; Vinblastine; Vinorelbine | 2002 |
Topoisomerase I-based nonplatinum combinations in non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Randomized Controlled Trials as Topic; Topoisomerase I Inhibitors | 2002 |
Vinorelbine: a review of its use in elderly patients with advanced non-small cell lung cancer.
Topics: Age Factors; Aged; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Injections, Intravenous; Liver Diseases; Lung Neoplasms; Vinblastine; Vinorelbine | 2002 |
Gemcitabine/carboplatin in advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Randomized Controlled Trials as Topic; Treatment Outcome | 2002 |
Past, present, and future of gemcitabine and carboplatin regimens in advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carboplatin; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Outpatients; Randomized Controlled Trials as Topic; Steroids; Taxoids | 2002 |
[New neoadjuvant approaches using gemcitabine in non-small-cell lung cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Neoadjuvant Therapy; Paclitaxel; Pneumonectomy; Randomized Controlled Trials as Topic; Remission Induction; Taxoids; Treatment Outcome | 2002 |
[Combinations of platinum salts and gemcitabine in the treatment of non-small-cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Etoposide; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Neoadjuvant Therapy; Paclitaxel; Pneumonectomy; Randomized Controlled Trials as Topic; Remission Induction; Reproducibility of Results; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Chemotherapy for elderly patients with advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Meta-Analysis as Topic; Paclitaxel; Randomized Controlled Trials as Topic; SEER Program; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
Active chemotherapy for bone metastasis in sarcomatoid renal cell carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bone Neoplasms; Carboplatin; Carcinoma, Renal Cell; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gemcitabine; Humans; Immunohistochemistry; Kidney Neoplasms; Neoplasm Staging; Nephrectomy; Paclitaxel; Sarcoma; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2003 |
Update on gemcitabine/carboplatin in patients with advanced non-small cell lung cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Meta-Analysis as Topic; Neoplasm Staging; Quality of Life; Randomized Controlled Trials as Topic | 2003 |
Gemcitabine combination chemotherapy of ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Salvage Therapy | 2003 |
Localized pleural malignant mesothelioma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality Therapy; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Male; Mesothelioma; Neoplasm Recurrence, Local; Paclitaxel; Pleural Neoplasms; Radiography, Thoracic; Tomography, X-Ray Computed | 2003 |
Ifosfamide in non-small cell lung cancer.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel; Vinblastine; Vinorelbine | 2003 |
Gemcitabine and platinum combinations in patients with breast cancer previously treated with anthracyclines and/or taxanes.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Carboplatin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Metastasis; Taxoids | 2004 |
State-of-the-art chemotherapy for advanced non-small cell lung cancer.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Taxoids; Treatment Outcome | 2004 |
[Docetaxel and non-small cell lung cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Taxoids; Vinblastine; Vinorelbine | 2004 |
Carboplatin/gemcitabine combination in advanced NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Randomized Controlled Trials as Topic | 2004 |
Analysis of treatment for small cell cancer of the bladder and report of three cases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Biomarkers, Tumor; Bone Neoplasms; Carboplatin; Carcinoma, Small Cell; Carcinoma, Transitional Cell; Cisplatin; Combined Modality Therapy; Cystectomy; Deoxycytidine; Disease Progression; Etoposide; Gemcitabine; Humans; Life Tables; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasms, Second Primary; Prostatectomy; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms; Urinary Diversion | 2004 |
Recurrent ovarian cancer: how important is it to treat to disease progression?
Topics: Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Recurrence; Risk; Taxoids; Time Factors; Topotecan | 2004 |
Significant responses to platinum-based chemotherapy in renal medullary carcinoma.
Topics: Adolescent; Anemia, Sickle Cell; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Carboplatin; Carcinoma, Renal Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kidney Medulla; Kidney Neoplasms; Male; Paclitaxel; Treatment Outcome | 2005 |
Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Gemcitabine; Humans; Lung Neoplasms; Randomized Controlled Trials as Topic; Risk Factors; Survival Analysis; Treatment Outcome | 2005 |
Gemcitabine and platinum-based chemotherapy in metastatic breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Treatment Outcome | 2004 |
Gemcitabine in combination with trastuzumab and/or platinum salts in breast cancer cells with HER2 overexpression.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Antagonism; Drug Synergism; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Heart Failure; Humans; Platinum Compounds; Receptor, ErbB-2; Time Factors; Trastuzumab; Treatment Outcome | 2004 |
Development of docetaxel in advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2004 |
Chemoresistance in non-small cell lung cancer.
Topics: Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Tubulin; Vinblastine; Vinorelbine | 2005 |
Docetaxel in the management of advanced pancreatic cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carboplatin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Humans; Irinotecan; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Taxoids; Thalidomide | 2005 |
Phase II study of first-line sequential chemotherapy with gemcitabine-carboplatin followed by docetaxel in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Taxoids; Treatment Outcome | 2005 |
Gemcitabine and carboplatin in second-line ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Survival Rate | 2005 |
Erlotinib in the treatment of non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quinazolines | 2005 |
Gemcitabine and carboplatin: is this the best combination for non-small cell lung cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Cost-Benefit Analysis; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Prognosis; Quality of Life; Survival Analysis | 2006 |
Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Epirubicin; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2006 |
Gemcitabine plus carboplatin in platinum-sensitive recurrent ovarian carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Prognosis; Quality of Life; Survival | 2006 |
Optimizing chemotherapy for advanced non-small cell lung cancer: focus on docetaxel.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Survival Rate; Taxoids | 2005 |
Management of platinum-sensitive recurrent ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel | 2006 |
The role of gemcitabine in first-line treatment of advanced ovarian carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Metastasis; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic | 2006 |
Optimal therapy for platinum-resistant recurrent ovarian cancer: doxorubicin, gemcitabine or topotecan?
Topics: Antineoplastic Agents; Carboplatin; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Topotecan | 2006 |
Gemcitabine in the treatment of advanced transitional cell carcinoma of the urothelium.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Comorbidity; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Methotrexate; Pharmacogenetics; Prognosis; Renal Insufficiency; Urinary Bladder Neoplasms; Urothelium; Vinblastine | 2006 |
[Bladder preservation possibilities in the treatment of muscle-invasive bladder cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Cystectomy; Deoxycytidine; Disease-Free Survival; Dose Fractionation, Radiation; Doxorubicin; Gemcitabine; Humans; Methotrexate; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Radiation-Sensitizing Agents; Radiotherapy Dosage; Taxoids; Time Factors; Urinary Bladder; Urinary Bladder Neoplasms; Vinblastine | 2006 |
Case of carcinosarcoma of urinary bladder obtained a pathologically complete response by neoadjuvant chemoradiotherapy.
Topics: Antineoplastic Agents; Carboplatin; Carcinosarcoma; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Radiotherapy, Adjuvant; Remission Induction; Urinary Bladder Neoplasms | 2007 |
Chemotherapy dose--response relationships in non-small cell lung cancer and implied resistance mechanisms.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Survival Rate; Vinblastine; Vinorelbine | 2007 |
Role of induction chemotherapy in resectable N2 non-small cell lung cancer.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Neoadjuvant Therapy; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Taxoids; Vinblastine; Vinorelbine | 2007 |
[Current situation and features of chemotherapy for breast neoplasms].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Practice Guidelines as Topic; Taxoids; Trastuzumab | 2007 |
[Gemcitabine and non small-cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Meta-Analysis as Topic | 2007 |
[Chemotherapy in lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Survival Rate | 2007 |
Gemcitabine in bladder cancer.
Topics: Administration, Intravesical; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Taxoids; Urinary Bladder Neoplasms; Urothelium | 2007 |
Gemcitabine and carboplatin in combination for the treatment of advanced, metastatic, non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Quality of Life; Survival Rate | 2007 |
Systemic therapy for unresectable and metastatic transitional cell carcinoma of the urothelium: first-line and beyond.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Paclitaxel; Receptor, ErbB-2; Trastuzumab; Urologic Neoplasms; Urothelium | 2008 |
Third generation triplet cytotoxic chemotherapy in advanced non-small cell lung cancer: a systematic overview.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Vinblastine; Vinorelbine | 2009 |
Pharmacogenomic approaches to individualizing chemotherapy for non-small-cell lung cancer: current status and new directions.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Gemcitabine; Genes, BRCA1; Humans; Lung Neoplasms; Pharmacogenetics; Prognosis; Taxoids | 2008 |
Gemcitabine and carboplatin in the treatment of transitional cell carcinoma of the urothelium: a single centre experience and review of the literature.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Survival Analysis; Urinary Bladder Neoplasms | 2010 |
Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Docetaxel; Gemcitabine; Glutamates; Guanine; Humans; Immunosuppressive Agents; Lung Neoplasms; Models, Economic; Pemetrexed; Quality-Adjusted Life Years; Radiation-Sensitizing Agents; Taxoids; United Kingdom | 2010 |
Gemcitabine plus paclitaxel versus carboplatin plus either gemcitabine or paclitaxel in advanced non-small-cell lung cancer: a literature-based meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic | 2010 |
Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?
Topics: Anaplastic Lymphoma Kinase; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cetuximab; Cisplatin; Clinical Trials as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Microtubule-Associated Proteins; Mutation; Paclitaxel; Patient Selection; Precision Medicine; Predictive Value of Tests; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptor Protein-Tyrosine Kinases; Serine Endopeptidases; Signal Transduction; Survival Analysis; Translocation, Genetic | 2010 |
Tolerability, efficacy, and safety of pegylated liposomal Doxorubicin in combination with Carboplatin versus gemcitabine-Carboplatin for the treatment of platinum-sensitive recurrent ovarian cancer: a systematic review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Polyethylene Glycols | 2010 |
[Metastatic non-small cell lung cancer: Systemic treatment of patients aged 70 and over].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Disease Progression; Drug Administration Schedule; Gemcitabine; Humans; Long-Term Care; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Palliative Care; Prognosis; Vinblastine; Vinorelbine | 2011 |
[Combination chemotherapy of paclitaxel, carboplatin and gemcitabine in patients who have received prior cisplatin-based chemotherapy].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Salvage Therapy; Urologic Neoplasms; Urothelium | 2011 |
Gemcitabine for unresectable, locally advanced or metastatic bladder cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Methotrexate; Paclitaxel; Randomized Controlled Trials as Topic; Urinary Bladder Neoplasms; Vinblastine | 2011 |
Histology as a treatment effect modifier in advanced non-small cell lung cancer: a systematic review of the evidence.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Evidence-Based Medicine; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Pemetrexed; Randomized Controlled Trials as Topic; Reproducibility of Results; Taxoids | 2011 |
Systemic chemotherapy in patients with advanced transitional cell carcinoma of the urothelium and impaired renal function.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Kidney; Kidney Function Tests; Neoplasm Invasiveness; Paclitaxel; Randomized Controlled Trials as Topic; Urologic Neoplasms; Urothelium | 2012 |
Primary hepatocellular carcinoma of the pancreas: a case report and review of the heterogeneous group of pancreatic hepatoid carcinomas.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Hepatocellular; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Middle Aged; Pancreatic Neoplasms | 2012 |
First-line chemotherapy in epithelial ovarian cancer.
Topics: Adenocarcinoma, Mucinous; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cisplatin; Clinical Trials as Topic; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Gemcitabine; Humans; Neoplasms, Glandular and Epithelial; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Poly(ADP-ribose) Polymerase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Topotecan; Vascular Endothelial Growth Factor A | 2012 |
A rational approach to the management of recurrent or persistent ovarian carcinoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Chemotherapy, Cancer, Regional Perfusion; Decision Making; Deoxycytidine; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Ovary; Paclitaxel; Polyethylene Glycols; Quality of Life; Randomized Controlled Trials as Topic | 2012 |
Pathological vertebral fracture after stereotactic body radiation therapy for lung metastases. Case report and literature review.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density; Carboplatin; Carcinoma, Transitional Cell; Cervical Vertebrae; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fractures, Spontaneous; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Osteoporosis, Postmenopausal; Pemetrexed; Radiosurgery; Radiotherapy, Conformal; Rib Fractures; Ribs; Spinal Fractures; Thoracic Vertebrae; Urinary Bladder Neoplasms | 2012 |
Pharmacogenetics of conventional chemotherapy in non-small-cell lung cancer: a changing landscape?
Topics: Biomarkers, Pharmacological; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Pharmacogenetics; Polymorphism, Single Nucleotide; Taxoids | 2012 |
Non-platinum doublets were as effective as platinum-based doublets for chemotherapy-naïve advanced non-small-cell lung cancer in the era of third-generation agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Odds Ratio; Paclitaxel; Platinum Compounds; Publication Bias; Research Report; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2013 |
Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic | 2013 |
[Contemporary trends of the adjutant chemotherapy in non-small cell lung cancer].
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Docetaxel; Evidence-Based Medicine; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Prognosis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2013 |
Assessment and management of renal impairment in chemotherapy for urogenital cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Gemcitabine; Glomerular Filtration Rate; Humans; Incidence; Kidney; Male; Renal Insufficiency, Chronic; Survival Rate; Testicular Neoplasms; Urogenital Neoplasms; Urothelium | 2013 |
Predictive role of repair enzymes in the efficacy of Cisplatin combinations in pancreatic and lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Cisplatin; Deoxycytidine; DNA Repair Enzymes; Gemcitabine; Humans; Lung Neoplasms; Pancreatic Neoplasms; Prognosis | 2014 |
Both carboplatin and bevacizumab improve pathological complete remission rate in neoadjuvant treatment of triple negative breast cancer: a meta-analysis.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Carboplatin; Carcinoma, Ductal, Breast; Deoxycytidine; Epothilones; Female; Gemcitabine; Humans; Mastectomy; Multicenter Studies as Topic; Neoadjuvant Therapy; Randomized Controlled Trials as Topic; Remission Induction; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms | 2014 |
An update on PARP inhibitors--moving to the adjuvant setting.
Topics: Adjuvants, Pharmaceutic; Antineoplastic Agents; Benzamides; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Carboplatin; Deoxycytidine; DNA Breaks, Double-Stranded; DNA Breaks, Single-Stranded; DNA Repair; Female; Gemcitabine; Humans; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors | 2015 |
Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Doxorubicin; Everolimus; Female; Folic Acid; Gemcitabine; Humans; Indazoles; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Nivolumab; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Glycols; Pyrimidines; Quinazolines; Recombinant Fusion Proteins; Sirolimus; Sulfonamides; Topotecan; TOR Serine-Threonine Kinases; Vinca Alkaloids | 2015 |
Chemotherapy plus Erlotinib versus Chemotherapy Alone for Treating Advanced Non-Small Cell Lung Cancer: A Meta-Analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Proteins; Paclitaxel; Pemetrexed; Protein Kinase Inhibitors; Publication Bias; Randomized Controlled Trials as Topic; Smoking; Treatment Outcome; Young Adult | 2015 |
Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond-A Comprehensive Review of the Current Literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Factors; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Indazoles; Neoplasm Recurrence, Local; Paclitaxel; Pemetrexed; Pyrimidines; Salvage Therapy; Sulfonamides; Urinary Bladder Neoplasms; Vinblastine | 2016 |
Vinca alkaloids in the therapeutic management of malignant pleural mesothelioma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Pleural Neoplasms; Vinblastine; Vinca Alkaloids; Vinorelbine | 2015 |
The influence of polypharmacy on grade III/IV toxicity, prior discontinuation of chemotherapy and overall survival in ovarian cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; Disease-Free Survival; Etoposide; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Polypharmacy; Randomized Controlled Trials as Topic; Survival Rate; Topotecan; Withholding Treatment; Young Adult | 2016 |
Efficacy and Safety of Gemcitabine Plus Either Taxane or Carboplatin in the First-Line Setting of Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Transitional Cell; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Neoplasm Metastasis; Survival Analysis; Taxoids; Treatment Outcome; Urologic Neoplasms | 2017 |
Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Immunotherapy; Indoles; Kidney Neoplasms; Kidney Pelvis; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Taxoids; Ureteral Neoplasms | 2017 |
Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives.
Topics: Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Chemotherapy, Adjuvant; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Nanoparticles; Neoadjuvant Therapy; Paclitaxel; Triple Negative Breast Neoplasms | 2016 |
Surgical treatment of recurrent urachal carcinoma with liver metastasis: a case report and literature review.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cystectomy; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Hepatectomy; Humans; Hysterectomy; Liver Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pelvic Neoplasms; Salvage Therapy; Tomography, X-Ray Computed; Urinary Bladder Neoplasms | 2016 |
Associations between hematologic toxicity and health-related quality of life during first-line chemotherapy in advanced non-small-cell lung cancer: a pooled analysis of two randomized trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Deoxycytidine; Fatigue; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Quality of Life; Randomized Controlled Trials as Topic; Vinorelbine | 2018 |
Immune checkpoint inhibitors for urothelial carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Neoplasm Invasiveness; Nivolumab; Ureteral Neoplasms; Urinary Bladder Neoplasms | 2018 |
SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Liver Neoplasms; Methotrexate; Nivolumab; Paclitaxel; Urinary Bladder Neoplasms; Vinblastine | 2019 |
Systematic Literature Review and Meta-Analysis of Response to First-Line Therapies for Advanced/Metastatic Urothelial Cancer Patients Who Are Cisplatin Ineligible.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Eligibility Determination; Female; Gemcitabine; Humans; Male; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Treatment Outcome; Urologic Neoplasms | 2019 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Gemcitabine; Humans; Pyrimidines; Randomized Controlled Trials as Topic; Triple Negative Breast Neoplasms | 2022 |
357 trial(s) available for gemcitabine and carboplatin
| Article | Year |
|---|---|
A phase I study of gemcitabine and carboplatin in non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged | 1996 |
Phase I studies of gemcitabine combined with carboplatin or paclitaxel.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Ovarian Neoplasms; Paclitaxel; Ribonucleotide Reductases | 1997 |
Paclitaxel in combination with carboplatin or gemcitabine for the treatment of advanced head and neck cancer.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Immunosuppression Therapy; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel | 1997 |
Phase I-II study of gemcitabine and carboplatin in stage IIIB-IV non-small-cell lung cancer.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Remission Induction; Thrombocytopenia | 1999 |
Phase I/II trial of paclitaxel by 1-hour infusion, carboplatin, and gemcitabine in the treatment of patients with advanced nonsmall cell lung carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate | 1999 |
Combination chemotherapy with carboplatin, docetaxel, and gemcitabine in advanced non-small-cell lung cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 1999 |
A phase II study of carboplatin plus gemcitabine in advanced non-small-cell lung cancer (NSCLC): a hoosier oncology group study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Enzyme Inhibitors; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Neutropenia; Remission Induction; Ribonucleotide Reductases; Survival Rate; Thrombocytopenia | 1999 |
Combination chemotherapy with paclitaxel plus carboplatin versus paclitaxel plus gemcitabine in inoperable non-small cell lung cancer: a phase III randomized study. Preliminary results. Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis | 2000 |
Phase II trial evaluating triplet chemotherapy using gemcitabine, paclitaxel, and carboplatin in the treatment of patients with advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Survival Analysis | 2000 |
Carboplatin-gemcitabine treatment of patients with transitional cell carcinoma of the bladder and impaired renal function.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Carboplatin; Carcinoma, Transitional Cell; Deoxycytidine; Female; Gemcitabine; Humans; Kidney Diseases; Male; Middle Aged; Survival Analysis; Urinary Bladder Neoplasms | 2000 |
Gemcitabine, paclitaxel, and carboplatin for advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Leukocyte Count; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Platelet Count | 2000 |
Interim results of a phase III trial. Paclitaxel/carboplatin vs paclitaxel/gemcitabine in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Thrombocytopenia | 2000 |
A phase I/II trial of paclitaxel, carboplatin, and gemcitabine in untreated patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Thrombocytopenia | 2000 |
Paclitaxel and carboplatin in combination with gemcitabine: a phase I-II trial in patients with advanced non-small-cell lung cancer. Gruppo Studio Tumori Polmonari Veneto (GSTPV).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Diarrhea; Disease-Free Survival; Female; Fever; Gemcitabine; Hematologic Diseases; Humans; Life Tables; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Remission Induction; Survival Analysis; Treatment Outcome | 2000 |
Phase I study of gemcitabine and carboplatin in advanced non-small cell lung carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Hyponatremia; Life Tables; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasm Staging; Nervous System Diseases; Neutropenia; Remission Induction; Survival Analysis; Survival Rate; Thrombocytopenia; Treatment Outcome; Vomiting | 2001 |
Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: carboplatin and gemcitabine followed by paclitaxel.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pilot Projects; Treatment Outcome | 2001 |
A prospective study of gemcitabine and carboplatin as first-line therapy in advanced non-small cell lung cancer: toxicity of a three- versus a four-week schedule.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Survival Analysis | 2001 |
Gemcitabine/carboplatin versus cisplatin/etoposide for patients with poor-prognosis small cell lung cancer: a phase III randomized trial with quality-of-life evaluation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Survival Analysis | 2001 |
A feasibility study of carboplatin with fixed dose of gemcitabine in "unfit" patients with advanced bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Treatment Outcome; Urinary Bladder Neoplasms | 2001 |
Combination chemotherapy of carboplatin and gemcitabine against solid tumors: a phase I trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Hematologic Diseases; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Treatment Outcome | 2001 |
Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: a randomized phase II study of combination chemotherapy against inoperable non-small-cell lung cancer previously untreated.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Time Factors | 2002 |
Activity of gemcitabine and carboplatin in advanced non-small cell lung cancer: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Treatment Outcome | 2002 |
Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Survival Rate; Treatment Outcome | 2002 |
Phase I trial of gemcitabine and carboplatin in metastatic non-small-cell lung cancer: a Groupe Français de Pneumo-Cancérologie Study.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fever; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Platelet Count; Thrombocytopenia; Vomiting | 2002 |
First-line chemotherapy with vinorelbine, gemcitabine, and carboplatin in the treatment of brain metastases from non-small-cell lung cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Gemcitabine (GEM) and carboplatin (CBDCA) versus cisplatin (CDDP) and vinblastine (VLB) in advanced non-small-cell lung cancer (NSCLC) stages III and IV: a phase III randomised trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival; Treatment Outcome; Vinblastine | 2002 |
Long-term follow-up of patients treated with paclitaxel/carboplatin-based chemotherapy for advanced non-small-cell lung cancer: sequential phase II trials of the Minnie Pearl Cancer Research Network.
Topics: Actuarial Analysis; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Gemcitabine versus gemcitabine/carboplatin in advanced non-small cell lung cancer: preliminary findings in a phase III trial of the Swedish Lung Cancer Study Group.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Survival Rate | 2002 |
A dose finding study of carboplatin and gemcitabine in advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Treatment Outcome | 2002 |
Prospective randomized study of four novel chemotherapy regimens in patients with advanced nonsmall cell lung carcinoma: a minnie pearl cancer research network trial.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Thrombocytopenia; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Carboplatin and gemcitabine in stage IV non small cell lung cancer: beyond cisplatin in palliative chemotherapy.
Topics: Aged; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Palliative Care; Survival Rate; Treatment Outcome | 2003 |
Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IV non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Survival; Thrombocytopenia; Treatment Outcome; Tumor Cells, Cultured | 2003 |
A phase III randomized evaluation of amifostine in stage IIIA/IIIB non-small cell lung cancer patients receiving concurrent carboplatin, paclitaxel, and radiation therapy followed by gemcitabine and cisplatin intensification: preliminary findings.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Cytoprotection; Deoxycytidine; Esophagitis; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Radiation Injuries; Radiation-Protective Agents | 2002 |
A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Darbepoetin alfa; Deoxycytidine; Docetaxel; Erythropoietin; Fatigue; Female; Gemcitabine; Humans; Injections, Subcutaneous; Male; Middle Aged; Neoplasms; Paclitaxel; Pilot Projects; Taxoids; Treatment Outcome | 2003 |
Gemcitabine combined with sequential paclitaxel and carboplatin in patients with urothelial cancers and other advanced malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cell Survival; Cohort Studies; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Urothelium | 2003 |
Gemcitabine and carboplatin in patients with locally advanced or metastatic non-small cell lung cancer: a prospective phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Survival Rate; Time Factors | 2003 |
Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: an alternative therapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Deoxycytidine; Female; Gemcitabine; Humans; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Quality of Life; Survival Rate; Urologic Neoplasms | 2003 |
Phase I trial of fixed dose-rate gemcitabine in combination with carboplatin in chemonaive advanced non-small-cell lung cancer: a Cancer Therapeutics Research Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Treatment Outcome | 2003 |
Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Mesothelioma; Middle Aged; Pleural Neoplasms; Survival Rate | 2003 |
Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cyclooxygenase 2; Deoxycytidine; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Glutathione S-Transferase pi; Glutathione Transferase; Humans; Isoenzymes; Lung Neoplasms; Male; Membrane Proteins; Microtubule Proteins; Middle Aged; Paclitaxel; Phosphoproteins; Predictive Value of Tests; Prostaglandin-Endoperoxide Synthases; Randomized Controlled Trials as Topic; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Stathmin; Survival Rate; Transcription, Genetic; Tubulin; Tumor Suppressor Proteins; Vinblastine; Vinorelbine | 2003 |
Phase I trial of docetaxel, carboplatin, and gemcitabine as first-line therapy for patients with high-risk epithelial tumors of müllerian origin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Epithelial Cells; Female; Gemcitabine; Humans; Middle Aged; Mullerian Ducts; Ovarian Neoplasms; Paclitaxel; Taxoids | 2003 |
Phase I combination trial of gemcitabine, paclitaxel, and carboplatin in patients with advanced malignancy.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Thrombocytopenia; Treatment Outcome | 2003 |
Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Prospective Studies; Survival Rate; Treatment Outcome | 2003 |
Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Mitomycin; Mitomycins; Neoplasm Staging; Quality of Life; Survival Rate; Time Factors; Vinblastine | 2003 |
Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group Protocol GOG 182-ICON5.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Liposomes; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Topotecan | 2003 |
Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Treatment Outcome | 2003 |
A phase II trial of three sequential doublets for the treatment of advanced müllerian malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Gemcitabine; Genital Neoplasms, Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Mixed Tumor, Mullerian; Ovarian Neoplasms; Peritoneal Neoplasms; Topotecan | 2003 |
Gemcitabine and low dose carboplatin in the treatment of elderly patients with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Survival Analysis; Survival Rate; Treatment Outcome | 2003 |
Phase II study of an alternate carboplatin and gemcitabine dosing schedule in advanced non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Radiotherapy, Adjuvant; Survival Analysis; Time Factors; Treatment Outcome | 2003 |
Phase I feasibility trial of carboplatin, paclitaxel, and gemcitabine in patients with previously untreated epithelial ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Drug Administration Schedule; Epithelial Cells; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms | 2004 |
Second-line chemotherapy with gemcitabine and carboplatin in paclitaxel-pretreated, platinum-sensitive ovarian cancer patients. A Hellenic Cooperative Oncology Group Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prospective Studies | 2004 |
Dose finding study for combination treatment with topotecan and gemcitabine of patients with recurrent ovarian cancer after failure of first-line chemotherapy with Paclitaxel and platinum.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Retreatment; Topotecan; Treatment Failure | 2004 |
Dose intense triplet chemotherapy with gemcitabine, carboplatin, paclitaxel with peripheral blood progenitor cell support for six cycles in advanced epithelial ovarian cancer.
Topics: Adolescent; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Maximum Tolerated Dose; Middle Aged; Ovarian Neoplasms; Paclitaxel; Transplantation, Autologous | 2004 |
A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Lung; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Treatment Outcome | 2004 |
Gemcitabine plus carboplatin combination therapy as second-line treatment in patients with relapsed breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Mastectomy; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Risk Assessment; Survival Analysis; Treatment Outcome | 2004 |
A phase I/II trial of induction chemotherapy with carboplatin and gemcitabine followed by concurrent vinorelbine and paclitaxel with chest radiation in patients with stage III non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Probability; Prognosis; Radiotherapy Dosage; Radiotherapy, Adjuvant; Remission Induction; Statistics, Nonparametric; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
A prospective study on lung toxicity in patients treated with gemcitabine and carboplatin: clinical, radiological and functional assessment.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung; Male; Middle Aged; Neoplasms; Prospective Studies; Pulmonary Diffusing Capacity | 2004 |
Triplet combination of gemcitabine, carboplatin, and paclitaxel in previously treated, relapsed ovarian and peritoneal carcinoma: an experience in Taiwan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Salvage Therapy | 2004 |
Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Salvage Therapy; Taxoids; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
Pilot study of outpatient paclitaxel, carboplatin and gemcitabine for advanced stage epithelial ovarian, peritoneal, and fallopian tube cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Pilot Projects | 2004 |
Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma; Carcinoma, Transitional Cell; Cisplatin; Contraindications; Deoxycytidine; Female; Gemcitabine; Hematologic Diseases; Humans; Kidney Function Tests; Life Tables; Male; Neoplasm Metastasis; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms | 2004 |
[Evaluation of advanced non-small-cell lung cancer (ANSCLC) chemotherapy in routine practice].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Fever; France; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Primary Health Care; Prospective Studies; Vinblastine; Vinorelbine | 2004 |
Results of a Phase II study of carboplatin plus gemcitabine in patients with untreated extensive small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Small Cell; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Thrombocytopenia | 2004 |
Carcinoma of unknown primary site: sequential treatment with paclitaxel/carboplatin/etoposide and gemcitabine/irinotecan: a Minnie Pearl Cancer Research Network phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Treatment Outcome | 2004 |
Experience with single-agent paclitaxel consolidation following primary chemotherapy with carboplatin, paclitaxel, and gemcitabine in advanced ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel | 2005 |
Phase II randomized trial of vinorelbine and gemcitabine versus carboplatin and paclitaxel in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality of Life; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
Paclitaxel, carboplatin, and gemcitabine in metastatic nasopharyngeal carcinoma: a Phase II trial using a triplet combination.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neutropenia; Paclitaxel; Severity of Illness Index; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2005 |
Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Mitomycin; Quality of Life; Survival Rate; Treatment Outcome | 2005 |
A phase II study of gemcitabine plus carboplatin in platinum-sensitive, recurrent ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms | 2005 |
A phase II study of paclitaxel, carboplatin, and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC-IV (AGO-OVAR protocol OVAR-8).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease-Free Survival; Epithelial Cells; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel | 2005 |
The outcome of elderly patients with advanced urothelial carcinoma after platinum-based combination chemotherapy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Infections; Male; Methotrexate; Middle Aged; Neutropenia; Prognosis; Survival Analysis; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2005 |
Gemcitabine versus FLEC regimen given intra-arterially to patients with unresectable pancreatic cancer: a prospective, randomized phase III trial of the Italian Society for Integrated Locoregional Therapy in Oncology.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2004 |
Carboplatin plus gemcitabine in patients with inoperable or metastatic pancreatic cancer: a phase II multicenter study by the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Greece; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Palliative Care; Pancreatic Neoplasms; Prognosis; Quality of Life; Risk Assessment; Survival Analysis; Terminally Ill; Treatment Outcome | 2005 |
Clinical significance of hypoxia-inducible factor-1a messenger RNA expression in locally advanced non-small-cell lung cancer after platinum agent and gemcitabine chemotherapy followed by surgery.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Female; Gemcitabine; Gene Expression; Humans; Hypoxia-Inducible Factor 1; Hypoxia-Inducible Factor 1, alpha Subunit; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Nuclear Proteins; Pneumonectomy; RNA, Messenger; Survival Analysis; Transcription Factors; Treatment Outcome | 2005 |
Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urothelium.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Treatment Outcome; Urinary Bladder Neoplasms | 2005 |
Cost-minimisation analysis comparing gemcitabine/cisplatin, paclitaxel/carboplatin and vinorelbine/cisplatin in the treatment of advanced non-small cell lung cancer in Italy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost Control; Deoxycytidine; Gemcitabine; Health Care Costs; Health Services; Humans; Italy; Lung Neoplasms; Paclitaxel; Retrospective Studies; Vinblastine; Vinorelbine | 2005 |
Phase II study of first-line sequential chemotherapy with gemcitabine-carboplatin followed by docetaxel in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Taxoids; Treatment Outcome | 2005 |
Randomized study of vinorelbine--gemcitabine versus vinorelbine--carboplatin in patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; International Agencies; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
Activity of carboplatin in patients with advanced non-small cell lung cancer pre-treated with a non-platinum combination.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
Phase II trial of the novel retinoid, bexarotene, and gemcitabine plus carboplatin in advanced non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bexarotene; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Hypertriglyceridemia; Lung Neoplasms; Male; Middle Aged; Survival Rate; Tetrahydronaphthalenes; Treatment Outcome | 2005 |
Chemotherapy for metastatic NSCLC: current status and future direction.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Mitomycin; Quality of Life; Survival Analysis; Treatment Outcome | 2005 |
Sequential gemcitabine-carboplatin followed by paclitaxel-carboplatin in the first-line treatment of advanced ovarian cancer: A phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel | 2006 |
Paclitaxel, carboplatin and gemcitabine combination as induction chemotherapy for stage IIIA N2 bulky non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Remission Induction; Survival Analysis; Treatment Outcome | 2005 |
Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Quality of Life; Statistics, Nonparametric; Survival Analysis; Sweden | 2005 |
Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Eruptions; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2005 |
Randomized multicentric phase II study of carboplatin/gemcitabine and cisplatin/vinorelbine in advanced non-small cell lung cancer GFPC 99-01 study (Groupe français de pneumo-cancérologie).
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Ribonucleotide Reductases; Treatment Outcome; Vinblastine; Vinorelbine | 2006 |
Second-line chemotherapy with weekly paclitaxel and gemcitabine in patients with small-cell lung cancer pretreated with platinum and etoposide: a single institution phase II trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel | 2006 |
The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. A Phase II study of the Hellenic Cooperative Oncology Group.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2006 |
Gemcitabine/carboplatin in patients with metastatic non-small-cell lung cancer: phase II study of 28-day and 21-day schedules.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2005 |
SCOTROC 2A: carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Dyspnea; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
Adding gemcitabine to paclitaxel/carboplatin combination increases survival in advanced non-small-cell lung cancer: results of a phase II-III study.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neutropenia; Paclitaxel; Prognosis; Risk Factors; Survival Rate; Thrombocytopenia; Treatment Outcome | 2006 |
A phase II study of gemcitabine and carboplatin combination chemotherapy in gallbladder carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Follow-Up Studies; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Treatment Outcome | 2006 |
Phase I/II study of weekly paclitaxel plus carboplatin and gemcitabine as first-line treatment of advanced-stage ovarian cancer: pathologic complete response and longitudinal assessment of impact on cognitive functioning.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cognition; Cognition Disorders; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Longitudinal Studies; Middle Aged; Ovarian Neoplasms; Paclitaxel; Quality of Life | 2006 |
Phase II study of PKC-alpha antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Humans; Immunosuppressive Agents; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Oligonucleotides, Antisense; Phosphorothioate Oligonucleotides; Protein Kinase C; Retrospective Studies; Ribonucleotide Reductases; Treatment Outcome | 2006 |
Phase II trial of a 2-h infusion of gemcitabine plus carboplatin as first-line chemotherapy for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Endpoint Determination; Female; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis | 2007 |
Adjuvant intra-arterial 5-fluoruracil, leucovorin, epirubicin and carboplatin with or without systemic gemcitabine after curative resection for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Karnofsky Performance Status; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms | 2006 |
Gemcitabine and oxaliplatin followed by paclitaxel and carboplatin as first line therapy for patients with suboptimally debulked, advanced epithelial ovarian cancer. A phase II trial of sequential doublets. The GO-First Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Paclitaxel; Survival Rate | 2006 |
A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quality of Life | 2006 |
Randomised trial of gemcitabine versus flec regimen given intra-arterially for patients with unresectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2003 |
[Carboplatin plus gemcitabine therapy versus carboplatin plus weekly paclitaxel therapy for advanced non-small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Rate; Thrombocytopenia | 2006 |
Rational drug sequencing of paclitaxel, gemcitabine and carboplatin in patients with untreated stage IV and select stage IIIB non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pleural Effusion; Survival Analysis; Treatment Outcome | 2006 |
Randomized phase II study of carboplatin/gemcitabine versus vinorelbine/gemcitabine in patients with advanced nonsmall cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) 0104.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Patient Selection; Survival; Treatment Outcome; Vinblastine; Vinorelbine | 2006 |
Three sequential chemotherapy doublets for the treatment of newly diagnosed advanced müllerian malignancies: the modified triple doublet regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Mixed Tumor, Mullerian; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Topotecan | 2006 |
Stimulation of erythrocyte phosphatidylserine exposure by paclitaxel.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Calcium; Carboplatin; Cell Size; Ceramides; Deoxycytidine; Endometrial Neoplasms; Erythrocytes; Female; Gemcitabine; Hematocrit; Humans; Mice; Mice, Inbred C57BL; Osmotic Pressure; Ovarian Neoplasms; Paclitaxel; Phosphatidylserines; Protein Binding; Sphingomyelin Phosphodiesterase; Time Factors | 2006 |
RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Gemcitabine; Gene Expression Profiling; Humans; Lung Neoplasms; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleoside Diphosphate Reductase; Survival Analysis; Treatment Outcome; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2006 |
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Quality of Life; Survival Analysis; Treatment Outcome | 2006 |
[Gemcitabine and carboplatin chemotherapy in advanced transitional cell carcinoma in regard to patients with impaired renal function].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gemcitabine; Humans; Kidney Failure, Chronic; Kidney Function Tests; Kidney Pelvis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Prospective Studies; Survival Rate; Ureter; Ureteral Neoplasms; Urinary Bladder; Urinary Bladder Neoplasms | 2006 |
Randomized, multicenter, open-label phase II study of gemcitabine plus single-dose versus split-dose carboplatin in the treatment of patients with advanced-stage non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Survival Analysis | 2006 |
Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Quality of Life; Survival Rate; Vinblastine; Vinorelbine | 2007 |
First-line gemcitabine and carboplatin in advanced ovarian carcinoma: a phase II study.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2006 |
Gemcitabine and carboplatin in carcinoma of unknown primary site: a phase 2 Adelaide Cancer Trials and Education Collaborative study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Australia; Carboplatin; Carcinoma, Large Cell; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms, Unknown Primary; Prognosis; Prospective Studies; Survival Rate; Treatment Outcome | 2006 |
Randomized phase II three-arm trial with three platinum-based doublets in metastatic non-small-cell lung cancer. An Italian Trials in Medical Oncology study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Italy; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Taxoids; Time Factors; Treatment Outcome | 2007 |
The efficacy and relationship between peak concentration and toxicity profile of fixed-dose-rate gemcitabine plus carboplatin in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate | 2007 |
Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cohort Studies; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Female; Gemcitabine; Humans; Kidney Diseases; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Survival Rate; Urinary Bladder Neoplasms | 2007 |
Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gemcitabine; Humans; Italy; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Survival Rate; Time Factors; Treatment Outcome; Turkey; Urinary Bladder Neoplasms; Urothelium | 2007 |
Gemcitabine/carboplatin in a modified 21-day administration schedule for advanced-stage non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Squamous Cell; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Thrombocytopenia; Treatment Outcome | 2006 |
Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group performance status 2 non-small-cell lung cancer patients: ECOG 1599.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis | 2007 |
Phase I study of carboplatin in combination with gemcitabine and irinotecan in patients with solid tumors: preliminary evidence of activity in small cell and neuroendocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Neuroendocrine; Carcinoma, Small Cell; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms | 2007 |
A novel triplet regimen with paclitaxel, carboplatin and gemcitabine (PACCAGE) as induction chemotherapy for locally advanced unresectable non small cell lung cancer (NSCLC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Survival Rate | 2007 |
Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): Feasibility and results.
Topics: Adult; Aged; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Humans; Leukopenia; Male; Mesothelioma; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Pleural Neoplasms; Pneumonectomy; Radiation Dosage; Radiotherapy, Adjuvant; Survival Analysis; Thrombocytopenia; Time Factors | 2007 |
A randomized phase II trial using two different treatment schedules of gemcitabine and carboplatin in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Humans; Immunosuppressive Agents; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Ribonucleotide Reductases; Survival Rate; Treatment Outcome; United States | 2006 |
Phase II trial of gemcitabine-carboplatin-paclitaxel as neoadjuvant chemotherapy for operable non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Humans; Immunosuppressive Agents; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Ribonucleotide Reductases; Severity of Illness Index; Survival Rate | 2006 |
A phase II study of induction therapy with carboplatin and gemcitabine among patients with locally advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Denmark; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Probability; Prognosis; Remission Induction; Survival Analysis; Treatment Outcome | 2006 |
A phase II trial of carboplatin and gemcitabine with exisulind (IND #65,056) in patients with advanced non-small cell lung cancer: an Eastern Cooperative Oncology Group study (E1501).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Sulindac; Survival Rate | 2006 |
Gemcitabine versus gemcitabine-carboplatin for patients with advanced non-small cell lung cancer and a performance status of 2: a prospective randomized phase II study of the Hellenic Cooperative Oncology Group.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Severity of Illness Index; Treatment Outcome | 2007 |
Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Génitales) study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Renal Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Prospective Studies; Survival Rate; Treatment Outcome | 2007 |
Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; ErbB Receptors; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Trastuzumab; Urinary Bladder Neoplasms | 2007 |
Phase II study of gemcitabine and carboplatin in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis | 2007 |
A phase II trial of gemcitabine plus carboplatin in advanced transitional cell carcinoma of the urothelium.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Urinary Bladder Neoplasms; Urothelium | 2007 |
Phase II trial of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary site.
Topics: Abdominal Neoplasms; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carboplatin; Carcinoembryonic Antigen; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Leukopenia; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasms, Unknown Primary; Neutropenia; Treatment Outcome | 2007 |
Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2007 |
Phase II multicenter trial with carboplatin and gemcitabine induction chemotherapy followed by radiotherapy concomitantly with low-dose paclitaxel and gemcitabine for stage IIIA and IIIB non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Radiotherapy Dosage; Remission Induction; Survival Rate; Treatment Outcome | 2007 |
Phase II clinical study of gemcitabine in the treatment of patients with advanced nasopharyngeal carcinoma after the failure of platinum-based chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Hematologic Diseases; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Staging; Platinum Compounds; Survival Rate; Treatment Outcome | 2008 |
Gemcitabine and pegylated liposomal doxorubicin alternating with cisplatin plus cyclophosphamide in platinum refractory/resistant, paclitaxel-pretreated, ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Epithelial Cells; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols | 2008 |
Dose escalating study of biweekly gemcitabine and carboplatin in patients with advanced cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Neoplasms; Patient Selection | 2007 |
A phase I dose escalation study of biweekly gemcitabine and carboplatin in completely resected stage IB-IIIA nonsmall cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Hematologic Diseases; Humans; Leukopenia; Life Expectancy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia | 2007 |
Paclitaxel/Carboplatin/gemcitabine versus gemcitabine/vinorelbine in advanced non-small-cell lung cancer: a phase II/III study of the Minnie Pearl Cancer Research Network.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Survival Rate; Vinblastine; Vinorelbine | 2007 |
Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Cimetidine; Deoxycytidine; Dexamethasone; Diphenhydramine; Female; Gemcitabine; Heart Diseases; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Ondansetron; Paclitaxel; Premedication; Proportional Hazards Models | 2008 |
Phase I and pharmacokinetic study of gemcitabine administered at fixed-dose rate, combined with docetaxel/melphalan/carboplatin, with autologous hematopoietic progenitor-cell support, in patients with advanced refractory tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Female; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Neoplasms; Taxoids; Transplantation, Autologous | 2007 |
Neoadjuvant chemotherapy with gemcitabine-containing regimens in patients with early-stage non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Drug Administration Schedule; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Survival Analysis; Time Factors; Treatment Outcome | 2008 |
The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; California; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Neutropenia; Proteasome Inhibitors; Pyrazines; Thrombocytopenia; Treatment Outcome | 2008 |
Phase II trial of gemcitabine/carboplatin followed by paclitaxel in patients with performance status=2,3 or other significant co-morbidity (HIV infection or s/p organ transplantation) in advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Comorbidity; Deoxycytidine; Female; Gemcitabine; HIV Infections; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Organ Transplantation; Paclitaxel | 2008 |
A phase II study of sequential docetaxel and gemcitabine followed by docetaxel and carboplatin as first-line therapy for non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Taxoids | 2008 |
Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Eicosanoids; Female; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Hydroxyurea; Immunohistochemistry; Lipoxygenase Inhibitors; Logistic Models; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Prognosis; Prospective Studies; Pyrazoles; Sulfonamides; Up-Regulation | 2008 |
Complete metabolic tumour response, assessed by 18-fluorodeoxyglucose positron emission tomography (18FDG-PET), after induction chemotherapy predicts a favourable outcome in patients with locally advanced non-small cell lung cancer (NSCLC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Female; Fluorodeoxyglucose F18; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Radiotherapy; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Treatment outcome in performance status 2 advanced NSCLC patients administered platinum-based combination chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Lung Neoplasms; Quality of Life; Treatment Outcome; Vinblastine; Vinorelbine | 2008 |
A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Trastuzumab | 2009 |
Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Placebos; Prognosis; Radiography; Radiotherapy Dosage; Radiotherapy, Conformal; Remission Induction; Survival Rate; Thoracic Neoplasms | 2008 |
Intensive anti-inflammatory therapy with dexamethasone in patients with non-small cell lung cancer: effect on chemotherapy toxicity and efficacy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Deoxycytidine; Dexamethasone; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Glucocorticoids; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Tissue Distribution; Treatment Outcome | 2009 |
Gemcitabine and carboplatin in intensively pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Patient Selection; Thrombocytopenia | 2007 |
A pharmacodynamic model for the time course of tumor shrinkage by gemcitabine + carboplatin in non-small cell lung cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Kinetics; Lung Neoplasms; Male; Middle Aged; Neoplasms; Time Factors | 2008 |
Phase II trial of gemcitabine/carboplatin (plus trastuzumab in HER2-positive disease) in patients with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Trastuzumab | 2008 |
[Phase II study of combination of gemcitabine and carboplatin in advanced non-small cell lung cancer (an interim report)].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging | 2008 |
[Randomized phase II study of carboplatin/paclitaxel followed by gemcitabine versus carboplatin/gemcitabine followed by docetaxel in patients with advanced nonsmall cell lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids | 2008 |
Comparison of gemcitabine and carboplatin versus cisplatin and etoposide for patients with poor-prognosis small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cause of Death; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Hospitalization; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Small Cell Lung Carcinoma; Treatment Outcome | 2009 |
Economic evaluation of taxane-based first-line chemotherapy in the treatment of patients with metastatic breast cancer in Greece: an analysis alongside a multicenter, randomized phase III clinical trial.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Female; Gemcitabine; Greece; Humans; Neoplasm Metastasis; Paclitaxel; Quality of Life; Quality-Adjusted Life Years; Survival Rate; Taxoids | 2009 |
Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladder.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Urinary Bladder Neoplasms | 2008 |
A phase II trial of gemcitabine/carboplatin with or without trastuzumab in the first-line treatment of patients with metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Receptor, ErbB-2; Trastuzumab | 2008 |
Carboplatin plus gemcitabine repeating doublet therapy in recurrent breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local | 2008 |
Treatment of malignant pleural mesothelioma with carboplatin, liposomized doxorubicin, and gemcitabine: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asbestos; Carboplatin; Deoxycytidine; Disease Progression; Doxorubicin; Female; Gemcitabine; Humans; Liposomes; Male; Maximum Tolerated Dose; Mesothelioma; Middle Aged; Neoplasm Staging; Pleural Effusion, Malignant; Prognosis; Survival Rate; Time Factors | 2008 |
Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Smoking; Taxoids; Vinblastine; Vinorelbine | 2008 |
Clinicopathologic and prognostic significance of overexpression of her-2/neu and p53 oncoproteins in gastric carcinoma using tissue microarray.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Signet Ring Cell; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Female; Follow-Up Studies; Gastrectomy; Gemcitabine; Humans; Immunoenzyme Techniques; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Receptor, ErbB-2; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tissue Array Analysis; Treatment Outcome; Tumor Suppressor Protein p53; Young Adult | 2007 |
Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; ErbB Receptors; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Proportional Hazards Models; Prospective Studies; Vinblastine; Vinorelbine | 2009 |
Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Taxoids; Treatment Outcome | 2009 |
RTOG 0017: a phase I trial of concurrent gemcitabine/carboplatin or gemcitabine/paclitaxel and radiation therapy ("ping-pong trial") followed by adjuvant chemotherapy for patients with favorable prognosis inoperable stage IIIA/B non-small cell lung cancer
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Combined Modality Therapy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Radiotherapy Dosage; Remission Induction; Survival Rate; Treatment Outcome | 2009 |
Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339).
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Pyrazines; Survival Rate; Treatment Outcome | 2009 |
A phase I trial of gemcitabine, docetaxel and carboplatin administered every 2 weeks as first line treatment in patients with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Taxoids | 2009 |
Impact of preoperative chemotherapy on pulmonary function tests in resectable early-stage non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Confidence Intervals; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Pneumonectomy; Preoperative Care; Probability; Respiratory Function Tests; Risk Assessment; Survival Analysis | 2009 |
Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polyethylene Glycols; Topotecan | 2009 |
Chemotherapy and quality of life in NSCLC PS 2 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Karnofsky Performance Status; Life Expectancy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Patient Compliance; Quality of Life; Surveys and Questionnaires; Treatment Outcome; Vinblastine; Vinorelbine | 2009 |
A landmark point analysis with cytotoxic agents for advanced NSCLC.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Prognosis; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine; Young Adult | 2009 |
A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Paclitaxel; Urinary Bladder Neoplasms | 2009 |
Venous thromboembolism in recurrent ovarian cancer-patients: A systematic evaluation of the North-Eastern German Society of Gynaecologic Oncology Ovarian Cancer Study Group (NOGGO).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cohort Studies; Deoxycytidine; Disease-Free Survival; Etoposide; Female; Gemcitabine; Germany; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Topotecan; Venous Thromboembolism | 2009 |
Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Quality of Life | 2009 |
A phase I study of gemcitabine and carboplatin in patients with advanced non-small cell lung cancer and a performance status of 2.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Prognosis; Survival Rate; Treatment Outcome; Young Adult | 2009 |
Phase II trial of neoadjuvant therapy with carboplatin, gemcitabine plus thalidomide for stages IIB and III non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pneumonectomy; Prognosis; Prospective Studies; Survival Rate; Thalidomide; Treatment Outcome | 2009 |
Phase II study of gemcitabine and carboplatin in metastatic breast cancers with prior exposure to anthracyclines and taxanes.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Taxoids; Treatment Outcome | 2010 |
Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2009 |
Randomized double-blind placebo-controlled trial of thalidomide in combination with gemcitabine and Carboplatin in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Placebos; Thalidomide; Treatment Outcome | 2009 |
Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II--results of EORTC study 30986.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Methotrexate; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Survival Analysis; Treatment Outcome; Urologic Neoplasms; Urothelium; Vinblastine | 2009 |
Fixed-dose rate gemcitabine plus carboplatin in relapsed, platinum-sensitive ovarian cancer patients: results of a three-arm Phase I study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms | 2009 |
A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Survival Rate; Treatment Outcome | 2010 |
Is neoadjuvant chemoradiotherapy a feasible strategy for stage IIIA-N2 non-small cell lung cancer? Mature results of the randomized IFCT-0101 phase II trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Survival Analysis; Vinblastine; Vinorelbine | 2010 |
Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; DNA Repair; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Ribonucleoside Diphosphate Reductase; Survival Rate; Tumor Suppressor Proteins | 2009 |
A phase 2 study of platinum and gemcitabine in patients with advanced salivary gland cancer: a trial of the NCIC Clinical Trials Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Survival Rate; Time Factors | 2010 |
The role of histology with common first-line regimens for advanced non-small cell lung cancer: a brief report of the retrospective analysis of a three-arm randomized trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2009 |
Outcomes associated with brain metastases in a three-arm phase III trial of gemcitabine-containing regimens versus paclitaxel plus carboplatin for advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
A retrospective analysis of outcomes across histological subgroups in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin for advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies; Survival Analysis | 2010 |
[Efficacy study of single-agent gemcitabine versus gemcitabine plus carboplatin in untreated elderly patients with stage IIIb/IV non-small-cell lung cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging | 2010 |
First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5): a feasibility study and comparative analysis of the SCOTROC series.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease-Free Survival; Feasibility Studies; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 2010 |
Carboplatin/gemcitabine alternating with carboplatin/pegylated liposomal doxorubicin and carboplatin/cyclophosphamide in platinum-refractory/resistant paclitaxel - pretreated ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Polyethylene Glycols; Prospective Studies; Survival Rate | 2010 |
Influence of comorbidity on survival, toxicity and health-related quality of life in patients with advanced non-small-cell lung cancer receiving platinum-doublet chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Comorbidity; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Quality of Life; Surveys and Questionnaires; Thrombocytopenia; Young Adult | 2010 |
High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; DNA-Binding Proteins; Docetaxel; Drug Resistance, Neoplasm; Endonucleases; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
A randomized phase II study comparing two schedules of the 21-day regimen of gemcitabine and carboplatin in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Thrombocytopenia; Treatment Outcome | 2010 |
Randomized phase II study of gemcitabine and carboplatin +/- sequential docetaxel in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome | 2011 |
Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Deoxycytidine; Dexamethasone; Drug Resistance, Neoplasm; Female; Gemcitabine; Hematopoietic Stem Cell Mobilization; Humans; Lymphoma; Male; Middle Aged; Neoplasm Recurrence, Local; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Remission Induction; Rituximab; Salvage Therapy; Survival Rate; Treatment Outcome; Young Adult | 2010 |
A Comparison of white and African American outcomes from a three-arm, randomized, phase III multicenter trial of advanced or metastatic non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate; Treatment Outcome; White People | 2010 |
Gemcitabine with carboplatin for advanced biliary tract cancers: a phase II single institution study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carboplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Missouri; Survival Rate; Time Factors; Treatment Outcome | 2010 |
Phase II study of carboplatin and gemcitabine as adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: a report from the Central Japan Lung Study Group, CJLSG 0503 trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Deoxycytidine; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Deoxycytidine; DNA Damage; DNA Repair; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Platinum Compounds; Time Factors; Treatment Outcome | 2010 |
Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Europe; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Ovarian Neoplasms; Paclitaxel; Proportional Hazards Models; Prospective Studies; Quality of Life; Time Factors; Treatment Outcome; Young Adult | 2010 |
[A phase II study of gemcitabine and carboplatin bi-weekly combination chemotherapy for complete resected non-small-cell lung cancer patients].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged | 2010 |
A phase II first-line study of gemcitabine, carboplatin, and bevacizumab in advanced stage nonsquamous non-small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Treatment Outcome | 2010 |
A randomized phase II trial of adjuvant chemotherapy with bi-weekly carboplatin plus paclitaxel versus carboplatin plus gemcitabine in patients with completely resected non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Survival Rate; Treatment Outcome | 2010 |
Efficacy and safety of endostar combined with chemotherapy in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Deoxycytidine; Docetaxel; Endostatins; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Recombinant Proteins; Survival Rate; Taxoids; Treatment Outcome | 2010 |
A phase III randomized trial of gemcitabine-oxaliplatin versus carboplatin-paclitaxel as first-line therapy in patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Survival Rate; Treatment Outcome | 2011 |
Iniparib plus chemotherapy in metastatic triple-negative breast cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Breast Neoplasms; Carboplatin; Cross-Over Studies; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Neoplasm Metastasis; Poly(ADP-ribose) Polymerase Inhibitors; Survival Analysis | 2011 |
[Clinical efficacy and adverse effects of taxol plus carboplatin or gemcitabine plus carboplatin in patients with advanced non-small-cell lung carcinoma].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel | 2010 |
Quality of life, geriatric assessment and survival in elderly patients with non-small-cell lung cancer treated with carboplatin-gemcitabine or carboplatin-paclitaxel: NVALT-3 a phase III study.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Geriatric Assessment; Humans; Lung Neoplasms; Male; Paclitaxel; Quality of Life; Survival Rate; Treatment Outcome | 2011 |
Phase II trial of induction gemcitabine and carboplatin followed by conformal thoracic radiation to 74 Gy with weekly paclitaxel and carboplatin in unresectable stage III non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Female; Follow-Up Studies; Gamma Rays; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prospective Studies; Radiography, Thoracic; Radiotherapy Dosage; Standard of Care; Survival Rate; Treatment Outcome | 2011 |
Randomized phase II study of carboplatin-paclitaxel or gemcitabine-vinorelbine in patients with advanced nonsmall cell lung cancer and a performance status of 2: West Japan Thoracic Oncology Group 0004.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infections; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2012 |
Supplementation with fish oil increases first-line chemotherapy efficacy in patients with advanced nonsmall cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dietary Supplements; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Vinblastine; Vinorelbine | 2011 |
A Phase II trial of erlotinib as maintenance treatment after gemcitabine plus platinum-based chemotherapy in patients with recurrent and/or metastatic nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Disease Progression; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Salvage Therapy; Survival Rate | 2012 |
Combination therapy consisting of gemcitabine, carboplatin, and docetaxel as an active treatment for advanced urothelial carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Taxoids; Urologic Neoplasms; Vinblastine | 2011 |
Biweekly gemcitabine-paclitaxel, gemcitabine-carboplatin, or gemcitabine-cisplatin as first-line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial.
Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Treatment Outcome | 2011 |
Pulmonary toxicity in Stage III non-small cell lung cancer patients treated with high-dose (74 Gy) 3-dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy: a secondary analysis of Cancer and Leukemia Grou
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Deoxycytidine; Female; Gemcitabine; Humans; Induction Chemotherapy; Lung; Lung Neoplasms; Male; Middle Aged; Organs at Risk; Paclitaxel; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal | 2011 |
Carboplatin and gemcitabine combination in metastatic triple-negative anthracycline- and taxane-pretreated breast cancer patients: a phase II study.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Breast Neoplasms; Bridged-Ring Compounds; Carboplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Middle Aged; Neutropenia; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Watchful Waiting | 2011 |
Second-line paclitaxel/carboplatin versus vinorelbine/carboplatin in patients who have advanced non-small-cell lung cancer pretreated with non-platinum-based chemotherapy: a multicenter randomized phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2011 |
Medical treatment choices for patients affected by advanced NSCLC in routine clinical practice: results from the Italian observational "SUN" (Survey on the lUng cancer maNagement) study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Italy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Practice Guidelines as Topic; Survival Analysis | 2011 |
[First line therapy for local advanced or metastatic urothelial cell carcinoma: randomized phase II study to investigate the combination of vinflunine with gemcitabine and vinflunine with carboplatin in patients unfit for cisplatin therapy with advanced o
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Urinary Bladder Neoplasms; Vinblastine | 2011 |
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; China; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Gene Deletion; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines | 2011 |
Carboplatin and gemcitabine in first-line treatment of elderly patients with advanced non-small cell lung cancer: data from a retrospective study.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Retrospective Studies; Treatment Outcome | 2011 |
Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Paclitaxel; Survival Rate; Vinblastine; Vinorelbine | 2011 |
Quality-of-life evaluation for advanced non-small-cell lung cancer: a comparison between vinorelbine plus gemcitabine followed by docetaxel versus paclitaxel plus carboplatin regimens in a randomized trial: Japan Multinational Trial Organization LC00-03 (
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality of Life; Self-Assessment; Surveys and Questionnaires; Taxoids; Vinblastine; Vinorelbine | 2011 |
[Short-term intermittent prophylactic administration of recombinant human thrombopoietin attenuates chemotherapy-induced thrombocytopenia in lung cancer patients].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Cisplatin; Deoxycytidine; Dizziness; Female; Fever; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platelet Count; Recombinant Proteins; Thrombocytopenia; Thrombopoietin | 2011 |
A randomized phase II trial of pemetrexed/gemcitabine/bevacizumab or pemetrexed/carboplatin/bevacizumab in the first-line treatment of elderly patients with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Fatigue; Female; Gemcitabine; Glutamates; Guanine; Humans; Infections; Kaplan-Meier Estimate; Lung Neoplasms; Male; Neutropenia; Pemetrexed; Thrombocytopenia; Thromboembolism; Time Factors; Treatment Outcome | 2012 |
Randomized phase II study of two schedules of carboplatin and gemcitabine for stage IIIB and IV advanced non-small cell lung cancer (JACCRO LC-01 study).
Topics: Adult; Aged; Alanine Transaminase; Alkaline Phosphatase; Anemia; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diarrhea; Drug Administration Schedule; Female; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Thrombocytopenia | 2011 |
Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arachidonate 5-Lipoxygenase; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Celecoxib; Cyclooxygenase 2; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Pyrazoles; Sulfonamides; Vascular Endothelial Growth Factor A | 2011 |
Phase III trial of induction gemcitabine or paclitaxel plus carboplatin followed by paclitaxel consolidation in ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Induction Chemotherapy; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Survival Rate; Young Adult | 2011 |
Phase I-II trial of gemcitabine-based first-line chemotherapies for small cell lung cancer in elderly patients with performance status 0-2: the G-STEP trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Multivariate Analysis; Prognosis; Proportional Hazards Models; Quality of Life; Treatment Outcome; Vinblastine; Vinorelbine | 2012 |
Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Germ Cells; Humans; Lung Neoplasms; Male; Middle Aged; Polymorphism, Genetic; Prognosis; Treatment Outcome | 2012 |
Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carboplatin; Cisplatin; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Ovarian Neoplasms; Paclitaxel; Polymorphism, Genetic; Topotecan; Young Adult | 2012 |
Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Contraindications; Deoxycytidine; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Quality of Life; Surveys and Questionnaires; Survival Rate; Urologic Neoplasms; Vinblastine | 2012 |
Phase I/II trial of custirsen (OGX-011), an inhibitor of clusterin, in combination with a gemcitabine and platinum regimen in patients with previously untreated advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oligonucleotides, Antisense; Survival Rate; Thionucleotides; Treatment Outcome | 2012 |
[Phase II trial of improved regimen with gemcitabine in patients with advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged | 2012 |
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Europe; Exons; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Patient Selection; Precision Medicine; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Taxoids; Time Factors; Treatment Outcome | 2012 |
RRM1 and ERCC1 expression in peripheral blood versus tumor tissue in gemcitabine/carboplatin-treated advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; DNA-Binding Proteins; Endonucleases; Female; Follow-Up Studies; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Regression Analysis; Ribonucleoside Diphosphate Reductase; Survival Rate; Tumor Suppressor Proteins; Young Adult | 2012 |
A phase I/II study of carboplatin plus gemcitabine for elderly patients with advanced non-small cell lung cancer: West Japan Thoracic Oncology Group Trial (WJTOG) 2905.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Hematologic Diseases; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Staging; Treatment Outcome | 2012 |
[A randomized controlled trial of the efficacy of combination of gemcitabine and carboplatin or paclitaxel and combination of paclitaxel and carboplatin in the treatment for advanced non-small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Remission Induction; Survival Rate; Thrombocytopenia | 2011 |
A phase II study of first-line chemotherapy with weekly carboplatin plus gemcitabine in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neutropenia; Thrombocytopenia; Treatment Outcome | 2012 |
An apoptosis methylation prognostic signature for early lung cancer in the IFCT-0002 trial.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Biomarkers, Tumor; Calcium-Calmodulin-Dependent Protein Kinases; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cytoskeleton; Death-Associated Protein Kinases; Deoxycytidine; Disease-Free Survival; DNA Methylation; ErbB Receptors; Female; Gemcitabine; Genes, p53; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prognosis; Promoter Regions, Genetic; RNA Interference; RNA, Small Interfering; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2012 |
Biweekly combination therapy with gemcitabine and carboplatin compared with gemcitabine monotherapy in elderly patients with advanced non-small-cell lung cancer: a randomized, phase-II study.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Leukopenia; Lung Neoplasms; Male; Neoplasm Staging; Treatment Outcome | 2012 |
Intermittent chemotherapy is a treatment choice for advanced urothelial cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Paclitaxel; Prospective Studies; Quality of Life; Serum Albumin; Survival Rate; Time Factors; Treatment Outcome; Urologic Neoplasms; Urothelium | 2012 |
Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Quality of Life; Vinblastine; Vinorelbine | 2012 |
Chemotherapy effectiveness after first-line gefitinib treatment for advanced lepidic predominant adenocarcinoma (formerly advanced bronchioloalveolar carcinoma): exploratory analysis of the IFCT-0401 trial.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Follow-Up Studies; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Prospective Studies; Quinazolines; Salvage Therapy; Survival Rate | 2012 |
Methotrexate-paclitaxel-epirubicin-carboplatin as second-line chemotherapy in patients with metastatic transitional cell carcinoma of the bladder pretreated with cisplatin-gemcitabine: a phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Methotrexate; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Salvage Therapy; Survival Rate; Urinary Bladder Neoplasms | 2013 |
Efficacies and safety of neoadjuvant gemcitabine plus carboplatin followed by immediate cystectomy in patients with muscle-invasive bladder cancer, including those unfit for cisplatin: a prospective single-arm study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Cisplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lymph Node Excision; Male; Middle Aged; Neoadjuvant Therapy; Prospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2013 |
Safety and efficacy of sequential chemotherapy with carboplatin plus gemcitabine followed by weekly paclitaxel in advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Treatment Outcome | 2013 |
Phase II study of biweekly carboplatin, gemcitabine, and bevacizumab as first-line treatment in patients with stage IIIB/IV NSCLC.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Hypertension; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Treatment Outcome | 2014 |
A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer: North Central Cancer Treatment Group Study N0528.
Topics: Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Dyspnea; Fatigue; Female; Gemcitabine; Humans; Hypothyroidism; Kaplan-Meier Estimate; Logistic Models; Lung Neoplasms; Male; Middle Aged; Neutropenia; Polymorphism, Single Nucleotide; Proportional Hazards Models; Quinazolines; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Fibroblast Growth Factor, Type 2; Stomatitis; Vascular Endothelial Growth Factor Receptor-3 | 2013 |
Randomized Phase II trial of paclitaxel and carboplatin followed by gemcitabine switch-maintenance therapy versus gemcitabine and carboplatin followed by gemcitabine continuation-maintenance therapy in previously untreated advanced non-small cell lung can
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel | 2013 |
Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Constipation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Treatment Outcome; Urologic Neoplasms; Urothelium | 2013 |
A phase II study of induction carboplatin and gemcitabine followed by chemoradiotherapy for the treatment of locally advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemoradiotherapy; Cisplatin; Deoxycytidine; Disease-Free Survival; Dose Fractionation, Radiation; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Humans; Induction Chemotherapy; Lymphatic Metastasis; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Staging; Radiotherapy, Intensity-Modulated; Remission Induction; Ribonucleotide Reductases; Survival Rate; Young Adult | 2013 |
Pharmacodynamic stimulation of thrombogenesis by angiotensin (1-7) in recurrent ovarian cancer patients receiving gemcitabine and platinum-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin I; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Cisplatin; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Peptide Fragments; Thrombocytopenia | 2013 |
Chemotherapy management of malignant pleural mesothelioma: a phase II study comparing two popular chemotherapy regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Neoplasm Staging; Pemetrexed; Pleural Neoplasms; Prospective Studies; Survival Rate; Treatment Outcome | 2013 |
Phase II randomized trial of carboplatin and gemcitabine with or without dexamethasone pre-treatment in patients with Stage IV non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dexamethasone; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Serum Albumin; Survival Rate; Treatment Outcome | 2013 |
Impact of beta blocker medication in patients with platinum sensitive recurrent ovarian cancer-a combined analysis of 2 prospective multicenter trials by the AGO Study Group, NCIC-CTG and EORTC-GCG.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Young Adult | 2013 |
A trial-based cost-effectiveness analysis of erlotinib alone versus platinum-based doublet chemotherapy as first-line therapy for Eastern Asian nonsquamous non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asia, Eastern; Carboplatin; Carcinoma, Non-Small-Cell Lung; Costs and Cost Analysis; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Models, Economic; Quinazolines; Time Factors | 2013 |
A randomized phase II non-comparative study of pemetrexed‑carboplatin and gemcitabine‑vinorelbine in anthracycline- and taxane-pretreated advanced breast cancer patients.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Carboplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Glutamates; Guanine; Humans; Middle Aged; Neoplasm Staging; Pemetrexed; Taxoids; Vinblastine; Vinorelbine | 2013 |
A phase II study of the combination of gemcitabine plus carboplatin as the neoadjuvant treatment in locally advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy | 2013 |
Does histology predict survival of advanced non-small cell lung cancer patients treated with platin-based chemotherapy? An analysis of the Eastern Cooperative Oncology Group Study E1594.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Neoplasms, Squamous Cell; Paclitaxel; Retrospective Studies; Taxoids; Treatment Outcome | 2013 |
Randomized phase II trial of non-platinum induction or consolidation chemotherapy plus concomitant chemoradiation in stage III NSCLC patients: mature results of the Spanish Lung Cancer Group 0008 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Consolidation Chemotherapy; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Taxoids; Treatment Outcome | 2013 |
Phase I dose-escalation study and population pharmacokinetic analysis of fixed dose rate gemcitabine plus carboplatin as second-line therapy in patients with ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma; Deoxycytidine; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Thrombocytopenia | 2013 |
Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; DNA-Binding Proteins; Docetaxel; Endonucleases; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; International Cooperation; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Taxoids; Treatment Outcome; Tumor Suppressor Proteins | 2013 |
A phase II trial of neoadjuvant nab-paclitaxel, carboplatin, and gemcitabine (ACaG) in patients with locally advanced carcinoma of the bladder.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Cystectomy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Neutropenia; Paclitaxel; Thrombocytopenia; Urinary Bladder Neoplasms | 2013 |
Treatment outcomes of paclitaxel for refractory or recurrent epithelial ovarian cancer patients in Thailand.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Cyclophosphamide; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Endometrial Neoplasms; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Survival Rate | 2013 |
A randomised trial comparing preoperative to perioperative chemotherapy in early-stage non-small-cell lung cancer (IFCT 0002 trial).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Paclitaxel; Perioperative Care; Preoperative Care; Quality of Life; Treatment Outcome; Vomiting | 2013 |
Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asia; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; Deoxycytidine; Disease-Free Survival; DNA Mutational Analysis; Double-Blind Method; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Genetic Predisposition to Disease; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Phenotype; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2013 |
[Efficacy and safety of pemetrexed or gemcitabine combined with carboplatin as the first-line therapy in elderly patients with advanced non-small cell lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Nausea; Neoplasm Staging; Neutropenia; Pemetrexed; Quality of Life; Survival Rate; Thrombocytopenia; Vomiting | 2013 |
Neoadjuvant chemotherapy with gemcitabine plus carboplatin followed by immediate radical cystectomy for muscle-invasive bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cystectomy; Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Neoplasm Invasiveness; Prospective Studies; Time Factors; Urinary Bladder Neoplasms | 2014 |
Combination of low-dose gemcitabine in 6-hour infusion and carboplatin is a favorable option for patients in poor performance status with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Survival Rate | 2014 |
Phase II study of low-dose paclitaxel with timed thoracic radiotherapy followed by adjuvant gemcitabine and carboplatin in unresectable stage III non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy; Thorax | 2014 |
Phase II trial of combination nab-paclitaxel, carboplatin and gemcitabine in first line therapy of advanced urothelial carcinoma.
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Demography; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Analysis; Treatment Outcome; Urologic Neoplasms; Urothelium | 2014 |
[ATP-tumor chemosensitivity assay directed chemotherapy in patients with cervical cancer].
Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Cisplatin; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Fluorouracil; Gemcitabine; Humans; Ifosfamide; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate; Uterine Cervical Neoplasms; Vincristine | 2013 |
Phase I study of elisidepsin (Irvalec®) in combination with carboplatin or gemcitabine in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Depsipeptides; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms | 2014 |
Associations between TS, TTF-1, FR-α, FPGS, and overall survival in patients with advanced non-small-cell lung cancer receiving pemetrexed plus carboplatin or gemcitabine plus carboplatin as first-line chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; DNA-Binding Proteins; Female; Folate Receptor 1; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Peptide Synthases; Prognosis; Retrospective Studies; Survival Rate; Thymidylate Synthase; Tissue Array Analysis; Transcription Factors | 2013 |
Independent radiologic review: bevacizumab in combination with gemcitabine and carboplatin in recurrent ovarian cancer.
Topics: Adult; Advisory Committees; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Radiology; Tomography, X-Ray Computed | 2014 |
A phase I study of concurrent individualized, isotoxic accelerated radiotherapy and cisplatin-vinorelbine-cetuximab in patients with stage III non-small-cell lung cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Chemoradiotherapy; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Precision Medicine; Radiotherapy Dosage; Remission Induction; Vinblastine; Vinorelbine | 2014 |
A correlative biomarker analysis of the combination of bevacizumab and carboplatin-based chemotherapy for advanced nonsquamous non-small-cell lung cancer: results of the phase II randomized ABIGAIL study (BO21015).
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; E-Selectin; Female; Fibroblast Growth Factor 2; Gemcitabine; Humans; Intercellular Adhesion Molecule-1; Lung Neoplasms; Male; Neuropilins; Paclitaxel; Placenta Growth Factor; Platelet Endothelial Cell Adhesion Molecule-1; Pregnancy Proteins; Prospective Studies; Survival Rate; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
A randomized phase II trial of gemcitabine plus carboplatin: biweekly versus standard schedules in patients with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Treatment Outcome | 2013 |
A phase II study of gemcitabine, carboplatin and bevacizumab for the treatment of platinum-sensitive recurrent ovarian cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Deoxycytidine; Drug Therapy, Combination; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms | 2014 |
Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antineoplastic Combined Chemotherapy Protocols; Broadly Neutralizing Antibodies; Carboplatin; Deoxycytidine; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Polyethylene Glycols; Taxoids | 2015 |
Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Neuroendocrine; Cisplatin; Deoxycytidine; Disease-Free Survival; Etoposide; Female; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Organoplatinum Compounds; Oxaliplatin; Prognosis; Proportional Hazards Models; Retrospective Studies; Treatment Outcome | 2014 |
Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Cyclophosphamide; Cystadenocarcinoma, Serous; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Topotecan; Young Adult | 2014 |
Phase Ib study of dovitinib in combination with gemcitabine plus cisplatin or gemcitabine plus carboplatin in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Cisplatin; Colonic Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Quinolones; Thromboembolism; Treatment Outcome; Urinary Bladder Neoplasms; Young Adult | 2014 |
Timing of thoracic radiotherapy in limited stage small cell lung cancer: results of early versus late irradiation from a single institution in Turkey.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Chemoradiotherapy; Cisplatin; Deoxycytidine; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Radiotherapy Dosage; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Time Factors | 2014 |
Concurrent gemcitabine and 3D radiotherapy in patients with stage III unresectable non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Radiation-Sensitizing Agents; Radiotherapy, Conformal; Treatment Outcome; Vinblastine | 2014 |
Changes in skeletal muscle mass during palliative chemotherapy in patients with advanced lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cachexia; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Drug Dosage Calculations; Female; Gemcitabine; Humans; Lumbosacral Region; Lung Neoplasms; Male; Middle Aged; Muscle, Skeletal; Palliative Care; Pilot Projects; Radiography; Sarcopenia; Sex Factors; Vinblastine; Vinorelbine | 2015 |
A randomized phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in locally advanced or metastatic squamous cell carcinoma of lung.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Squamous Cell; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Prospective Studies; Treatment Outcome; Young Adult | 2014 |
Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carboplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Proportional Hazards Models; Risk Factors; Time Factors; Treatment Outcome; Triple Negative Breast Neoplasms; United States | 2014 |
Intratumoral chemotherapy with paclitaxel liposome combined with systemic chemotherapy: a new method of neoadjuvant chemotherapy for stage III unresectable non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Injections, Intralesional; Kaplan-Meier Estimate; Liposomes; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel | 2015 |
Pemetrexed and gemcitabine versus carboplatin and gemcitabine in non-small cell lung cancer: a randomized noninferiority phase II study in one center.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Pemetrexed; Treatment Outcome | 2015 |
Prognostic value of ERCC1, RRM1, and TS proteins in patients with resected non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; China; Deoxycytidine; Disease-Free Survival; DNA-Binding Proteins; Drug Administration Schedule; Endonucleases; Gemcitabine; Glutamates; Guanine; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lung Neoplasms; Male; Pemetrexed; Precision Medicine; Predictive Value of Tests; Prospective Studies; Ribonucleoside Diphosphate Reductase; Thymidylate Synthase; Tumor Suppressor Proteins | 2015 |
A phase I pilot study of the insulin-like growth factor 1 receptor pathway modulator AXL1717 in combination with gemcitabine HCl and carboplatin in previously untreated, locally advanced, or metastatic non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pilot Projects; Podophyllotoxin; Prognosis; Receptor, IGF Type 1; Tissue Distribution | 2015 |
Concurrent chemo-radiation with or without induction gemcitabine, Carboplatin, and Paclitaxel: a randomized, phase 2/3 trial in locally advanced nasopharyngeal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemoradiotherapy; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Paclitaxel; Patient Compliance; Quality of Life; Radiation-Sensitizing Agents | 2015 |
Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; BRCA1 Protein; BRCA2 Protein; Carboplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Gene Expression Profiling; Genomic Instability; Humans; Mastectomy, Segmental; Middle Aged; Mutation; Neoadjuvant Therapy; Neoplasm Staging; Treatment Outcome; Triple Negative Breast Neoplasms | 2015 |
First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Survival Analysis; Treatment Outcome | 2015 |
Phase I study of combination of vorinostat, carboplatin, and gemcitabine in women with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Hydroxamic Acids; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Vorinostat | 2015 |
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802).
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Survival Analysis; Treatment Outcome | 2015 |
Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Survival Rate | 2015 |
Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2016 |
Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Protocols; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Research Design; Survival Analysis; Time Factors; Treatment Outcome; Triple Negative Breast Neoplasms | 2015 |
TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.
Topics: Aged; Anemia; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Cancer Vaccines; Carboplatin; Carcinoma, Non-Small-Cell Lung; CD56 Antigen; Cisplatin; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Erlotinib Hydrochloride; Fatigue; Female; Gemcitabine; Humans; Immunotherapy; Lectins, C-Type; Lung Neoplasms; Lymphocyte Activation; Lymphocytes; Male; Membrane Glycoproteins; Middle Aged; Mucin-1; Neutropenia; Paclitaxel; Pemetrexed; Predictive Value of Tests; Receptors, IgG | 2016 |
A randomized phase II trial of ERCC1 and RRM1 mRNA expression-based chemotherapy versus docetaxel/carboplatin in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; DNA-Binding Proteins; Docetaxel; Endonucleases; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Survival Rate; Taxoids; Treatment Outcome; Tumor Suppressor Proteins; Vinblastine; Vinorelbine; Young Adult | 2016 |
Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Geriatric Assessment; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Quality of Life; Survival Rate; Taxoids | 2016 |
A multicenter randomized controlled open-label trial to assess the efficacy of compound kushen injection in combination with single-agent chemotherapy in treatment of elderly patients with advanced non-small cell lung cancer: study protocol for a randomiz
Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Protocols; Deoxycytidine; Disease-Free Survival; Docetaxel; Drugs, Chinese Herbal; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Lung Neoplasms; Male; Paclitaxel; Proportional Hazards Models; Quality of Life; Research Design; Taxoids; Time Factors; Treatment Outcome | 2016 |
Impact of Chemotherapy on Retroperitoneal Lymph Nodes in Ovarian Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carboplatin; Deoxycytidine; Female; Fibrosis; Gemcitabine; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Ovarian Neoplasms; Prognosis; Retroperitoneal Space; Taxoids | 2016 |
Models for change in tumour size, appearance of new lesions and survival probability in patients with advanced epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Gemcitabine; Humans; Models, Biological; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Survival Analysis | 2016 |
Health-related quality of life in elderly patients with advanced non-small cell lung cancer comparing carboplatin and weekly paclitaxel doublet chemotherapy with monotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Decision Making; Deoxycytidine; Europe; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality of Life; Surveys and Questionnaires; Time Factors; Vinblastine; Vinorelbine | 2016 |
Panitumumab, Gemcitabine, and Carboplatin as Treatment for Women With Metastatic Triple-Negative Breast Cancer: A Sarah Cannon Research Institute Phase II Trial.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Class I Phosphatidylinositol 3-Kinases; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Panitumumab; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins p21(ras); PTEN Phosphohydrolase; Signal Transduction; Treatment Outcome; Triple Negative Breast Neoplasms; Tumor Suppressor Protein p53 | 2016 |
Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cohort Studies; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nivolumab; Pemetrexed; Proto-Oncogene Proteins p21(ras); Survival Rate | 2016 |
Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nivolumab; Paclitaxel; Pemetrexed; Taxoids | 2016 |
Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Austria; Carboplatin; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Quality of Life; Topotecan | 2016 |
Measurement of health-related quality of life during chemotherapy - the importance of timing.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Prospective Studies; Quality of Life; Survival Rate; Time Factors; Vinblastine; Vinorelbine | 2017 |
Thyroid V40 Predicts Primary Hypothyroidism After Intensity Modulated Radiation Therapy for Nasopharyngeal Carcinoma.
Topics: Adult; Age Factors; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemoradiotherapy; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Hypothyroidism; Incidence; Induction Chemotherapy; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Paclitaxel; Pituitary Gland; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Regression Analysis; Thyroid Gland; Time Factors | 2017 |
Histology-based Combination Induction Chemotherapy for Elderly Patients with Clinical Stage III Non-small Cell Lung Cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Neoplasm Staging; Pemetrexed; Treatment Outcome | 2017 |
Intercalating and maintenance gefitinib plus chemotherapy versus chemotherapy alone in selected advanced non-small cell lung cancer with unknown EGFR status.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Smokers | 2017 |
Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Dioxoles; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Early Termination of Clinical Trials; Europe; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Prospective Studies; Tetrahydroisoquinolines; Time Factors; Topotecan; Trabectedin; Treatment Outcome | 2017 |
SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy-Induced Febrile Neutropenia; Cisplatin; Deoxycytidine; Diarrhea; Epistaxis; Fatigue; Female; Gemcitabine; Humans; Lethargy; Lung Neoplasms; Male; Middle Aged; Nausea; Pemetrexed; Protein Kinase Inhibitors; Thrombocytopenia; Vomiting | 2017 |
A phase II study of biweekly gemcitabine and carboplatin in completely resected stage IB-IIIA non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prospective Studies | 2018 |
Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Treatment Outcome; Triple Negative Breast Neoplasms | 2018 |
Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bayes Theorem; Benzimidazoles; Bile Duct Neoplasms; Breast Neoplasms; Carboplatin; Carcinoma, Basal Cell; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Genes, BRCA1; Genes, BRCA2; Germ-Line Mutation; Humans; Induction Chemotherapy; Kidney Neoplasms; Kidney Pelvis; Liver Neoplasms; Lung Neoplasms; Maintenance Chemotherapy; Male; Maximum Tolerated Dose; Mesothelioma; Middle Aged; Nausea; Neoplasm Metastasis; Neutropenia; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Prostatic Neoplasms; Skin Neoplasms; Thrombocytopenia; Treatment Outcome | 2018 |
Pharmacometabonomics Analysis Reveals Serum Formate and Acetate Potentially Associated with Varying Response to Gemcitabine-Carboplatin Chemotherapy in Metastatic Breast Cancer Patients.
Topics: Acetates; Adult; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Pharmacological; Breast Neoplasms; Carboplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Formates; Gemcitabine; Humans; Lymphatic Metastasis; Magnetic Resonance Spectroscopy; Middle Aged; Prognosis; ROC Curve; Taxoids | 2018 |
Expression of Estrogen Receptor-α and Survival in Advanced-stage Non-small Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Estrogen Receptor alpha; Female; Gemcitabine; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Retrospective Studies | 2018 |
Time-to-Treatment-Failure and Related Outcomes Among 1000+ Advanced Non-Small Cell Lung Cancer Patients: Comparisons Between Older Versus Younger Patients (Alliance A151711).
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Paclitaxel; Pemetrexed; Prospective Studies; Survival Rate; Time-to-Treatment; Treatment Failure | 2018 |
nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Mastectomy; Middle Aged; Paclitaxel; Progression-Free Survival; Triple Negative Breast Neoplasms | 2018 |
The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of platinum-based chemotherapy in patients with metastatic triple negative breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lymphocyte Count; Lymphocytes; Middle Aged; Neoplasm Metastasis; Neutrophils; Paclitaxel; Retrospective Studies; Survival Rate; Triple Negative Breast Neoplasms | 2018 |
Multicenter Phase 2 Trial of Gemcitabine, Carboplatin, and Sorafenib in Patients With Metastatic or Unresectable Transitional-Cell Carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Progression-Free Survival; Sorafenib; Survival Analysis; Urologic Neoplasms | 2018 |
A randomised phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in advanced squamous cell lung carcinoma (C-TONG1002).
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Quality of Life; Survival Rate | 2019 |
IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Capecitabine; Carboplatin; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Mastectomy; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Placebos; Randomized Controlled Trials as Topic; Treatment Outcome; Triple Negative Breast Neoplasms | 2019 |
Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Carboplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Retreatment; Treatment Outcome; Triple Negative Breast Neoplasms | 2019 |
A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Imidazoles; Maintenance Chemotherapy; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; p38 Mitogen-Activated Protein Kinases; Progression-Free Survival; Pyridines; Young Adult | 2020 |
A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carboplatin; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Patient Safety; Polyethylene Glycols; Survival Rate; Topotecan; Treatment Outcome | 2020 |
Microwave ablation plus chemotherapy versus chemotherapy in advanced non-small cell lung cancer: a multicenter, randomized, controlled, phase III clinical trial.
Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Microwaves; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Paclitaxel; Pemetrexed; Progression-Free Survival; Prospective Studies; Radiofrequency Ablation; Treatment Outcome; Vinorelbine | 2020 |
Phase II Study on Biweekly Combination Therapy of Gemcitabine plus Carboplatin for the Treatment of Elderly Patients with Advanced Non-Small Cell Lung Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Treatment Outcome | 2020 |
Five-year safety and efficacy data from a phase Ib study of nivolumab and chemotherapy in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nivolumab; Paclitaxel; Pemetrexed; Progression-Free Survival; Treatment Outcome | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Durvalumab in frail and elderly patients with stage four non-small cell lung cancer: Study protocol of the randomized phase II DURATION trial.
Topics: Aged; Aged, 80 and over; Albumins; Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Frail Elderly; Gemcitabine; Germany; Humans; Immunotherapy; Lung Neoplasms; Male; Multicenter Studies as Topic; Neoplasm Staging; Paclitaxel; Progression-Free Survival; Prospective Studies; Randomized Controlled Trials as Topic; Vinorelbine | 2020 |
A randomised Phase II trial of carboplatin and gemcitabine ± vandetanib in first-line treatment of patients with advanced urothelial cell cancer not suitable to receive cisplatin.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Double-Blind Method; Drug Combinations; Female; Gemcitabine; Humans; Male; Neoplasm Staging; Piperidines; Quinazolines; Treatment Outcome | 2020 |
Randomized Phase II Study of First-Line Biweekly Gemcitabine and Carboplatin Versus Biweekly Gemcitabine and Carboplatin plus Maintenance Gemcitabine in Elderly Patients with Untreated Non-Small Cell Lung Cancer: LOGIK0801.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Treatment Outcome | 2020 |
A randomized phase II trial of cisplatin plus gemcitabine versus carboplatin plus gemcitabine in patients with completely resected non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT0703).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Postoperative Period; Ribonucleoside Diphosphate Reductase; Treatment Outcome | 2020 |
Pemetrexed-Based Chemotherapy Is Inferior to Pemetrexed-Free Regimens in Thyroid Transcription Factor 1 (TTF-1)-Negative, EGFR/ALK-Negative Lung Adenocarcinoma: A Propensity Score Matched Pairs Analysis.
Topics: Adenocarcinoma of Lung; Aged; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; DNA-Binding Proteins; ErbB Receptors; Female; Follow-Up Studies; Gemcitabine; Gene Rearrangement; Humans; Lung Neoplasms; Male; Matched-Pair Analysis; Middle Aged; Mutation; Pemetrexed; Prognosis; Propensity Score; Retrospective Studies; Survival Rate; Transcription Factors | 2020 |
First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset.
Topics: Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Confidence Intervals; Cross-Over Studies; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Genes, erbB-1; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Programmed Cell Death 1 Receptor; Progression-Free Survival; Treatment Outcome | 2020 |
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carboplatin; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Maintenance Chemotherapy; Male; Middle Aged; Progression-Free Survival; Survival Analysis; Urologic Neoplasms; Urothelium | 2020 |
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Survival Analysis | 2020 |
Predicting Chemotherapy-Induced Neutropenia and Granulocyte Colony-Stimulating Factor Response Using Model-Based In Vitro to Clinical Translation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Cells, Cultured; Deoxycytidine; Doxorubicin; Filgrastim; Gemcitabine; Humans; Incidence; Models, Biological; Myelopoiesis; Neoplasms; Neutropenia; Paclitaxel; Polyethylene Glycols; Primary Cell Culture; Risk Assessment; Treatment Outcome | 2020 |
Addition of carboplatin-gemcitabine as second-line neoadjuvant chemotherapy in non-responsive locally advanced breast cancer patients to standard neoadjuvant chemotherapy and evaluation of factors affecting response: a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Prognosis; Prospective Studies; Salvage Therapy; Young Adult | 2021 |
Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Disease Progression; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Mesothelioma, Malignant; Netherlands; Pemetrexed; Prospective Studies; Treatment Outcome | 2021 |
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Progression-Free Survival; Survival Rate | 2021 |
Gemcitabine, carboplatin and veliparib in multiple relapsed/refractory germ cell tumours: The GCT-SK-004 phase II trial.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasms, Germ Cell and Embryonal; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Young Adult | 2021 |
Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Combined Modality Therapy; Dendritic Cells; Deoxycytidine; Female; Gemcitabine; Humans; Immunotherapy, Adoptive; Middle Aged; Neoplasm Staging; Ovarian Neoplasms | 2021 |
A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Macrophage Colony-Stimulating Factor; Treatment Outcome; Triple Negative Breast Neoplasms | 2022 |
A phase 1b study of crenigacestat (LY3039478) in combination with gemcitabine and cisplatin or gemcitabine and carboplatin in patients with advanced or metastatic solid tumors.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzazepines; Carboplatin; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Neoplasms; Neoplasms, Second Primary | 2022 |
Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Gemcitabine; Humans; Pyrimidines; Randomized Controlled Trials as Topic; Triple Negative Breast Neoplasms | 2022 |
Phase II Trials of Iniparib (BSI-201) in Combination with Gemcitabine and Carboplatin in Patients with Recurrent Ovarian Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Recurrence; Treatment Outcome | 2023 |
Design and rationale of a single-arm phase II study of neoadjuvant Durvalumab and Gemcitabine associated with Cisplatin or Carboplatin for upper urinary tract urothelial cancer: the iNDUCT trial (NCT04617756).
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Gemcitabine; Humans; Kidney Neoplasms; Kidney Pelvis; Neoadjuvant Therapy; Retrospective Studies; Ureteral Neoplasms; Urinary Bladder Neoplasms | 2023 |
398 other study(ies) available for gemcitabine and carboplatin
| Article | Year |
|---|---|
Gemcitabine shows promise as combination agent in NSCLC.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Survival Rate | 1996 |
Severe hemolytic uremic syndrome in an advanced ovarian cancer patient treated with carboplatin and gemcitabine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Middle Aged; Ovarian Neoplasms | 1999 |
Intravenous cereport (RMP-7) enhances delivery of hydrophilic chemotherapeutics and increases survival in rats with metastatic tumors in the brain.
Topics: Animals; Antineoplastic Agents; Autoradiography; Blood-Brain Barrier; Bradykinin; Brain; Brain Neoplasms; Carboplatin; Carmustine; Deoxycytidine; Gemcitabine; Male; Rats; Rats, Inbred F344; Vinblastine; Vinorelbine | 2000 |
Preclinical in vivo antitumor efficacy of nedaplatin with gemcitabine against human lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Organoplatinum Compounds; Tumor Cells, Cultured | 2001 |
Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Survival Rate; Urinary Bladder Neoplasms | 2001 |
Gemcitabine in the treatment of ovarian cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Ovarian Neoplasms; Treatment Outcome | 2001 |
Carboplatin and gemcitabine in metastatic transitional cell carcinoma of the urothelium: effective treatment of patients with poor prognostic features.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pilot Projects; Prognosis; Treatment Outcome; Urologic Neoplasms; Urothelium | 2001 |
[Concomitant radiochemotherapy for non-small-cell lung cancer: towards an ideal strategy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Ifosfamide; Immunologic Factors; Lung Neoplasms; Mitomycin; Neoplasm Metastasis; Paclitaxel; Radiation-Sensitizing Agents; Randomized Controlled Trials as Topic; Vinblastine; Vinorelbine | 2001 |
Drug interactions and cytotoxic effects of paclitaxel in combination with carboplatin, epirubicin, gemcitabine or vinorelbine in breast cancer cell lines and tumor samples.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Drug Screening Assays, Antitumor; Epirubicin; Female; Gemcitabine; Humans; Paclitaxel; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 2001 |
Interactions of gemcitabine, carboplatin and paclitaxel in molecularly defined non-small-cell lung cancer cell lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Screening Assays, Antitumor; Drug Synergism; Gemcitabine; Genes, p53; Genes, Retinoblastoma; Humans; Lung Neoplasms; Paclitaxel; Tumor Cells, Cultured | 2001 |
Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer--a dose-finding study by the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Ovarian Cancer Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Gemcitabine; Germany; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Thrombocytopenia; Treatment Outcome | 2001 |
[Phase III clinical trials concerning non-small-cell lung carcinoma (NSCLC) presented at the ASCO 2001].
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Paclitaxel; Taxoids; Time Factors; Vinblastine; Vinorelbine | 2001 |
[An autopsy case of pulmonary and central nervous system metastatic osteosarcoma treated with thirty-six courses of chemotherapy over four years].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carboplatin; Cisplatin; Dacarbazine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Methotrexate; Osteosarcoma; Paclitaxel; Spinal Cord Neoplasms; Survivors; Taxoids; Vincristine; Vindesine | 2002 |
Salvage chemotherapy for advanced sarcoma patients: a single-institution experience survey.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dacarbazine; Deoxycytidine; Gemcitabine; Humans; Ifosfamide; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Salvage Therapy; Sarcoma; Soft Tissue Neoplasms; Treatment Outcome | 2002 |
Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma. Carboplatin and gemcitabine followed by paclitaxel.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel | 2002 |
An in vitro tumor model: analysis of angiogenic factor expression after chemotherapy.
Topics: 3T3 Cells; Animals; Carboplatin; Cytokines; Deoxycytidine; Drug Screening Assays, Antitumor; Endothelial Growth Factors; Fibroblast Growth Factor 2; Gemcitabine; Humans; Intercellular Signaling Peptides and Proteins; Lymphokines; Mice; Neoplasms; Paclitaxel; Transforming Growth Factor beta; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
[Gemcitabine in the treatment of advanced non-small cell lung cancer: report of one case].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Treatment Outcome | 2002 |
Combined platinum containing treatment in NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Prognosis | 2002 |
[New data presented at ASCO 2002 concerning small cell bronchial cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carboplatin; Carcinoma, Small Cell; Cisplatin; Deoxycytidine; Etoposide; Gemcitabine; Humans; Imatinib Mesylate; Lung Neoplasms; Piperazines; Prognosis; Pyrimidines; Quinolones; Smoking; Smoking Prevention; Survival Analysis; Treatment Outcome | 2002 |
[Therapeutic strategies in advanced non-small cell bronchial cancers: platin-based combinations].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Patient Selection; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Timing is everything, or could be.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel | 2003 |
Extensive cutaneous metastasis of transitional cell carcinoma of the bladder.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carboplatin; Carcinoma, Transitional Cell; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Immunohistochemistry; Male; Neoplasm Staging; Severity of Illness Index; Skin Neoplasms; Treatment Refusal; Urinary Bladder Neoplasms | 2003 |
Effect of metal-based anticancer drugs on wild type and metallothionein null cell lines.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Cadmium Chloride; Carboplatin; Cell Division; Cell Line; Chlorides; Cisplatin; Copper Sulfate; Deoxycytidine; Dose-Response Relationship, Drug; Electrophoresis, Polyacrylamide Gel; Ferrous Compounds; Fibroblasts; Gemcitabine; Inhibitory Concentration 50; Metallothionein; Metals, Heavy; Mice; Mice, Knockout; Paclitaxel; Spectrophotometry, Atomic; Survival Analysis; Survival Rate; Vinblastine; Zinc Compounds | 2003 |
Digital necrosis related to carboplatin and gemcitabine therapy in systemic sclerosis.
Topics: Antineoplastic Agents; Carboplatin; Deoxycytidine; Drug Therapy, Combination; Female; Fingers; Gangrene; Gemcitabine; Humans; Immunosuppressive Agents; Infarction; Middle Aged; Necrosis; Scleroderma, Systemic | 2003 |
Combination chemotherapy with topotecan for non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Vinblastine; Vinorelbine | 2003 |
Fanconi's anemia and clinical radiosensitivity report on two adult patients with locally advanced solid tumors treated by radiotherapy.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Anus Neoplasms; Carboplatin; Carcinoma, Squamous Cell; Cobalt Radioisotopes; Combined Modality Therapy; Cytogenetics; Deoxycytidine; Dose Fractionation, Radiation; Fanconi Anemia; Flow Cytometry; Gemcitabine; Humans; Lymphatic Metastasis; Male; Mouth Neoplasms; Mutation; Neoplasms, Second Primary; Oropharyngeal Neoplasms; Radiation Tolerance; Radioisotope Teletherapy; Radiotherapy Dosage; Salvage Therapy; Time Factors; Tongue Neoplasms | 2003 |
Safety and efficacy of convection-enhanced delivery of gemcitabine or carboplatin in a malignant glioma model in rats.
Topics: Animals; Antineoplastic Agents; Basal Ganglia; Brain Neoplasms; Brain Stem; Carboplatin; Convection; Deoxycytidine; Disease Models, Animal; Dose-Response Relationship, Drug; Gemcitabine; Glioma; Injections, Intralesional; Male; Rats; Rats, Inbred F344 | 2003 |
Highlights from the 10th World Conference on Lung Cancer. Vancouver, British Columbia, Canada, August 10-14, 2003.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; ErbB Receptors; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Quinazolines; Taxoids | 2003 |
An in vitro study of the inhibitory activity of gemcitabine and platinum agents in human endometrial carcinoma cell lines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Endometrial Neoplasms; Female; Gemcitabine; Humans; Inhibitory Concentration 50 | 2004 |
Dexamethasone as a chemoprotectant in cancer chemotherapy: hematoprotective effects and altered pharmacokinetics and tissue distribution of carboplatin and gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Area Under Curve; Bone Marrow; Carboplatin; Deoxycytidine; Dexamethasone; Dose-Response Relationship, Drug; Drug Antagonism; Gemcitabine; Glucocorticoids; Injections, Intravenous; Injections, Subcutaneous; Longevity; Male; Mice; Mice, Inbred Strains | 2004 |
Recurrent ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials, Phase I as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Retreatment; Topotecan; Treatment Failure | 2004 |
Pretreatment with dexamethasone increases antitumor activity of carboplatin and gemcitabine in mice bearing human cancer xenografts: in vivo activity, pharmacokinetics, and clinical implications for cancer chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Carboplatin; Colonic Neoplasms; Deoxycytidine; Dexamethasone; Drug Synergism; Gemcitabine; Glioma; Half-Life; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasms; Transplantation, Heterologous | 2004 |
Gemcitabine plus carboplatin; and gemcitabine, docetaxel, and carboplatin combined chemotherapy regimens in patients with metastatic urothelial carcinoma previously treated with a platinum-based regimen: preliminary report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pilot Projects; Taxoids; Treatment Outcome; Ureteral Neoplasms; Urinary Bladder Neoplasms | 2004 |
Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cell Line, Tumor; Cell Survival; Cyclophosphamide; Deoxycytidine; Disease Models, Animal; DNA, Neoplasm; Docetaxel; Doxorubicin; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Epirubicin; Female; Floxuridine; Gemcitabine; Gene Expression Regulation, Neoplastic; Guanine Nucleotide Exchange Factors; Humans; Mice; Mice, Nude; Neoplastic Stem Cells; Paclitaxel; Proto-Oncogene Proteins; Receptor, ErbB-2; Taxoids; Transplantation, Heterologous; Trastuzumab; Tumor Stem Cell Assay; Up-Regulation; Vinblastine; Vinorelbine | 2004 |
[Active chemotherapy with gemcitabine, carboplatin and docetaxel for three patients with MVAC-resistant liver metastasis of urothelial carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Gemcitabine; Humans; Kidney Neoplasms; Liver Neoplasms; Male; Methotrexate; Middle Aged; Taxoids; Urinary Bladder Neoplasms; Vinblastine | 2004 |
Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Survival; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Protease Inhibitors; Pyrazines; Tumor Cells, Cultured | 2004 |
Our experience with 23 consecutive patients on gemcitabine/carboplatin chemotherapy for treatment of metastasized transitional cell carcinoma of the urothelium.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Urologic Neoplasms; Urothelium | 2004 |
Overexpressed decorin in pancreatic cancer: potential tumor growth inhibition and attenuation of chemotherapeutic action.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carboplatin; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Decorin; Deoxycytidine; Drug Interactions; Extracellular Matrix; Extracellular Matrix Proteins; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Male; Middle Aged; Pancreas; Pancreatic Neoplasms; Proteoglycans; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Up-Regulation | 2004 |
Activity of bortezomib in advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Gemcitabine; Humans; Lung Neoplasms; Protease Inhibitors; Pyrazines; Taxoids | 2004 |
Response of combination platinum and gemcitabine chemotherapy for recurrent epithelial ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Retrospective Studies; Survival Analysis | 2004 |
[Efficacy of selective continuous transarterial infusion chemotherapy on advanced pancreatic cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Gemcitabine; Humans; Infusion Pumps, Implantable; Infusions, Intra-Arterial; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Remission Induction; Survival Rate | 2004 |
[Acute myocardial infarction induced by lung cancer chemotherapy after radiation of left lung].
Topics: Angioplasty, Balloon, Coronary; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Myocardial Infarction | 2005 |
Chemotherapy for non-small cell lung cancer in elderly patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Retrospective Studies; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
Preoperative chemotherapy does not increase complications after nonsmall cell lung cancer resection.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Lymph Node Excision; Male; Mediastinum; Middle Aged; Neoadjuvant Therapy; Pneumonectomy; Postoperative Complications; Radiotherapy, Adjuvant; Survival Analysis; Thoracotomy; Vinblastine; Vinorelbine | 2005 |
Is the tolerance to MIP chemotherapy different between English and other European populations?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials, Phase III as Topic; Decision Making; Deoxycytidine; England; Europe; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Mitomycin; Randomized Controlled Trials as Topic; Reproducibility of Results | 2005 |
Pre-exenterative chemotherapy, a novel therapeutic approach for patients with persistent or recurrent cervical cancer.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Area Under Curve; Carboplatin; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Pelvic Exenteration; Pilot Projects; Recurrence; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Uterine Cervical Neoplasms | 2005 |
Prolonged stabilization of platinum-resistant ovarian cancer in a single patient consuming a fermented soy therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Complementary Therapies; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Female; Gemcitabine; Genistein; Glucuronides; Humans; Isoflavones; Middle Aged; Ovarian Neoplasms; Paclitaxel; Soy Milk; Topotecan | 2006 |
Gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Survival Analysis; Survival Rate; Treatment Outcome | 2005 |
Role of gross tumor volume on outcome and of dose parameters on toxicity of patients undergoing chemoradiotherapy for locally advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Prognosis; Radiotherapy Dosage; Radiotherapy, Conformal; Retrospective Studies; Survival Analysis; Survival Rate | 2005 |
Gemcitabine and carboplatin in the treatment of locally advanced and metastatic non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Malaysia; Male; Middle Aged; Neoplasm Metastasis; Retrospective Studies; Survival Rate | 2005 |
The development of gemcitabine and carboplatin in the treatment of non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms | 2005 |
Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Carcinoma, Small Cell; Cisplatin; Deoxycytidine; DNA Mutational Analysis; Female; Follow-Up Studies; Gemcitabine; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Paclitaxel; Polymerase Chain Reaction; Proto-Oncogene Proteins c-kit; Proto-Oncogene Proteins c-met; Receptor Protein-Tyrosine Kinases; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Survival Analysis; Survival Rate; Treatment Outcome | 2005 |
Molecular mechanism of phenoxodiol-induced apoptosis in ovarian carcinoma cells.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Carboplatin; Carcinoma; Caspase 2; Caspases; Cell Line, Tumor; Deoxycytidine; Drug Interactions; Enzyme Activation; Female; Gemcitabine; Humans; Isoflavones; Mice; Ovarian Neoplasms; Paclitaxel; Proteasome Endopeptidase Complex; Transplantation, Heterologous | 2006 |
[A 65-year-old man with liver metastases after lung cancer resection that responded to concomitant use of gemcitabine and carboplatin].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymph Node Excision; Male; Pneumonectomy; Postoperative Period; Quality of Life | 2006 |
Is thrombotic microangiopathy associated with antitumoral activity?
Topics: Acute Kidney Injury; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Kidney; Middle Aged; Ovarian Neoplasms | 2006 |
[A case of non-small cell lung cancer accompanied with hemorrhage after chemotherapy including gemcitabine].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Hemorrhage; Humans; Lung Diseases; Lung Neoplasms; Male; Middle Aged; Radiography, Thoracic; Tomography, X-Ray Computed | 2006 |
Cost-minimization analysis for Portugal of five doublet chemotherapy regimens from two phase III trials in the treatment of advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Costs and Cost Analysis; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; National Health Programs; Paclitaxel; Portugal; Taxoids | 2006 |
Pelvic chemoradiotherapy after chemotherapy for metastatic bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Combined Modality Therapy; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Pelvic Neoplasms; Prognosis; Radiotherapy Dosage; Urinary Bladder Neoplasms | 2006 |
Advanced non-small-cell lung cancer: 'triplets' better than 'doublets'?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel | 2006 |
[Analysis of antineoplastic drugs used in Cancer Center, Sun Yat-sen University, during the period of 1996-2005].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carboplatin; China; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Drug Costs; Drug Utilization Review; Gemcitabine; Humans; Neoplasms; Paclitaxel; Rituximab; Vinblastine; Vinorelbine | 2006 |
[Myositis as a 'radiation-recall phenomenon' following palliative chemotherapy with carboplatin-gemcitabin for non-small-cell pulmonary carcinoma].
Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Myositis; Palliative Care; Radiation-Sensitizing Agents | 2006 |
[Experience with gemcitabine-carboplatin chemotherapy in relapsed ovarian cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Retrospective Studies; Survival Analysis; Treatment Outcome | 2006 |
Experience of the treatment with gemcitabine, docetaxel, and carboplatin (GDC) chemotherapy for patients with small-cell carcinoma of the prostate.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Deoxycytidine; Docetaxel; Fatal Outcome; Gemcitabine; Humans; Male; Middle Aged; Pelvic Neoplasms; Prostatic Neoplasms; Taxoids | 2006 |
Acute transient encephalopathy following paclitaxel treatment in an adolescent with a recurrent suprasellar germinoma.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Carboplatin; Cerebral Ventricle Neoplasms; Combined Modality Therapy; Consciousness Disorders; Cranial Irradiation; Cyclophosphamide; Cytarabine; Dacarbazine; Deoxycytidine; Etoposide; Female; Gemcitabine; Germinoma; Hematopoietic Stem Cell Transplantation; Humans; Hypophysectomy; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pituitary Neoplasms; Temozolomide; Thiotepa; Topotecan | 2008 |
Basal cell carcinoma metastatic to cervical lymph nodes and lungs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Fine-Needle; Carboplatin; Carcinoma, Basal Cell; Carcinoma, Papillary; Deoxycytidine; Diagnostic Errors; Docetaxel; Gemcitabine; Head and Neck Neoplasms; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neck Dissection; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Radiotherapy; Seminoma; Skin Neoplasms; Taxoids; Testicular Neoplasms; Thyroid Neoplasms; Thyroidectomy; Unnecessary Procedures | 2006 |
Reversible posterior leukoencephalopathy syndrome after carboplatin therapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Neurotoxicity Syndromes; Pleural Neoplasms | 2007 |
Transcleral orbital invasion by a radiation and chemotherapy-resistant choroidal metastasis of a pulmonary adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Choroid Neoplasms; Deoxycytidine; Drug Resistance; Eye Enucleation; Female; Gemcitabine; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Neoplasm Invasiveness; Orbital Neoplasms; Radiation Tolerance; Radiotherapy Dosage; Sclera | 2007 |
Chemotherapy resistance and oncogene expression in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy, Needle; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Flow Cytometry; Gemcitabine; Humans; Lung Neoplasms; Male; Oncogenes; Ploidies; Probability; Sensitivity and Specificity; Taxoids; Treatment Outcome; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Vinblastine | 2007 |
[A case of advanced large cell lung carcinoma for whom fourth-line chemotherapy of cisplatin and gemcitabine proved effective for the first time].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Drug Combinations; Gemcitabine; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Remission Induction; Taxoids; Tegafur; Vinblastine; Vinorelbine | 2007 |
Patient attitudes towards chemotherapy as assessed by patient versus physician: a prospective observational study in advanced non-small cell lung cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Attitude to Health; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Outcome Assessment, Health Care; Patient Compliance; Patient Satisfaction; Physician-Patient Relations; Prospective Studies; Ribonucleotide Reductases; Surveys and Questionnaires | 2007 |
Improved survival with single-agent paclitaxel consolidation/maintenance therapy in advanced ovarian carcinoma.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Survival Rate | 2006 |
Pick the winner designs in phase II cancer clinical trials.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Humans; Immunosuppressive Agents; Lung Neoplasms; Randomized Controlled Trials as Topic; Ribonucleotide Reductases; Treatment Outcome | 2006 |
Gemcitabine and carboplatin chemotherapy safely administered to a patient with homocystinuria.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Homocystinuria; Humans; Lung Neoplasms; Male; Middle Aged | 2006 |
EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; ErbB Receptors; Female; Gemcitabine; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2007 |
Moving forward in advanced bladder cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Doxorubicin; ErbB Receptors; Gemcitabine; Humans; Methotrexate; Paclitaxel; Receptor, ErbB-2; Trastuzumab; Urinary Bladder Neoplasms; Vinblastine | 2007 |
Shortness of breath and hypoxemia after chemotherapy with carboplatin and gemcitabine.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bronchiolitis Obliterans; Carboplatin; Deoxycytidine; Dyspnea; Gemcitabine; Humans; Hypoxia; Male; Pneumonia; Urinary Bladder Neoplasms | 2007 |
A novel human ex vivo model for the analysis of molecular events during lung cancer chemotherapy.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Caspase 3; Cell Proliferation; Cells, Cultured; Deoxycytidine; DNA; Drug Resistance; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; In Vitro Techniques; Lung Neoplasms; Tissue Survival; Treatment Outcome; Vinblastine; Vinorelbine | 2007 |
Developmental chemotherapy and management of recurrent ovarian cancer.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Drugs, Investigational; Enzyme Inhibitors; Etoposide; Female; Gemcitabine; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Recurrence; Research Design; Taxoids; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome | 2003 |
Potential interaction of chemotherapy and gefitinib in the induction of hematologic neoplasia.
Topics: Adenocarcinoma; Aged; Anemia, Refractory; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Interactions; ErbB Receptors; Gefitinib; Gemcitabine; Hematopoiesis; Humans; Leukemia, Promyelocytic, Acute; Lung Neoplasms; Male; Neoplasm Proteins; Neoplasms, Second Primary; Protein Kinase Inhibitors; Quinazolines | 2007 |
Pharmacokinetics and pharmacodynamics of paclitaxel with carboplatin or gemcitabine, and effects of CYP3A5 and MDR1 polymorphisms in patients with urogenital cancers.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carboplatin; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Deoxycytidine; Gemcitabine; Genotype; Humans; Male; Metabolic Clearance Rate; Middle Aged; Paclitaxel; Polymorphism, Genetic; Prostate-Specific Antigen; Urogenital Neoplasms | 2007 |
[Peak concentration of gemcitabine at fixed-dose-rate and its hematological toxicity profile].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Neutropenia; Thrombocytopenia | 2007 |
Management of platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cost-Benefit Analysis; Deoxycytidine; Disease-Free Survival; Drug Costs; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Quality of Life | 2007 |
Progression of disease despite good endoscopic local control of upper tract urothelial carcinoma.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Papillary; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease Progression; Docetaxel; Electrocoagulation; Gemcitabine; Humans; Kidney Neoplasms; Kidney Pelvis; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Neoplasm Recurrence, Local; Nephrectomy; Paclitaxel; Taxoids; Ureteroscopy | 2007 |
Carbon beam therapy in recurrent ovarian cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbon; Carboplatin; Carcinoma, Endometrioid; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Hysterectomy; Irinotecan; Lymph Node Excision; Neoplasm Recurrence, Local; Omentum; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Radiotherapy, High-Energy; Remission Induction; Salvage Therapy | 2008 |
Combined systemic therapy and radiotherapy for bladder cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Cystectomy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Methotrexate; Neoplasm Staging; Paclitaxel; Prospective Studies; Radiation-Sensitizing Agents; Randomized Controlled Trials as Topic; Salvage Therapy; Time Factors; Urinary Bladder; Urinary Bladder Neoplasms; Vinblastine | 2007 |
Bevacizumab: optimal dose, schedule, and duration of therapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; Vascular Endothelial Growth Factor A | 2007 |
[Short-term outcome of neoadjuvant gemcitabine-carboplatin therapy for muscle-invasive bladder cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Muscle Neoplasms; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Treatment Outcome; Urinary Bladder Neoplasms | 2008 |
[Transhepatic arterial chemoembolization with gemcitabine and carboplatin for the treatment of stage III hepatocellular carcinoma].
Topics: Adult; Aged; Alanine Transaminase; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carboplatin; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Leukopenia; Liver Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Quality of Life; Remission Induction; Survival Rate; Young Adult | 2007 |
CXCR7 transcription in human non-small cell lung cancer and tumor-free lung tissues; possible regulation upon chemotherapy.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization; Lung Neoplasms; Macrophages, Alveolar; Receptors, CXCR; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transcription, Genetic | 2008 |
Does saturable formation of gemcitabine triphosphate occur in patients?
Topics: Adipose Tissue; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Body Weight; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Creatinine; Cytidine Triphosphate; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Models, Biological; Prodrugs; Prospective Studies; Randomized Controlled Trials as Topic | 2008 |
[Combination of carboplatin and gemcitabine is a safe and feasible regimen in adjuvant therapy for stage II and IIIA NSCLC].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging | 2008 |
Neoadjuvant chemotherapy with reduced-dose carboplatin and gemcitabine for non-small cell lung cancer in a patient with Fanconi anemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Bronchial Neoplasms; Bronchoscopy; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Deoxycytidine; Fanconi Anemia; Gemcitabine; Humans; Lung Neoplasms; Male; Neoadjuvant Therapy; Pulmonary Artery; Whole-Body Irradiation | 2008 |
Dose enhancement effect of anticaner drugs associated with increased temperature in vitro.
Topics: Antineoplastic Agents; Carboplatin; Cell Proliferation; Cell Survival; Combined Modality Therapy; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Gemcitabine; HeLa Cells; Humans; Hyperthermia, Induced; Ifosfamide; Organoplatinum Compounds; Oxaliplatin; Taxoids; Temperature; Vinblastine; Vinorelbine | 2008 |
Predictive value of individualized tumor response testing by ATP-based chemotherapy response assay in ovarian cancer.
Topics: Adenosine Triphosphate; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Sensitivity and Specificity; Single-Blind Method; Treatment Outcome; Tumor Cells, Cultured | 2008 |
Unilateral blindness as a presenting symptom of lung cancer treated with erlotinib.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2008 |
A pilot study evaluating the efficacy and toxicity of biweekly gemcitabine and pegylated liposomal doxorubicin in recurrent platinum-resistant epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Drug Evaluation; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Pilot Projects; Polyethylene Glycols | 2008 |
Biweekly carboplatin/gemcitabine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: report of efficacy, quality of life and geriatric assessment.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Creatinine; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Patient Selection; Quality of Life; Survival Analysis; Treatment Outcome; Urologic Neoplasms | 2007 |
Single agent gemcitabine in the second-line treatment of advanced non-small cell lung cancer after treatment with taxane + platinum regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Retrospective Studies; Taxoids | 2008 |
mRNA expression of RRM1, ERCC1 and ERCC2 is not associated with chemosensitivity to cisplatin, carboplatin and gemcitabine in human lung cancer cell lines.
Topics: Adenocarcinoma; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Drug Screening Assays, Antitumor; Endonucleases; Gemcitabine; Gene Expression Profiling; Humans; In Vitro Techniques; Inhibitory Concentration 50; Lung Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Tumor Suppressor Proteins; Xeroderma Pigmentosum Group D Protein | 2008 |
[Chemotherapy and renal toxicity].
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carboplatin; Carmustine; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Kidney; Kidney Diseases; Lomustine; Methotrexate; Organoplatinum Compounds; Oxaliplatin | 2008 |
Triplet combination of gemcitabine, paclitaxel, and carboplatin followed by maintenance 5-fluorouracil and folinic acid in patients with metastatic nasopharyngeal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Deoxycytidine; Feasibility Studies; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Nasopharyngeal Neoplasms; Paclitaxel; Prognosis; Quality of Life; Survival Rate | 2008 |
FHIT and p53 status and response to platinum-based treatment in advanced non-small cell lung cancer.
Topics: Acid Anhydride Hydrolases; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Proteins; Neoplasm Staging; Polymerase Chain Reaction; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome; Tumor Suppressor Protein p53 | 2008 |
[A case of left urothelial carcinoma with multiple bone metastasis, liver metastasis and right adrenal metastasis successfully treated with combination chemotherapy of gemcitabine and carboplatin].
Topics: Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Tomography, X-Ray Computed; Urethral Neoplasms | 2008 |
Low expression of Bax predicts poor prognosis in resected non-small cell lung cancer patients with non-squamous histology.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; bcl-2-Associated X Protein; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Galectin 3; Gemcitabine; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Radiotherapy Dosage; Retrospective Studies; Survival Rate; Tissue Array Analysis; Tumor Suppressor Protein p53 | 2008 |
Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; CA-125 Antigen; Carboplatin; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Retrospective Studies | 2008 |
Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.
Topics: Adenocarcinoma; Adult; Aged; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Etoposide; Female; Gemcitabine; Gene Expression Profiling; Genes, ras; Humans; Immunoblotting; Lung Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Middle Aged; Mutation; Oligonucleotide Array Sequence Analysis; Paclitaxel; Polymerase Chain Reaction; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents; Small Cell Lung Carcinoma; Tumor Suppressor Protein p53; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2008 |
[Combination therapy consisting of gemcitabine, docetaxel and carboplatin as a second-line chemotherapy for patients with MVAC-treated metastatic urothelial carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Doxorubicin; Drug Administration Schedule; Gemcitabine; Hematologic Diseases; Humans; Methotrexate; Neoplasm Metastasis; Retrospective Studies; Taxoids; Urologic Neoplasms; Vinblastine | 2008 |
Costs of first-line doublet chemotherapy and lifetime medical care in advanced non-small-cell lung cancer in the United States.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Health Care Costs; Humans; Lung Neoplasms; Male; Population Surveillance; Retrospective Studies; Taxoids; United States | 2009 |
Dyspnea evolution after high-dose radiotherapy in patients with non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; Combined Modality Therapy; Deoxycytidine; Dyspnea; Female; Gemcitabine; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Radiotherapy Dosage; Statistics, Nonparametric; Treatment Outcome; Vinblastine; Vinorelbine | 2009 |
Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Outcome and Process Assessment, Health Care; Paclitaxel; Radiography; Retrospective Studies; Vascular Endothelial Growth Factor A | 2009 |
Selective pulmonary artery perfusion for the treatment of primary lung cancer: Improved drug exposure of the lung.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Carboplatin; Chemotherapy, Cancer, Regional Perfusion; Deoxycytidine; Female; Gemcitabine; Lung Neoplasms; Swine | 2009 |
[Feasibility and response of gemcitabine and carboplatin biweekly combination chemotherapy for patients with postoperative recurrence non-small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Time Factors | 2009 |
Triple cytotoxic therapy for advanced ovarian cancer: a failed application, not a failed strategy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Topotecan; Treatment Failure | 2009 |
Re: Dyspnea evolution after high-dose radiotherapy in patients with non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Dyspnea; Female; Gemcitabine; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Radiotherapy Dosage; Treatment Outcome; Vinblastine; Vinorelbine | 2009 |
Chemotherapy-related posterior reversible leukoencephalopathy syndrome.
Topics: Anticonvulsants; Antineoplastic Agents; Brain; Carboplatin; Deoxycytidine; Diagnosis, Differential; Electroencephalography; Female; Gemcitabine; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Posterior Leukoencephalopathy Syndrome; Small Cell Lung Carcinoma; Status Epilepticus; Tomography, X-Ray Computed | 2009 |
Generating genome-scale candidate gene lists for pharmacogenomics.
Topics: Anticoagulants; Antineoplastic Agents; Area Under Curve; Carboplatin; Deoxycytidine; Gefitinib; Gemcitabine; Gene Expression Regulation; Genes; Genome, Human; Humans; Oligonucleotide Array Sequence Analysis; Pharmacogenetics; Quinazolines; Warfarin | 2009 |
Complete and durable response of choroid metastasis from non-small cell lung cancer with systemic bevacizumab and chemotherapy.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Choroid Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Prognosis; Treatment Outcome | 2009 |
Clinical utility of CA-125 for maintenance therapy in the treatment of advanced stage ovarian carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies | 2009 |
Final overall results of a study with a novel triplet induction chemotherapy regimen (PACCAGE) followed by consolidation radiotherapy in locally advanced inoperable non-small cell lung cancer (NSCLC).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Dose Fractionation, Radiation; Feasibility Studies; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Remission Induction; Salvage Therapy; Survival Rate; Treatment Outcome | 2009 |
XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Docetaxel; Endonucleases; Female; Gemcitabine; Gene Frequency; Genotype; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Nuclear Proteins; Paclitaxel; Polymorphism, Single Nucleotide; Taxoids; Transcription Factors; Treatment Outcome; Vinblastine; Vinorelbine; Xeroderma Pigmentosum Group A Protein | 2009 |
Gemcitabine and carboplatin treatment in patients with relapsing ovarian cancer.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Deoxycytidine; Disease Progression; Endometrial Neoplasms; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Prognosis; Prospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2009 |
Single-agent versus combination chemotherapy in patients with advanced non-small cell lung cancer and a performance status of 2: prognostic factors and treatment selection based on two large randomized clinical trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Regression Analysis; Survival Rate; Vinblastine; Vinorelbine | 2009 |
High frequency of radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with concurrent radiotherapy and gemcitabine after induction with gemcitabine and carboplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Mexico; Middle Aged; Neoplasm Staging; Radiation Pneumonitis; Radiation-Sensitizing Agents; Radiotherapy Dosage; Survival Rate | 2009 |
[Case of malignant pleural mesothelioma with long-term disease control after 4 different lines of systemic chemotherapy and pleurodesis].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Drainage; Gemcitabine; Glutamates; Guanine; Humans; Male; Mesothelioma; Pemetrexed; Pleural Neoplasms; Pleurodesis; Quality of Life; Time Factors; Vinblastine; Vinorelbine | 2009 |
Carboplatin-gemcitabine in the therapy of advanced ovarian cancer: dose reduction consideration.
Topics: Adenocarcinoma; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Deoxycytidine; Epistaxis; Fatigue; Female; Gemcitabine; Humans; Leukopenia; Liver Neoplasms; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Pelvic Neoplasms; Remission Induction; Splenic Neoplasms; Thrombocytopenia | 2010 |
Gefitinib in combination with gemcitabine and carboplatin in never smokers with non-small cell lung carcinoma: a retrospective analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Deoxycytidine; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Lymph Nodes; Male; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2009 |
Preclinical and clinical aspects of carboplatin and gemcitabine combined with whole-body hyperthermia for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Cycle; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Hyperthermia, Induced; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Pilot Projects; Prognosis; Survival Rate; Treatment Outcome; Tumor Cells, Cultured | 2009 |
Different impact of excision repair cross-complementation group 1 on survival in male and female patients with inoperable non-small-cell lung cancer treated with carboplatin and gemcitabine.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Retrospective Studies; Sex Factors; Treatment Outcome | 2009 |
Gemcitabine: new indication. Relapsed ovarian cancer: simply more toxic. Increases haematologic toxicity but not overall survival.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Drug Approval; Europe; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Randomized Controlled Trials as Topic; Ribonucleotide Reductases | 2009 |
Effects of taxane-based chemotherapy on inhibin B and gonadotropins as biomarkers of spermatogenesis.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carboplatin; Deoxycytidine; Docetaxel; Fertility; Follicle Stimulating Hormone; Gemcitabine; Humans; Infertility, Male; Inhibins; Luteinizing Hormone; Male; Middle Aged; Neoplasms; Paclitaxel; Spermatogenesis; Taxoids; Testis; Ultrasonography; Young Adult | 2010 |
Chemotherapy-associated toxicity in a large cohort of elderly patients with non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Gemcitabine; Humans; Incidence; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Prognosis; SEER Program; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
[A case of adenocarcinoma of the lung with a long-term therapeutic effect due to S-1 administered as the sixth regimen].
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Combinations; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Oxonic Acid; Quinazolines; Taxoids; Tegafur | 2009 |
ABC transporter gene expression in benign and malignant ovarian tissue.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; Carboplatin; Cyclophosphamide; Cystadenoma; Deoxycytidine; Female; Gemcitabine; Gene Expression; Humans; Multidrug Resistance-Associated Protein 2; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; ROC Curve; Up-Regulation | 2010 |
[Clinical evaluation of calculating carboplatin doses using modification of diet in renal disease (MDRD) estimate and adverse events].
Topics: Age Factors; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Creatinine; Deoxycytidine; Female; Gemcitabine; Glomerular Filtration Rate; Humans; Lung Neoplasms; Male; Middle Aged; Sex Factors; Thrombocytopenia | 2009 |
Second and third line treatment in advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Paclitaxel; Pemetrexed; Taxoids | 2009 |
High response of second-line chemotherapy with pemetrexed or gemcitabine combined with carboplatin in patients with non-small-cell lung cancer experiencing progression following 6 months after concluding platinum-based chemotherapy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Survival Rate; Time Factors; Treatment Outcome | 2011 |
Memoirs of differential radiation doses: Gemcitabine induced radiation recall.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carboplatin; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Gemcitabine; Humans; Mastectomy; Radiodermatitis; Radiotherapy; Radiotherapy Dosage | 2010 |
[Combination chemotherapy with gemcitabine and paclitaxel in a hemodialysis patient with metastatic urothelial carcinoma].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; Gemcitabine; Humans; Kidney Failure, Chronic; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Renal Dialysis; Urinary Bladder Neoplasms | 2010 |
RRM1 single nucleotide polymorphism -37C-->A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Ribonucleoside Diphosphate Reductase; Treatment Outcome; Tumor Suppressor Proteins | 2010 |
[Current status of adjuvant chemotherapy for resected lung cancer at our institute--focus on clinical trial enrollment].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Patient Selection; Small Cell Lung Carcinoma; Tegafur; Uracil; Vinblastine; Vinorelbine | 2010 |
Third-line gemcitabine monotherapy for platinum-resistant advanced urothelial cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Prospective Studies; Salvage Therapy; Survival Rate; Time Factors; Treatment Outcome; Urologic Neoplasms; Urothelium | 2010 |
A retrospective analysis of outcomes by age in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel vs. paclitaxel plus carboplatin for advanced non-small cell lung cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies; Survival Analysis; Treatment Outcome | 2011 |
Hand-foot hyperpigmentation skin lesions associated with combination gemcitabine-carboplatin (GemCarbo) therapy.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Foot; Gemcitabine; Hand; Humans; Hyperpigmentation; Lung Neoplasms; Male | 2011 |
Haemolytic uraemic syndrome associated with gemcitabine.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Male; Urinary Bladder Neoplasms; Urothelium | 2010 |
Two lung masses with different responses to pemetrexed.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Neoplasms, Second Primary; Pemetrexed | 2010 |
Biological activity of gemcitabine against canine osteosarcoma cell lines in vitro.
Topics: Animals; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Carboplatin; Cell Line, Tumor; Cell Survival; Deoxycytidine; Diphosphonates; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Drug Therapy, Combination; Gemcitabine; Osteosarcoma; Pamidronate | 2010 |
Modest reductions in dose intensity and drug-induced neutropenia have no major impact on survival of patients with non-small cell lung cancer treated with platinum-doublet chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Retrospective Studies; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Comparison of cisplatin- and carboplatin-based third-generation chemotherapy in 1,014 Chinese patients with advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Retrospective Studies; Taxoids; Vinblastine; Vinorelbine | 2011 |
Chemoresistance testing of human ovarian cancer cells and its in vitro model.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Gemcitabine; Humans; Models, Biological; Ovarian Neoplasms; Paclitaxel; Topotecan | 2010 |
Induction chemotherapy for unresectable urothelial carcinoma of the bladder.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cystectomy; Deoxycytidine; Epidemiologic Methods; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Remission Induction; Urinary Bladder Neoplasms | 2011 |
[Digital necrosis related to gemcitabine].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Deoxycytidine; Fingers; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Necrosis; Paclitaxel; Palliative Care | 2010 |
Factors for hematopoietic toxicity of carboplatin: refining the targeting of carboplatin systemic exposure.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Blood Platelets; Carboplatin; Cell Proliferation; Deoxycytidine; Etoposide; Female; France; Gemcitabine; Humans; Leukocyte Count; Male; Middle Aged; Models, Biological; Neutropenia; Neutrophils; Paclitaxel; Platelet Count; Prospective Studies; Risk Assessment; Risk Factors; Thrombocytopenia; Young Adult | 2010 |
[Second-line therapy in patients with malignant pleural mesothelioma. A French retrospective study (2005-2006)].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Disease Progression; Feasibility Studies; Female; France; Gemcitabine; Glutamates; Guanine; Humans; Male; Mesothelioma; Middle Aged; Pemetrexed; Pleural Neoplasms; Retrospective Studies; Survival Analysis; Treatment Outcome | 2010 |
Complete response to carboplatin, gemcitabine, and paclitaxel in a patient with advanced metastatic renal medullary carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Renal Cell; Child; Deoxycytidine; Gemcitabine; Humans; Kidney Neoplasms; Male; Paclitaxel; Sickle Cell Trait; Treatment Outcome | 2010 |
Gemcitabine causes minimal modulation of carboplatin-DNA monoadduct formation and repair in bladder cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Line, Tumor; Deoxycytidine; DNA Adducts; DNA Repair; Drug Resistance, Neoplasm; Gemcitabine; Humans; Urinary Bladder Neoplasms | 2010 |
E phage gene transfection enhances sensitivity of lung and colon cancer cells to chemotherapeutic agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Carcinoma; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Genetic Therapy; Humans; Lung Neoplasms; Membrane Potential, Mitochondrial; Mitochondria; Paclitaxel; Transfection; Viral Proteins | 2010 |
Genetic polymorphisms in the endothelial nitric oxide synthase gene correlate with overall survival in advanced non-small-cell lung cancer patients treated with platinum-based doublet chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Introns; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Minisatellite Repeats; Neoplasm Staging; Nitric Oxide Synthase Type III; Paclitaxel; Polymorphism, Single Nucleotide; Survival Rate; Treatment Outcome | 2010 |
Analysis of the cytotoxic activity of carboplatin and gemcitabine combination.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Flow Cytometry; Gemcitabine; Humans; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2010 |
Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Gemcitabine; Health Care Surveys; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Vinblastine; Vinorelbine | 2011 |
Traditional Chinese medicine herbal treatment may have a relevant impact on the prognosis of patients with stage IV adenocarcinoma of the lung treated with platinum-based chemotherapy or combined targeted therapy and chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Drugs, Chinese Herbal; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Medicine, Chinese Traditional; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Organoplatinum Compounds; Outpatients; Paclitaxel; Platinum Compounds; Prognosis; Quinazolines; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2011 |
Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Acinar Cell; Cell Line, Tumor; Cell Movement; Cell Shape; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Gene Expression Profiling; Humans; Lung Neoplasms; Middle Aged; Neoplasm Invasiveness; Pancreatic Neoplasms; Quinazolines; Sequence Deletion | 2011 |
Congenital retroperitoneal vascular anomalies: impact on pelvic surgery.
Topics: Adenocarcinoma, Papillary; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lymphatic Metastasis; Middle Aged; Ovarian Neoplasms; Pelvis; Radiography; Treatment Outcome; Vascular Malformations; Vena Cava, Inferior | 2011 |
Platinum-based doublet chemotherapy in pre-treated malignant pleural mesothelioma (MPM) patients: a mono-institutional experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease Progression; Drug Resistance; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Leukopenia; Male; Mesothelioma; Middle Aged; Neoplasm Staging; Pemetrexed; Platinum Compounds; Pleural Neoplasms; Thrombocytopenia | 2011 |
Progressive multifocal leukoencephalopathy following chemotherapy for lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Immunocompromised Host; Leukoencephalopathy, Progressive Multifocal; Lung Neoplasms; Magnetic Resonance Imaging; Male; Tomography, X-Ray Computed | 2011 |
[A case of coexisting malignant mesothelioma and squamous cell carcinoma of the lung].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carboplatin; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Fatal Outcome; Gemcitabine; Humans; Lung Neoplasms; Male; Mesothelioma; Neoplasms, Multiple Primary; Neovascularization, Pathologic; Tomography, X-Ray Computed | 2011 |
Exploring palliative treatment outcomes in women with advanced or recurrent ovarian clear cell carcinoma.
Topics: Adenocarcinoma, Clear Cell; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Palliative Care; Topotecan; Treatment Outcome | 2011 |
Single nucleotide polypmorphisms in ERCC1 are associated with disease progression, and survival in patients with advanced stage ovarian and primary peritoneal carcinoma; a Gynecologic Oncology Group study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease Progression; DNA-Binding Proteins; Doxorubicin; Endonucleases; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polymorphism, Single Nucleotide; Topotecan | 2011 |
Roles of BCL-2 and MDR1 expression in the efficacy of paclitaxel-based lung cancer chemoradiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Proto-Oncogene Proteins c-bcl-2; Radiotherapy Dosage; Survival Rate; Taxoids; Treatment Outcome | 2011 |
[Relationship between the protein expression of ERCC1, BRCA, β-tubulin and K-ras and the efficacy and prognosis in advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; ras Proteins; Remission Induction; Survival Rate; Taxoids; Tubulin; Vinblastine; Vinorelbine | 2011 |
Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.
Topics: Aged; Anaplastic Lymphoma Kinase; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Crizotinib; Deoxycytidine; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Gene Amplification; Humans; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Treatment Outcome | 2011 |
Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy.
Topics: Adult; Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; DNA Repair; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Polymorphism, Single Nucleotide; Proportional Hazards Models; Regression Analysis; Survival Rate; Taxoids | 2012 |
Circulating tumor cells count and characterization in a male breast cancer patient.
Topics: Breast Neoplasms, Male; Carboplatin; Carcinoma, Ductal, Breast; Cell Count; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Epirubicin; Gemcitabine; Humans; Male; Middle Aged; Neoplastic Cells, Circulating; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids | 2011 |
Feasibility of intravenous gemcitabine and an intraperitoneal platinum agent in the treatment of ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Retrospective Studies; Thrombocytopenia; Treatment Outcome | 2011 |
Combination chemotherapy for older adults with advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Paclitaxel; Vinblastine; Vinorelbine | 2011 |
Ethnic difference in hematological toxicity in patients with non-small cell lung cancer treated with chemotherapy: a pooled analysis on Asian versus non-Asian in phase II and III clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asian People; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Ethnicity; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Review Literature as Topic | 2011 |
Acute digital ischemia complicating gemcitabine and carboplatin combination chemotherapy for ovarian cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Gemcitabine; Hand; Humans; Ischemia; Middle Aged; Ovarian Neoplasms | 2011 |
Implications of delayed initiation of radiotherapy: accelerated repopulation after induction chemotherapy for stage III non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Time Factors; Tomography, X-Ray Computed | 2011 |
SMAC mimetic (JP1201) sensitizes non-small cell lung cancers to multiple chemotherapy agents in an IAP-dependent but TNF-α-independent manner.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Carboplatin; Carcinoma, Non-Small-Cell Lung; Caspase 3; Caspase 9; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Inhibitor of Apoptosis Proteins; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Mitochondrial Proteins; Molecular Mimicry; Paclitaxel; RNA Interference; Tumor Burden; Tumor Necrosis Factor-alpha; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2011 |
[Effectiveness of systemic chemotherapy of GEM+CBDCA+5-FU/LV and hepatic arterial infusion of CDDP in a case of advanced, combined hepatocellular-cholangiocarcinoma with multiple lung metastases].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carboplatin; Carcinoma, Hepatocellular; Cholangiocarcinoma; Cisplatin; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Hepatic Artery; Humans; Infusions, Intra-Arterial; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male | 2011 |
Bevacizumab-induced laryngeal necrosis.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cisplatin; Clinical Trials, Phase I as Topic; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Humans; Laryngeal Diseases; Lung Neoplasms; Middle Aged; Necrosis; Neoplasm Recurrence, Local; Paclitaxel; Pemetrexed; Tubulin Modulators | 2012 |
Video-assisted thoracoscopic surgery is more favorable than thoracotomy for administration of adjuvant chemotherapy after lobectomy for non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Patient Compliance; Pneumonectomy; Postoperative Complications; Psychosurgery; Retrospective Studies; Thoracic Surgery, Video-Assisted; Thoracotomy; Treatment Outcome | 2011 |
[Results of chemotherapy for gynecologic cancer patients in ambulatory care].
Topics: Ambulatory Care; Ambulatory Care Facilities; Anemia, Hypochromic; Antineoplastic Agents; Carboplatin; Cisplatin; Cyclophosphamide; Deoxycytidine; Doxorubicin; Endometrial Neoplasms; Female; Gemcitabine; Genital Neoplasms, Female; Hospitalization; Humans; Middle Aged; Neutropenia; Outpatients; Ovarian Neoplasms; Paclitaxel; Quality of Life; Russia; Thrombocytopenia; Treatment Outcome; Uterine Cervical Neoplasms | 2011 |
Carboplatin-gemcitabine combination chemotherapy upregulates AKR1B10 expression in bladder cancer.
Topics: Aged; Aged, 80 and over; Aldehyde Reductase; Aldo-Keto Reductases; Carboplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Drug Therapy, Combination; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Urinary Bladder Neoplasms | 2013 |
Chemotherapy-induced toxicity is highly heritable in Drosophila melanogaster.
Topics: Animals; Carboplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drosophila melanogaster; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Female; Fertility; Floxuridine; Gemcitabine; High-Throughput Screening Assays; Humans; Methotrexate; Mitomycin; Models, Animal; Neoplasms; Topotecan | 2012 |
Gemcitabine and carboplatin for pretreated metastatic breast cancer: the predictive value of immunohistochemically defined subtypes.
Topics: Aged; Breast Neoplasms; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Immunohistochemistry; Middle Aged; Neoplasm Metastasis; Predictive Value of Tests; Receptor, ErbB-2; Survival Analysis | 2013 |
Analysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Deoxycytidine; Etoposide; Female; Fibroblast Growth Factor 2; Gemcitabine; Humans; Intercellular Adhesion Molecule-1; Interleukin-8; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Multivariate Analysis; Neovascularization, Pathologic; Proportional Hazards Models; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Survival Analysis; Thalidomide; Treatment Outcome; Vascular Endothelial Growth Factor A | 2012 |
Clinical course of plasmacytoid urothelial carcinoma of the upper urinary tract: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carboplatin; Carcinoma; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Kidney Neoplasms; Kidney Pelvis; Lymph Node Excision; Lymphatic Metastasis; Male; Nephrectomy; Treatment Failure; Urothelium | 2012 |
Pathological responses to gemcitabine/platinum-based neoadjuvant chemotherapy for muscle-invasive urothelial cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2012 |
The T393C polymorphism of GNAS1 as a predictor for chemotherapy sensitivity and survival in advanced non-small-cell lung cancer patients treated with gemcitabine plus platinum.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chromogranins; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Genotype; GTP-Binding Protein alpha Subunits, Gs; Humans; Lung Neoplasms; Male; Middle Aged; Polymorphism, Genetic; Polymorphism, Restriction Fragment Length; Prognosis; Proportional Hazards Models | 2012 |
HADHA is a potential predictor of response to platinum-based chemotherapy for lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Electrophoresis, Gel, Two-Dimensional; Etoposide; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Mitochondrial Trifunctional Protein; Mitochondrial Trifunctional Protein, alpha Subunit; Multienzyme Complexes; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Small Cell Lung Carcinoma; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tumor Cells, Cultured | 2011 |
Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cross-Sectional Studies; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate | 2012 |
A population-based study on the patterns of use of different chemotherapy regimens in Swiss patients with early breast cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Carboplatin; Confidence Intervals; Cyclophosphamide; Deoxycytidine; Doxorubicin; Epirubicin; Female; Fluorouracil; Gemcitabine; Health Services Accessibility; Humans; Logistic Models; Lymphatic Metastasis; Medication Adherence; Methotrexate; Middle Aged; Multivariate Analysis; Neoplasm Staging; Odds Ratio; Paclitaxel; Receptors, Estrogen; Switzerland; Taxoids; Vinblastine; Vinorelbine | 2012 |
[Selected arterial infusion chemotherapy combined with target drugs for non-small cell lung cancer with multiple brain metastase].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Deoxycytidine; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Humans; Infusions, Intra-Arterial; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nimustine; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Skin Diseases; Survival Analysis; Treatment Outcome | 2012 |
[Basic investigation for classification of anticancer drugs by pharmacological effects].
Topics: Antineoplastic Agents; Carboplatin; Cell Survival; Cisplatin; Deoxycytidine; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Lung Neoplasms; MCF-7 Cells; Paclitaxel; Time Factors; Tumor Cells, Cultured | 2012 |
Effects of gemcitabine and gemcitabine in combination with carboplatin on five canine transitional cell carcinoma cell lines.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Carboplatin; Carcinoma, Transitional Cell; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dog Diseases; Dogs; Drug Synergism; Drug Therapy, Combination; Gemcitabine | 2012 |
Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Phosphatidylinositol 3-Kinases; Polymorphism, Single Nucleotide; Prognosis; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Stomach Neoplasms; Survival Rate; Taxoids; TOR Serine-Threonine Kinases; Vinblastine; Vinorelbine | 2012 |
Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancer.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Ascites; Blotting, Western; Carboplatin; Cell Line, Tumor; Cisplatin; Cystadenocarcinoma, Serous; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Immunohistochemistry; Mice; Mice, SCID; Middle Aged; Ovarian Neoplasms; Paclitaxel; Topotecan; Xenograft Model Antitumor Assays | 2012 |
Combined chemotherapy with gemcitabine and carboplatin for metastatic urothelial carcinomas in patients with high renal insufficiency.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Male; Neoplasm Metastasis; Renal Insufficiency; Urologic Neoplasms; Urothelium | 2013 |
Bronchoesophageal fistula in a patient with stage IIIB non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bronchial Fistula; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Esophageal Fistula; Fatal Outcome; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Tomography, X-Ray Computed | 2012 |
Relationship of circulating tumor cells to the effectiveness of cytotoxic chemotherapy in patients with metastatic non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplastic Cells, Circulating; Prognosis; Survival Rate; Young Adult | 2012 |
Neoadjuvant gemcitabine plus carboplatin for locally advanced bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Nausea; Neoadjuvant Therapy; Neoplasm Staging; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine; Vomiting | 2013 |
Combination of gemcitabine and carboplatin as first line treatment in elderly patients or those unfit for cisplatin-based chemotherapy with advanced transitional cell carcinoma of the urinary tract.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Urinary Bladder Neoplasms | 2013 |
[Gemcitabine and cisplatin (GC) or gemcitabine and carboplatin (GCarbo) in patients with metastatic urothelial cancer].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Neoplasm Metastasis; Treatment Outcome; Urologic Neoplasms | 2013 |
Identification of unique synergistic drug combinations associated with downexpression of survivin in a preclinical breast cancer model system.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Caspase 3; Cell Line, Tumor; Deoxycytidine; Docetaxel; Down-Regulation; Doxorubicin; Drug Screening Assays, Antitumor; Fatty Acids, Monounsaturated; Female; Fluvastatin; Gemcitabine; Humans; Hydroxamic Acids; Indoles; Inhibitor of Apoptosis Proteins; Panobinostat; Receptor, ErbB-2; Survivin; Taxoids | 2012 |
Gastropleural fistula in a patient with recurrent ovarian cancer receiving combination therapy with Carboplatin, gemcitabine, and bevacizumab.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Female; Gastric Fistula; Gemcitabine; Humans; Intestinal Fistula; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms | 2013 |
A three-drug induction chemotherapy with gemcitabine, carboplatin, and paclitaxel for stage III non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel | 2013 |
A retrospective study: platinum-based induction chemotherapy combined with gemcitabine or paclitaxel for stage IIB-IIIA central non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2013 |
Vitamin D receptor genetic variants are associated with chemotherapy response and prognosis in patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; DNA, Neoplasm; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Genotype; Haplotypes; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Prognosis; Receptors, Calcitriol; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2013 |
Common variations of DNA repair genes are associated with response to platinum-based chemotherapy in NSCLCs.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Confidence Intervals; Deoxycytidine; Disease-Free Survival; DNA-Binding Proteins; Docetaxel; Female; Gemcitabine; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Odds Ratio; Paclitaxel; Polymorphism, Single Nucleotide; Proportional Hazards Models; Taxoids; Vinblastine; Vinorelbine; X-ray Repair Cross Complementing Protein 1; Xeroderma Pigmentosum Group D Protein | 2013 |
Molecular profiling for druggable genetic abnormalities in carcinoma of unknown primary.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arginine; Biopsy; Carboplatin; Carcinoma; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Gefitinib; Gemcitabine; Humans; Immunohistochemistry; Leucine; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Neoplasms, Unknown Primary; Point Mutation; Quinazolines; Tomography, X-Ray Computed | 2013 |
Comparative effectiveness of three platinum-doublet chemotherapy regimens in elderly patients with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; SEER Program; Survival Analysis; Taxoids; Treatment Outcome; United States | 2013 |
Acute oesophageal toxicity related to paclitaxel-based concurrent chemoradiotherapy for non-small cell lung cancer.
Topics: Acute Disease; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Comorbidity; Deoxycytidine; Docetaxel; Esophageal Diseases; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Risk Factors; Survival Rate; Taxoids | 2013 |
[Analysis of drug therapy of lung cancer in Hungary].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Databases, Factual; Deoxycytidine; Docetaxel; Drug Administration Schedule; Erlotinib Hydrochloride; Etoposide; Gemcitabine; Glutamates; Guanine; Humans; Hungary; Inpatients; Insurance, Health; Lung Neoplasms; Paclitaxel; Pemetrexed; Prescription Drugs; Quinazolines; Retrospective Studies; Taxoids; Topotecan | 2013 |
Sleeve lobectomy compared with pneumonectomy after induction therapy for non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Pneumonectomy; Proportional Hazards Models; Survival Rate; Vinblastine; Vinorelbine | 2013 |
XPG is predictive gene of clinical outcome in advanced non-small-cell lung cancer with platinum drug therapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Cisplatin; Deoxycytidine; Disease-Free Survival; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Nuclear Proteins; Polymorphism, Single Nucleotide; Transcription Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2013 |
Survival of mesothelioma in a palliative medical care unit in egypt.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality Therapy; Deoxycytidine; Egypt; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Morphine; Pain; Palliative Care; Pleural Neoplasms; Quality of Life; Retrospective Studies; Survival; Survival Rate; Vinblastine; Vinorelbine | 2013 |
Clinical Significance of ABCG2 Haplotype-tagging Single Nucleotide Polymorphisms in Patients With Unresectable Non-Small Cell Lung Cancer Treated With First-line Platinum-based Chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Bridged-Ring Compounds; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Haplotypes; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Paclitaxel; Polymorphism, Single Nucleotide; Predictive Value of Tests; Survival Rate; Taxoids; Treatment Outcome | 2015 |
NICE guidance on bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cost-Benefit Analysis; Deoxycytidine; Drug Costs; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Practice Guidelines as Topic; Quality-Adjusted Life Years; Survival Analysis; Time Factors; Treatment Outcome | 2013 |
The method of GFR determination impacts the estimation of cisplatin eligibility in patients with advanced urothelial cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Cohort Studies; Creatinine; Deoxycytidine; Female; Gemcitabine; Glomerular Filtration Rate; Humans; Linear Models; Male; Patient Selection; Renal Insufficiency; Retrospective Studies | 2014 |
Establishing the optimal nebulization system for paclitaxel, docetaxel, cisplatin, carboplatin and gemcitabine: back to drawing the residual cup.
Topics: Antineoplastic Agents; Carboplatin; Cisplatin; Deoxycytidine; Docetaxel; Equipment Design; Gemcitabine; Nebulizers and Vaporizers; Paclitaxel; Taxoids | 2013 |
Patients treated with platinum-doublet chemotherapy for advanced non--small-cell lung cancer have inferior outcomes if previously treated with platinum-based chemoradiation.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Chemoradiotherapy; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate | 2013 |
Variation in drug sensitivity of malignant mesothelioma cell lines with substantial effects of selenite and bortezomib, highlights need for individualized therapy.
Topics: Amino Acid Transport System y+; Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; Carboplatin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Multidrug Resistance-Associated Proteins; Pemetrexed; Pyrazines; Selenious Acid | 2013 |
Treatment outcome of palliative chemotherapy in inoperable cholangiocarcinoma in Thailand.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Carboplatin; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Palliative Care; Prognosis; Retrospective Studies; Survival Rate | 2013 |
Re-challenge chemotherapy with gemcitabine plus carboplatin in patients with non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Remission Induction; Retrospective Studies; Survival Rate | 2013 |
Targeted therapies for locally advanced or metastatic squamous cell carcinoma of the lung.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Clinical Trials as Topic; Deoxycytidine; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Molecular Targeted Therapy; Mutation; Neoplasm Staging; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; SOXB1 Transcription Factors; Survival Analysis; Taxoids; Treatment Outcome; Tumor Suppressor Protein p53 | 2013 |
[Outcomes of chemotherapy in patients with EGFR mutation-negative non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; ErbB Receptors; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Remission Induction; Survival Rate; Vinblastine; Vinorelbine | 2013 |
Survival analysis in advanced non small cell lung cancer treated with platinum based chemotherapy in combination with paclitaxel, gemcitabine and etoposide.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2013 |
Carboplatin-containing regimens as front-line treatment for advanced non-small-cell lung cancer in two groups of elderly.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Retrospective Studies; Vinblastine; Vinorelbine | 2014 |
USANZ: Time-trends in use and impact on outcomes of perioperative chemotherapy in patients treated with radical cystectomy for urothelial bladder cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Odds Ratio; Perioperative Period; Retrospective Studies; Survival Analysis; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2013 |
Expression of RRM1 and RRM2 as a novel prognostic marker in advanced non-small cell lung cancer receiving chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Proportional Hazards Models; Ribonucleoside Diphosphate Reductase; Tumor Suppressor Proteins; Vinblastine; Vinorelbine | 2014 |
The combination of gemcitabine and carboplatin shows similar efficacy in the treatment of platinum-resistant and platinum-sensitive recurrent epithelial ovarian cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Retrospective Studies | 2014 |
Bevacizumab-induced transient sixth nerve palsy in ovarian cancer: A case report.
Topics: Abducens Nerve Diseases; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms | 2016 |
Triple combination of bevacizumab, gemcitabine and platinum salt in metastatic collecting duct carcinoma.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Renal Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Maintenance Chemotherapy; Middle Aged; Treatment Outcome | 2013 |
Clinical outcome of paclitaxel and carboplatin as second-line chemotherapy for advanced urothelial carcinoma resistant to first-line therapy with gemcitabine and cisplatin.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Retrospective Studies; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2014 |
Efficacy and feasibility of gemcitabine and carboplatin as first-line chemotherapy in elderly patients with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Retrospective Studies; Treatment Outcome | 2013 |
Downfall of iniparib: a PARP inhibitor that doesn't inhibit PARP after all.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bias; Carboplatin; Clinical Trials as Topic; Deoxycytidine; Drugs, Investigational; Female; Gemcitabine; Humans; Lung Neoplasms; Molecular Targeted Therapy; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Research Design; Treatment Failure; Triple Negative Breast Neoplasms | 2014 |
Genomic polymorphisms of SLC29A3 associated with overall survival in advanced non-small-cell lung cancer treated with gemcitabine.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Genotype; Humans; Leukocytes, Mononuclear; Lung Neoplasms; Male; Middle Aged; Nucleoside Transport Proteins; Paclitaxel; Polymorphism, Single Nucleotide; Proportional Hazards Models; Prospective Studies; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2014 |
In vitro chemosensitivity assay of ascites in epithelial ovarian cancer.
Topics: Antineoplastic Agents; Ascites; Carboplatin; Carcinoma, Ovarian Epithelial; Coloring Agents; Deoxycytidine; Disease Progression; Drug Screening Assays, Antitumor; Epirubicin; Etoposide; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Retrospective Studies; Survival Rate; Tetrazolium Salts; Thiazoles; Time Factors; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2013 |
Learning from errors: response to gefitinib in kidney urothelial carcinoma with EGFR mutations.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Deoxycytidine; ErbB Receptors; Female; Gefitinib; Gemcitabine; Humans; Kidney; Kidney Neoplasms; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Urothelium | 2014 |
Cisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer. An analysis of Veterans Health Administration data.
Topics: Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Glutamates; Guanine; Hospitalization; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Registries; Retrospective Studies; Survival Rate; Taxoids; United States; United States Department of Veterans Affairs; Vinblastine; Vinorelbine | 2014 |
Neoadjuvant gemcitabine and carboplatin followed by immediate cystectomy may be associated with a survival benefit in patients with clinical T2 bladder cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Cystectomy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lymph Node Excision; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate; Urinary Bladder Neoplasms | 2014 |
[Treatment and prognosis of 117 patients with advanced urothelial carcinoma of the bladder].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Leukopenia; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies; Survival Rate; Thrombocytopenia; Urinary Bladder Neoplasms; Urothelium | 2014 |
Carboplatin-based combination chemotherapy for elderly patients with advanced bladder cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cystectomy; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lymphatic Metastasis; Male; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms | 2015 |
Delivery of perioperative chemotherapy for bladder cancer in routine clinical practice.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Canada; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cohort Studies; Cystectomy; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Neoadjuvant Therapy; Retrospective Studies; Treatment Outcome; Urinary Bladder; Urinary Bladder Neoplasms; Vinblastine; Young Adult | 2014 |
Low-dose maintenance gemcitabine-carboplatin chemotherapy could be an alternative to continuous standard chemotherapy for patients with metastatic urothelial carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Retrospective Studies; Urologic Neoplasms | 2014 |
Impact of itraconazole on the survival of heavily pre-treated patients with triple-negative breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Inflammatory Breast Neoplasms; Itraconazole; Middle Aged; Retrospective Studies; Survival Rate; Taxoids; Triple Negative Breast Neoplasms | 2014 |
Cost-effectiveness of neoadjuvant chemotherapy before radical cystectomy for muscle-invasive bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cost-Benefit Analysis; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Neoadjuvant Therapy; Quality of Life; Retrospective Studies; Survival Rate; United States; Urinary Bladder Neoplasms | 2014 |
Predictive and prognostic value of circulating endothelial cells in non-small cell lung cancer patients treated with standard chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Endothelium, Vascular; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neoplastic Cells, Circulating; Prognosis; Prospective Studies; ROC Curve; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2015 |
Rituximab, Gemcitabine, Cisplatin and Methylprednisolone (R-GEM-P) is an effective regimen in relapsed diffuse large B-cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Drug Administration Schedule; Drug Substitution; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Methylprednisolone; Middle Aged; Neutropenia; Recurrence; Retrospective Studies; Rituximab; Salvage Therapy; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2015 |
A predictive model for evaluating responsiveness to pemetrexed treatment in patients with advanced colorectal cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carboplatin; Cisplatin; Colorectal Neoplasms; Cyclobutanes; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Logistic Models; Male; Middle Aged; Multivariate Analysis; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Prognosis | 2014 |
Heterozygote advantage of methylenetetrahydrofolate reductase polymorphisms on clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Heterozygote; Humans; Lung Neoplasms; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Polymorphism, Genetic; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2014 |
Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Bile Ducts, Intrahepatic; Capecitabine; Carboplatin; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Treatment Outcome | 2014 |
Prognostic value of cyclooxygenase-2 gene polymorphisms in advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy.
Topics: Adult; Aged; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cyclooxygenase 2; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Polymorphism, Single Nucleotide; Proportional Hazards Models; Treatment Outcome; Vinblastine; Vinorelbine | 2016 |
Oncological outcomes of advanced muscle-invasive bladder cancer with a micropapillary variant after radical cystectomy and adjuvant platinum-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Papillary; Carcinoma, Transitional Cell; Case-Control Studies; Chemotherapy, Adjuvant; Cisplatin; Cohort Studies; Cystectomy; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Lymph Node Excision; Lymph Nodes; Male; Methotrexate; Middle Aged; Multivariate Analysis; Muscle, Smooth; Neoplasm Staging; Proportional Hazards Models; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2015 |
Using Drosophila melanogaster to identify chemotherapy toxicity genes.
Topics: Animals; Antineoplastic Agents; Carboplatin; Deoxycytidine; DNA Transposable Elements; Drosophila melanogaster; Drosophila Proteins; Fertility; Gemcitabine; Mitomycin; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Polymorphism, Single Nucleotide; Quantitative Trait Loci; Repressor Proteins; Ribonucleoside Diphosphate Reductase; Trans-Activators | 2014 |
Differences in the recurrence pattern after neoadjuvant chemotherapy compared to surgery alone in patients with muscle-invasive bladder cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carboplatin; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Retrospective Studies; Urinary Bladder Neoplasms | 2015 |
Third-line chemotherapy with carboplatin, gemcitabine and liposomised doxorubicin for malignant pleural mesothelioma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Mesothelioma; Middle Aged; Neoplasms, Mesothelial; Pleural Neoplasms; Polyethylene Glycols; Retrospective Studies; Salvage Therapy | 2015 |
Predictive role of neutrophil gelatinase-associated lipocalin in early diagnosis of platin-induced renal injury.
Topics: Acute Kidney Injury; Acute-Phase Proteins; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Carboplatin; Cisplatin; Creatinine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Lipocalin-2; Lipocalins; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Prognosis; Proto-Oncogene Proteins; Taxoids | 2015 |
Outcome of recurrent uterine papillary serous carcinoma treated with platinum-based chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Papillary; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Cystic, Mucinous, and Serous; Paclitaxel; Retrospective Studies; Survival Rate; Treatment Outcome; Uterine Neoplasms | 2015 |
Gemcitabine + platinum combination chemotherapy in patients with metastatic cancer who suffer from severe and irreversible hepatic impairment: a single center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Liver Diseases; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Retrospective Studies; Severity of Illness Index; Treatment Outcome; Turkey | 2014 |
Genome-wide association study of myelosuppression in non-small-cell lung cancer patients with platinum-based chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Blood Platelets; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Genome-Wide Association Study; Hemoglobins; Humans; Leukocytes; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Polymorphism, Single Nucleotide; Taxoids; Vinblastine; Vinorelbine | 2016 |
A Validated Prediction Model for Overall Survival From Stage III Non-Small Cell Lung Cancer: Toward Survival Prediction for Individual Patients.
Topics: Age Factors; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Models, Statistical; Neoplasm Staging; Nomograms; Probability; Radiotherapy Dosage; Regression Analysis; Severity of Illness Index; Sex Factors; Vinblastine; Vinorelbine | 2015 |
Homology modelling and molecular docking of MDR1 with chemotherapeutic agents in non-small cell lung cancer.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Binding Sites; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Mice; Molecular Docking Simulation; Molecular Sequence Data; Paclitaxel; Sequence Alignment; Structural Homology, Protein; Taxoids; Thermodynamics | 2015 |
Impact of perioperative chemotherapy on survival in patients with advanced primary urethral cancer: results of the international collaboration on primary urethral carcinoma.
Topics: Adenocarcinoma; Aged; Albumin-Bound Paclitaxel; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Ifosfamide; Kaplan-Meier Estimate; Male; Middle Aged; Mitomycin; Neoadjuvant Therapy; Paclitaxel; Perioperative Care; Retrospective Studies; Urethra; Urethral Neoplasms; Urinary Diversion | 2015 |
Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Quinazolines; Retrospective Studies; Survival Rate | 2015 |
Use of Adjuvant Cisplatin-Based Versus Carboplatin-Based Chemotherapy in Non-Small-Cell Lung Cancer: Findings From the Florida Initiative for Quality Cancer Care.
Topics: Academic Medical Centers; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Docetaxel; Etoposide; Female; Florida; Gemcitabine; Humans; Lung Neoplasms; Male; Medical Audit; Middle Aged; Paclitaxel; Pneumonectomy; Practice Patterns, Physicians'; Quality of Health Care; Taxoids; Time Factors; Vinblastine; Vinorelbine | 2015 |
Gemcitabine plus split-dose cisplatin could be a promising alternative to gemcitabine plus carboplatin for cisplatin-unfit patients with advanced urothelial carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Urologic Neoplasms | 2015 |
Correlation between BRCA1 and TopBP1 protein expression and clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; BRCA1 Protein; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carrier Proteins; Cisplatin; Deoxycytidine; Disease-Free Survival; DNA-Binding Proteins; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nuclear Proteins; Paclitaxel; Prognosis; Survival Analysis; Treatment Outcome | 2015 |
Sequential chemotherapy using gemcitabine + carboplatin followed by gemcitabine + carboplatin + docetaxel for advanced upper-tract urothelial cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Creatinine; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome; Urologic Neoplasms | 2015 |
Association of TERT Polymorphisms with Clinical Outcome of Non-Small Cell Lung Cancer Patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Gene Expression; Heterozygote; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Polymorphism, Single Nucleotide; Prognosis; Survival Analysis; Telomerase; Treatment Outcome; Vinblastine; Vinorelbine | 2015 |
Chemotherapy-associated anemia in patients with lung cancer: an epidemiological, retrospective and multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blood Transfusion; Bridged-Ring Compounds; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Hematinics; Hemoglobins; Humans; Incidence; Iron; Lung Neoplasms; Male; Middle Aged; Observational Studies as Topic; Prevalence; Retrospective Studies; Small Cell Lung Carcinoma; Spain; Taxoids; Vinblastine; Vinorelbine; Young Adult | 2015 |
Impact of renal function of patients with advanced urothelial cancer on eligibility for first-line chemotherapy and treatment outcomes.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Cohort Studies; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Glomerular Filtration Rate; Humans; Male; Methotrexate; Middle Aged; Multivariate Analysis; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2015 |
Circulating endothelial cells for evaluation of tumor response in non-small cell lung cancer patients receiving first-line chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Endothelial Cells; Etoposide; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Paclitaxel; Prospective Studies; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2015 |
Combination Chemotherapy with Itraconazole for Treating Metastatic Pancreatic Cancer in the Second-line or Additional Setting.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Itraconazole; Male; Middle Aged; Pancreatic Neoplasms; Retrospective Studies; Taxoids | 2015 |
[A Patient with Recurrent Ovarian Cancer Who Was Hypersensitive to Carboplatin Exhibited Complete Response to Gemcitabine and Nedaplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Drug Hypersensitivity; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Ovarian Neoplasms; Recurrence | 2015 |
Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Child; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Etoposide; Female; Follow-Up Studies; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Male; Mediastinal Neoplasms; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Germ Cell and Embryonal; Prognosis; Retroperitoneal Neoplasms; Salvage Therapy; Survival Rate; Testicular Neoplasms; Transplantation, Autologous; Young Adult | 2015 |
Changing trends in utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Vessels; Carboplatin; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Glomerular Filtration Rate; Humans; Lymphatic Metastasis; Lymphatic Vessels; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Renal Insufficiency, Chronic; Retrospective Studies; Survival Rate; Treatment Outcome; Urinary Bladder Neoplasms | 2015 |
Using Whole-Exome Sequencing to Identify Genetic Markers for Carboplatin and Gemcitabine-Induced Toxicities.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Exome; Female; Gemcitabine; Genetic Markers; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Polymorphism, Single Nucleotide; Thrombocytopenia | 2016 |
Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cytoreduction Surgical Procedures; Deoxycytidine; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Multivariate Analysis; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm, Residual; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Taxoids; Time Factors; Topotecan | 2015 |
An Effective and Well Tolerated Strategy of Bladder Preservation Therapy in Cisplatin-Ineligible Patients With Muscle-Invasive Bladder Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Chemoradiotherapy; Cisplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Invasiveness; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2016 |
Comparison of the Efficacy between Pemetrexed plus Platinum and Non-Pemetrexed plus Platinum as First-Line Treatment in Patients with Wild-Type Epidermal Growth Factor Receptor Nonsquamous Non-Small Cell Lung Cancer: A Retrospective Analysis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; ErbB Receptors; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Pemetrexed; Prognosis; Retrospective Studies; Survival Rate; Vinblastine; Vinorelbine | 2016 |
Predictive factors for survival and correlation to toxicity in advanced Stage III non-small cell lung cancer patients with concurrent chemoradiation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Radiation Injuries; Radiotherapy, Conformal; Retrospective Studies; Taxoids; Treatment Outcome | 2016 |
The high incidence of vascular thromboembolic events in patients with metastatic or unresectable urothelial cancer treated with platinum chemotherapy agents.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Transitional Cell; Case-Control Studies; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Incidence; Kidney Neoplasms; Kidney Pelvis; Logistic Models; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Retrospective Studies; Stroke; Ureteral Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms; Venous Thromboembolism | 2016 |
Changes of Lymphocyte Subgroups in Non-Small Cell Lung Cancer Patients Before and During Chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; CD28 Antigens; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cisplatin; Deoxycytidine; Female; Flow Cytometry; Gemcitabine; Humans; Lung Neoplasms; Lymphocytes; Male; Middle Aged; Paclitaxel; Time Factors | 2015 |
Long-term results in malignant pleural mesothelioma treated with neoadjuvant chemotherapy, extrapleural pneumonectomy and intensity-modulated radiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Neoadjuvant Therapy; Pemetrexed; Pleural Neoplasms; Pneumonectomy; Proportional Hazards Models; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Adjuvant; Radiotherapy, Intensity-Modulated; Treatment Outcome | 2015 |
Singapore Cancer Network (SCAN) Guidelines for Front-Line Systemic Therapy of Newly Diagnosed Advanced Epithelial Ovarian Cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Infusions, Parenteral; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Polyethylene Glycols; Singapore | 2015 |
Molecular Dissection of Induced Platinum Resistance through Functional and Gene Expression Analysis in a Cell Culture Model of Bladder Cancer.
Topics: Antineoplastic Agents; Apoptosis; Biological Transport; Carboplatin; Cell Line, Tumor; Cisplatin; Deoxycytidine; DNA Adducts; DNA Damage; DNA Repair; Doxorubicin; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Profiling; Glutathione; Humans; Mass Spectrometry; Methotrexate; Organoplatinum Compounds; Oxaliplatin; Urinary Bladder Neoplasms; Vinblastine | 2016 |
Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Case-Control Studies; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase III as Topic; Cytoreduction Surgical Procedures; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Grading; Neoplasm, Residual; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate; Topotecan; Treatment Outcome; Young Adult | 2016 |
The Efficacy of Low-Dose Paclitaxel Added to Combination Chemotherapy of Carboplatin and Gemcitabine or Pegylated Liposomal Doxorubicin.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Cystadenocarcinoma, Serous; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Endometrial Neoplasms; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Pilot Projects; Polyethylene Glycols; Prognosis; Remission Induction; Retrospective Studies; Survival Rate | 2016 |
Insights from HuR biology point to potential improvement for second-line ovarian cancer therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Cycle Proteins; Cell Line, Tumor; Cell Nucleus; Cytoplasm; Deoxycytidine; Deoxycytidine Kinase; ELAV-Like Protein 1; Female; G2 Phase Cell Cycle Checkpoints; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Nuclear Proteins; Ovarian Neoplasms; Protein Transport; Protein-Tyrosine Kinases; Retrospective Studies | 2016 |
A retrospective analysis of efficacy and safety of adding bevacizumab to chemotherapy as first- and second-line therapy in advanced non-small-cell lung cancer (NSCLC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Pemetrexed; Retrospective Studies; Taxoids; Treatment Outcome | 2016 |
Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer.
Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Cell Proliferation; Deoxycytidine; Dioxoles; Doxorubicin; Female; Gemcitabine; Humans; Mice; Middle Aged; Neoadjuvant Therapy; Ovarian Neoplasms; Polyethylene Glycols; Precision Medicine; Tetrahydroisoquinolines; Trabectedin; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
[Overexpression of Keap1 inhibits the cell proliferation and metastasis and overcomes the drug resistance in human lung cancer A549 cells].
Topics: A549 Cells; Antineoplastic Agents; Carboplatin; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Kelch-Like ECH-Associated Protein 1; Lung Neoplasms; NF-E2-Related Factor 2; Transfection | 2016 |
Re: Vinflunine-gemcitabine Versus Vinflunine-carboplatin as First-line Chemotherapy in Cisplatin-unfit Patients with Advanced Urothelial Carcinoma: Results of an International Randomized Phase II Trial (JASINT1).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Treatment Outcome; Vinblastine | 2016 |
Case Report: A Non-small Cell Lung Cancer Patient Treated with GcMAF, Sonodynamic Therapy and Tumor Treating Fields.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Macrophage-Activating Factors; Male; Pemetrexed; Treatment Outcome; Ultrasonic Therapy; Vitamin D-Binding Protein | 2016 |
Carcinoma of Gall bladder with distant metastasis to breast parenchyma. Report of a case and review of literature.
Topics: Adult; Breast Neoplasms; Carboplatin; Carcinoma; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Neoplasm Metastasis; Palliative Medicine | 2016 |
The utility of neoadjuvant gemcitabine plus carboplatin followed by immediate radical cystectomy in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cystectomy; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Muscle, Smooth; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm, Residual; Survival Rate; Treatment Outcome; Urinary Bladder Neoplasms | 2017 |
Adjuvant Chemotherapy After Radical Cystectomy for Urothelial Bladder Cancer: Outcome and Prognostic Factors for Survival in a French Multicenter, Contemporary Cohort.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; France; Gemcitabine; Humans; Lymphatic Metastasis; Male; Methotrexate; Middle Aged; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2017 |
Associations of genetic polymorphisms of the transporters organic cation transporter 2 (OCT2), multidrug and toxin extrusion 1 (MATE1), and ATP-binding cassette subfamily C member 2 (ABCC2) with platinum-based chemotherapy response and toxicity in non-sma
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Cisplatin; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Genotype; Haplotypes; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Staging; Organic Cation Transport Proteins; Organic Cation Transporter 2; Pemetrexed; Polymorphism, Single Nucleotide; Prognosis; Prospective Studies; Survival Rate; Taxoids; Young Adult | 2016 |
Population Pharmacodynamic Model for Bayesian Prediction of Myelosuppression Profiles Based on Routine Clinical Data after Gemcitabine and Carboplatin Treatment.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bayes Theorem; Blood Cell Count; Carboplatin; Deoxycytidine; Erythrocytes; Female; Forecasting; Gemcitabine; Humans; Leukocytes; Male; Middle Aged; Models, Biological; Neoplasms; Retrospective Studies; Treatment Outcome | 2016 |
Neutrophil-to-lymphocyte ratio as a prognostic marker in locally advanced nasopharyngeal carcinoma: A pooled analysis of two randomised controlled trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; DNA, Viral; Epstein-Barr Virus Infections; Female; Fluorouracil; Gemcitabine; Herpesvirus 4, Human; Humans; Leukocyte Count; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Multivariate Analysis; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Staging; Neutrophils; Prognosis; Proportional Hazards Models; Radiotherapy; Randomized Controlled Trials as Topic; Singapore; Survival Rate | 2016 |
Nanoscale Coordination Polymers Codeliver Carboplatin and Gemcitabine for Highly Effective Treatment of Platinum-Resistant Ovarian Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Nanoparticles; Ovarian Neoplasms; Platinum; Polymers; Treatment Outcome | 2016 |
[Anti-PLD1 and anti-PD1 in advanced urothelial cancers: promises from early phase trials].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carboplatin; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Programmed Cell Death 1 Receptor; Urologic Neoplasms; Vinblastine | 2016 |
Early chemotherapy discontinuation and mortality in older patients with metastatic bladder cancer: The AGEVIM multicenter cohort study.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Creatinine; Deoxycytidine; Female; Gemcitabine; Health Status; Humans; Male; Neoplasm Metastasis; Prospective Studies; Serum Albumin; Survival Rate; Time Factors; Tumor Burden; Urinary Bladder Neoplasms; Withholding Treatment | 2017 |
Impact of the Copper Transporter Protein 1 (CTR1) Polymorphism on Adverse Events among Advanced NonSmall Cell Lung Cancer Patients Treated with a Carboplatin/Gemcitabine Regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cation Transport Proteins; Copper Transporter 1; Deoxycytidine; Female; Gemcitabine; Gene Frequency; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Polymorphism, Single Nucleotide | 2016 |
Microdose-Induced Drug-DNA Adducts as Biomarkers of Chemotherapy Resistance in Humans and Mice.
Topics: Animals; Antineoplastic Agents; Biomarkers; Carboplatin; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; DNA Adducts; DNA Repair; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Mass Spectrometry; Mice; Mutation; Neoplasms; Platinum; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2017 |
Quality-of-life evaluation during platinum-based neoadjuvant chemotherapies for urothelial carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prognosis; Prospective Studies; Quality of Life; Urologic Neoplasms | 2017 |
Survival prognostic factors for metachronous second primary head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Head and Neck Neoplasms; Humans; Hydroxyurea; Male; Methotrexate; Middle Aged; Neoplasm Staging; Neoplasms, Second Primary; Paclitaxel; Prognosis; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Taxoids; Treatment Outcome; Young Adult | 2017 |
Effects of sequential paclitaxel-carboplatin followed by gemcitabine-based chemotherapy compared with paclitaxel-carboplatin therapy administered to patients with advanced epithelial ovarian cancer: A retrospective, STROBE-compliant study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Survival Analysis; Young Adult | 2016 |
CYFRA 21-1 is an early predictor of chemotherapeutic effectiveness in advanced nonsmall cell lung cancer: An observational study.
Topics: Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Keratin-19; Lung Neoplasms; Male; Middle Aged; Predictive Value of Tests; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; ROC Curve; Taxoids; Weight Loss | 2016 |
Time-Series Modeling and Simulation for Comparative Cost-Effective Analysis in Cancer Chemotherapy: An Application to Platinum-Based Regimens for Advanced Non-small Cell Lung Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Computer Simulation; Cost-Benefit Analysis; Deoxycytidine; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Models, Economic; Paclitaxel; Quality-Adjusted Life Years; Vinblastine; Vinorelbine | 2017 |
Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatin.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Doxorubicin; Drug Hypersensitivity; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Retrospective Studies | 2017 |
Palliative Chemotherapy for Bladder Cancer: Treatment Delivery and Outcomes in the General Population.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Palliative Care; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine; Young Adult | 2017 |
Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: A single institution experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bevacizumab; Carboplatin; Cyclophosphamide; Databases, Factual; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Cystic, Mucinous, and Serous; Niacinamide; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Phenylurea Compounds; Retrospective Studies; Sorafenib; Young Adult | 2017 |
PARP inhibitor increases chemosensitivity by upregulating miR-664b-5p in BRCA1-mutated triple-negative breast cancer.
Topics: Base Sequence; BRCA1 Protein; Carboplatin; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclins; Deoxycytidine; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; MicroRNAs; Middle Aged; Mutation; Neoplasm Invasiveness; Poly(ADP-ribose) Polymerase Inhibitors; Triple Negative Breast Neoplasms; Up-Regulation | 2017 |
Evaluating the association of multiple single nucleotide polymorphisms with response to gemcitabine and platinum combination chemotherapy in urothelial carcinoma of the bladder
.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Deoxycytidine; Female; Gemcitabine; Genotype; Humans; Introns; Logistic Models; Male; Middle Aged; Models, Genetic; N-Acetylgalactosaminyltransferases; Pharmacogenetics; Pharmacogenomic Variants; Phenotype; Polymorphism, Single Nucleotide; Polypeptide N-acetylgalactosaminyltransferase; Prospective Studies; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2017 |
Degradable Starch Microspheres Transcatheter Arterial Chemoembolization (DSM-TACE) in Intrahepatic Cholangiocellular Carcinoma (ICC): Results from a National Multi-Center Study on Safety and Efficacy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carboplatin; Chemoembolization, Therapeutic; Cholangiocarcinoma; Cisplatin; Cohort Studies; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Male; Middle Aged; Mitomycin; Starch | 2017 |
Acquired resistance to oxaliplatin is not directly associated with increased resistance to DNA damage in SK-N-ASrOXALI4000, a newly established oxaliplatin-resistant sub-line of the neuroblastoma cell line SK-N-AS.
Topics: Antineoplastic Agents; Carboplatin; Cell Line, Tumor; Cisplatin; Deoxycytidine; DNA Damage; DNA Repair; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gemcitabine; Humans; In Situ Hybridization, Fluorescence; Neuroblastoma; Organoplatinum Compounds; Oxaliplatin; Ploidies; Ultraviolet Rays | 2017 |
Difference in toxicity reporting between patients and clinicians during systemic chemotherapy in patients with urothelial carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Constipation; Deoxycytidine; Diarrhea; Feeding and Eating Disorders; Female; Gemcitabine; Humans; Male; Nausea; Patient Reported Outcome Measures; Prospective Studies; Quality of Life; Retrospective Studies; Treatment Outcome; Urologic Neoplasms | 2017 |
Hypoxia Induces Multidrug Resistance via Enhancement of Epidermal Growth Factor-Like Domain 7 Expression in Non-Small Lung Cancer Cells.
Topics: A549 Cells; ATP Binding Cassette Transporter, Subfamily B, Member 1; Calcium-Binding Proteins; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; EGF Family of Proteins; Endothelial Growth Factors; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; RNA Interference; RNA, Small Interfering | 2017 |
The renal safety and efficacy of combined gemcitabine plus cisplatin and gemcitabine plus carboplatin chemotherapy in Chinese patients with a solitary kidney after nephroureterectomy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Creatinine; Deoxycytidine; Female; Gemcitabine; Glomerular Filtration Rate; Humans; Kidney; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Retrospective Studies; Risk Factors; Ureteral Neoplasms | 2017 |
Universal tolerance of nab-paclitaxel for gynecologic malignancies in patients with prior taxane hypersensitivity reactions.
Topics: Adult; Aged; Albumins; Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cisplatin; Deoxycytidine; Docetaxel; Drug Hypersensitivity; Female; Gemcitabine; Genital Neoplasms, Female; Humans; Middle Aged; Nervous System Diseases; Neutropenia; Paclitaxel; Retreatment; Retrospective Studies; Taxoids; Thrombocytopenia | 2017 |
Platinum-based Neoadjuvant Chemotherapy Improves Oncological Outcomes in Patients with Locally Advanced Upper Tract Urothelial Carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Staging; Nephrectomy; Prognosis; Progression-Free Survival; Proportional Hazards Models; Retrospective Studies; Survival Rate; Ureter; Ureteral Neoplasms; Urologic Surgical Procedures | 2018 |
Bilateral macular infarction after gemcitabine and carboplatin chemotherapy.
Topics: Adult; Antimetabolites, Antineoplastic; Carboplatin; Deoxycytidine; Drug Therapy, Combination; Female; Gemcitabine; Humans; Infarction; Macula Lutea; Retinal Diseases; Uterine Cervical Neoplasms; Visual Acuity | 2018 |
[Efficacy of GC Therapy for the Patient of iTNBC with Resistance to TAC Therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Taxoids; Tomography, X-Ray Computed; Triple Negative Breast Neoplasms | 2017 |
The Pharmacological Costs of Second-Line Treatments for Recurrent Ovarian Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Deoxycytidine; Dioxoles; Disease-Free Survival; Doxorubicin; Drug Costs; European Union; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Randomized Controlled Trials as Topic; Survival Rate; Tetrahydroisoquinolines; Trabectedin | 2017 |
Neoadjuvant Chemotherapy for Patients with Muscle-invasive Urothelial Bladder Cancer Candidates for Curative Surgery: A Prospective Clinical Trial Based on Cisplatin Feasibility.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Feasibility Studies; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Prospective Studies; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms | 2017 |
Significance of sarcopenia as a prognostic factor for metastatic urothelial carcinoma patients treated with systemic chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Carboplatin; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Muscle, Skeletal; Prognosis; Retrospective Studies; Sarcopenia; Tomography, X-Ray Computed; Urologic Neoplasms | 2018 |
[Clinical analysis of 36 cases of advanced non-small cell lung cancer (NSCLC) with performance status (PS) scores between 2 and 4].
Topics: Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Hypoxia; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pemetrexed; Remission Induction; Response Evaluation Criteria in Solid Tumors; Severity of Illness Index; Taxoids | 2017 |
Palliative treatment with carboplatin as late line therapy to patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Palliative Care; Receptor, ErbB-2; Receptors, Estrogen; Retreatment; Trastuzumab; Treatment Outcome | 2018 |
Acceptance of Adjuvant and Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer in Germany: A Survey of Current Practice.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Germany; Humans; Muscles; Neoadjuvant Therapy; Neoplasm Invasiveness; Practice Patterns, Physicians'; Surveys and Questionnaires; Urinary Bladder Neoplasms; Urology | 2018 |
Chemotherapy treatment is associated with altered PD-L1 expression in lung cancer patients.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Biopsy; Bronchoscopy; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Immunohistochemistry; Leukocytes, Mononuclear; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Programmed Cell Death 1 Receptor | 2018 |
[Pulmonary Pleomorphic Carcinoma Relapsed after Surgery Surviving Long-term by Chemotherapy and Nivolumab].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Nivolumab | 2018 |
Do older patients with non-small cell lung cancer also benefit from first-line platinum-based doublet chemotherapy? Observations from a pooled analysis of 730 prospectively-treated patients (Alliance Study A151622).
Topics: Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pemetrexed; Prospective Studies | 2018 |
Nivolumab-induced cold agglutinin syndrome successfully treated with rituximab.
Topics: Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Breast Neoplasms; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lymphoma, B-Cell, Marginal Zone; Neoplasms, Second Primary; Nivolumab; Rituximab; Syndrome | 2018 |
Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Cystadenocarcinoma, Serous; Deoxycytidine; DNA Repair; DNA Replication; Female; Follow-Up Studies; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Organ Culture Techniques; Organoids; Ovarian Neoplasms; Prognosis; Pyrazines; Pyrazoles | 2018 |
Genetic Variants in the Wingless Antagonist Genes (
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Axin Protein; Carboplatin; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Epistasis, Genetic; Female; Gemcitabine; Genetic Variation; Genotype; Humans; India; Intercellular Signaling Peptides and Proteins; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Pemetrexed; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Prognosis; Proportional Hazards Models; Smoking; Wnt Proteins | 2018 |
Prognostic Value of Patient Knowledge of Cancer on Quality of Life in Advanced Lung Cancer During Chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Health Knowledge, Attitudes, Practice; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Quality of Life; Surveys and Questionnaires; Survival Rate | 2020 |
Successful Bridging Chemotherapy with Gemcitabine, Carboplatin, and Dexamethasone before Unrelated Stem Cell Transplantation for Hepatosplenic T-cell Lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Deoxycytidine; Dexamethasone; Female; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Liver Neoplasms; Lymphoma, T-Cell, Peripheral; Middle Aged; Splenic Neoplasms | 2019 |
Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Circulating Tumor DNA; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Multicenter Studies as Topic; Mutation; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic | 2018 |
Value of adjuvant chemotherapy in patients with resected stage IB solid predominant and solid non-predominant lung adenocarcinoma.
Topics: Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Pemetrexed; Retrospective Studies; Survival Rate; Vinorelbine | 2019 |
Retrospective Analysis of Taxane-Based Therapy in Small Bowel Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Intestinal Neoplasms; Intestine, Small; Male; Middle Aged; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2019 |
Chemotherapy regimen is associated with venous thromboembolism risk in patients with urothelial tract cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Methotrexate; Retrospective Studies; SEER Program; United States; Urologic Neoplasms; Venous Thromboembolism; Vinblastine | 2019 |
Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Carboplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Longitudinal Studies; Models, Statistical; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate | 2019 |
Treatment of Metastatic Urothelial Cancer in 2018.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; B7-H1 Antigen; Carboplatin; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Immunotherapy; Programmed Cell Death 1 Receptor; Taxoids; Urologic Neoplasms; Urothelium | 2019 |
Comparison of clinico-pathological characteristics and survival of recurrent ovarian cancer patients on seven different chemo-protocols.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Progression-Free Survival; Topotecan; Treatment Outcome; Young Adult | 2019 |
Effectiveness of first-line treatments in metastatic squamous non-small-cell lung cancer.
Topics: Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Gemcitabine; Humans; Immunotherapy; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Treatment Outcome | 2019 |
Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Computer Simulation; Cost-Benefit Analysis; Deoxycytidine; Drug Costs; Gemcitabine; Humans; Models, Economic; Progression-Free Survival; Quality-Adjusted Life Years; Sweden; Urologic Neoplasms | 2019 |
Sarcopenia as a significant predictive factor of neutropenia and overall survival in urothelial carcinoma patients underwent gemcitabine and cisplatin or carboplatin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Retrospective Studies; Sarcopenia; Thrombocytopenia; Tomography, X-Ray Computed; Urologic Neoplasms | 2020 |
Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer before olaparib maintenance: Still getting any benefit? A case-control study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Case-Control Studies; Cystadenocarcinoma, Serous; Cytoreduction Surgical Procedures; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Genes, BRCA1; Genes, BRCA2; Germ-Line Mutation; Humans; Maintenance Chemotherapy; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines | 2019 |
Cost-effectiveness of Osimertinib as a Second-line Treatment in Patients With EGFR-mutated Advanced Non-Small Cell Lung Cancer in China.
Topics: Acrylamides; Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; China; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; ErbB Receptors; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Mutation; Paclitaxel; Pemetrexed; Protein Kinase Inhibitors; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic | 2019 |
Genes and variants in hematopoiesis-related pathways are associated with gemcitabine/carboplatin-induced thrombocytopenia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; DNA; Female; Gemcitabine; Genome-Wide Association Study; Hematopoiesis; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Middle Aged; Polymorphism, Single Nucleotide; Predictive Value of Tests; Thrombocytopenia | 2020 |
Salvage treatment for children with relapsed/refractory germ cell tumors: The Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) experience.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Ifosfamide; Infant; Male; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Oxaliplatin; Paclitaxel; Prognosis; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate | 2020 |
Exosomes as a Surrogate Marker for Autophagy in Peripheral Blood, Correlative Data from Phase I Study of Chloroquine in Combination with Carboplatin/Gemcitabine in Advanced Solid Tumors.
Topics: Antimalarials; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Biomarkers; Carboplatin; Chloroquine; Deoxycytidine; Drug Therapy, Combination; Exosomes; Gemcitabine; Humans; Neoplasms; Tumor Cells, Cultured | 2019 |
Is it time to redefine cisplatin ineligibility in metastatic urothelial cancer?
Topics: Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Urologic Neoplasms; Vinblastine | 2020 |
The combination of artesunate and carboplatin exerts a synergistic anti-tumour effect on non-small cell lung cancer.
Topics: A549 Cells; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Artesunate; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; G2 Phase Cell Cycle Checkpoints; Gemcitabine; Humans; Lung Neoplasms; Mitochondria; Signal Transduction | 2020 |
Association Between RET Fusions and Efficacy of Pemetrexed-based Chemotherapy for Patients With Advanced NSCLC in China: A Multicenter Retrospective Study.
Topics: Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Gene Rearrangement; Humans; Lung Neoplasms; Male; Middle Aged; Oncogene Proteins, Fusion; Paclitaxel; Pemetrexed; Prognosis; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Retrospective Studies; Survival Rate | 2020 |
Treatment strategies for recurrent ovarian cancer in older adult patients in Japan: a study based on real-world data.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Drug Resistance, Neoplasm; Evidence-Based Medicine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Survival Rate | 2020 |
Patient reported symptoms associated with quality of life during chemo- or immunotherapy for bladder cancer patients with advanced disease.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Denmark; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Gemcitabine; Humans; Imidazoles; Longitudinal Studies; Male; Middle Aged; Patient Reported Outcome Measures; Prognosis; Prospective Studies; Quality of Life; Surveys and Questionnaires; Urinary Bladder Neoplasms | 2020 |
Single-Cell RNA Sequencing of Hematopoietic Stem and Progenitor Cells Treated with Gemcitabine and Carboplatin.
Topics: Carboplatin; Cell Cycle; Cells, Cultured; Deoxycytidine; Gemcitabine; Gene Expression; Gene Ontology; Hematopoietic Stem Cells; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; RNA-Seq; Sequence Alignment; Single-Cell Analysis | 2020 |
Damage-associated molecular patterns (DAMPs) related to immunogenic cell death are differentially triggered by clinically relevant chemotherapeutics in lung adenocarcinoma cells.
Topics: A549 Cells; Adenocarcinoma of Lung; Adenosine Triphosphate; Alarmins; Antineoplastic Agents; Apoptosis; Autophagy; Calreticulin; Carboplatin; Caspase 3; Cell Survival; Cisplatin; Deoxycytidine; Etoposide; Gemcitabine; HMGB1 Protein; Humans; Immunogenic Cell Death; Lung Neoplasms; Paclitaxel; Prognosis | 2020 |
NEPA as antiemetic prophylaxis after failure of 5HT
Topics: Adult; Antiemetics; Carboplatin; Deoxycytidine; Dexamethasone; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Middle Aged; Nausea; Palonosetron; Pre-Exposure Prophylaxis; Pyridines; Retrospective Studies; Serotonin 5-HT3 Receptor Antagonists; Treatment Failure; Vomiting | 2021 |
Bevacizumab in recurrent ovarian cancer: could it be particularly effective in patients with clear cell carcinoma?
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Confidence Intervals; Cystadenocarcinoma, Serous; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Odds Ratio; Ovarian Neoplasms; Paclitaxel; Progression-Free Survival; Retrospective Studies | 2021 |
Genetic association of gemcitabine/carboplatin-induced leukopenia and neutropenia in non-small cell lung cancer patients using whole-exome sequencing.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Exome Sequencing; Gemcitabine; Genome-Wide Association Study; Humans; Leukopenia; Lung Neoplasms; Neutropenia | 2020 |
Whole-genome sequencing and gene network modules predict gemcitabine/carboplatin-induced myelosuppression in non-small cell lung cancer patients.
Topics: Bone Marrow; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Gene Regulatory Networks; Humans; Lung Neoplasms; Whole Genome Sequencing | 2020 |
Two cycles of neoadjuvant chemotherapy improves survival in patients with high-risk upper tract urothelial carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Kidney Neoplasms; Male; Methotrexate; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Nephroureterectomy; Proportional Hazards Models; Retrospective Studies; Sex Factors; Survival Rate; Ureteral Neoplasms; Vinblastine | 2021 |
Combination of DN604 with gemcitabine led to cell apoptosis and cell motility inhibition via p38 MAPK signaling pathway in NSCLC.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Movement; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Nude; Molecular Structure; Neoplasms, Experimental; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Signal Transduction; Structure-Activity Relationship; Tumor Cells, Cultured | 2020 |
Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker.
Topics: Administration, Intravenous; Animals; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bone Marrow; Carboplatin; Contrast Media; Creatinine; Cytochrome P-450 Enzyme System; Deoxycytidine; Drug Dosage Calculations; Drug Interactions; Female; Gemcitabine; Glomerular Filtration Rate; Glucuronosyltransferase; Humans; Iohexol; Kidney; Metabolic Clearance Rate; Mice; Microsomes, Liver; Models, Animal; Paclitaxel; Specific Pathogen-Free Organisms; Tandem Mass Spectrometry; Tissue Distribution | 2020 |
Clinical benefits of adjuvant chemotherapy with carboplatin and gemcitabine in patients with non-small cell lung cancer: a single-center retrospective study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies | 2020 |
Recurrence patterns after bevacizumab in platinum-sensitive, recurrent epithelial ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cohort Studies; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Topotecan | 2020 |
JMJD1C knockdown affects myeloid cell lines proliferation, viability, and gemcitabine/carboplatin-sensitivity.
Topics: Carboplatin; Cell Proliferation; Cell Survival; Deoxycytidine; Gemcitabine; Gene Knockdown Techniques; Humans; Jumonji Domain-Containing Histone Demethylases; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloid Cells; Oxidoreductases, N-Demethylating | 2021 |
Anti-tumor effects and cell motility inhibition of the DN604-gemcitabine combined treatment in human bladder cancer models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Cell Movement; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Neoplasms, Experimental; Structure-Activity Relationship; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2021 |
Checkpoint Kinase 1 Pharmacological Inhibition Synergizes with DNA-Damaging Agents and Overcomes Platinum Resistance in Basal-Like Breast Cancer.
Topics: Apoptosis; Breast Neoplasms; Carboplatin; Caspases; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Cisplatin; Deoxycytidine; DNA Damage; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Neoplasm Invasiveness; Platinum | 2020 |
Gemcitabine, cisplatin, and dexamethasone and ifosfamide, carboplatin, and etoposide regimens have similar efficacy as salvage treatment for relapsed/refractory aggressive lymphoma: A retrospectively comparative study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Dexamethasone; Etoposide; Female; Gemcitabine; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Salvage Therapy; Young Adult | 2020 |
Social and Clinical Correlates of Neoadjuvant Chemotherapy in Medicare Beneficiaries With Muscle Invasive Bladder Cancer From 2004-2015.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Medicare; Muscles; Neoadjuvant Therapy; Neoplasm Invasiveness; Retrospective Studies; Social Class; United States; Urinary Bladder; Urinary Bladder Neoplasms | 2021 |
FDA Approves Pembrolizumab + Chemotherapy Combination for Locally Recurrent Unresectable or Metastatic TNBC.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Double-Blind Method; Drug Approval; Gemcitabine; Humans; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Randomized Controlled Trials as Topic; Triple Negative Breast Neoplasms; United States; United States Food and Drug Administration | 2020 |
[A Case of Ipsilateral Breast Tumor Recurrence(IBTR)after Breast-Conserving Surgery Which Successfully Resected after Chemotherapy Using Carboplatin plus Gemcitabine].
Topics: Adult; Breast Neoplasms; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Mastectomy; Mastectomy, Segmental; Neoplasm Recurrence, Local | 2020 |
Use of Gemcitabine plus Carboplatin is Associated with Poor Outcomes in Urothelial Carcinoma Patients with Chronic Kidney Disease Stage 4-5.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Glomerular Filtration Rate; Humans; Male; Middle Aged; Prognosis; Renal Insufficiency, Chronic; Retrospective Studies; Survival Rate; Urinary Bladder Neoplasms | 2021 |
Drug-eluting bead bronchial arterial chemoembolization vs. chemotherapy in treating advanced non-small cell lung cancer: comparison of treatment efficacy, safety and quality of life.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoembolization, Therapeutic; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Quality of Life; Retrospective Studies; Surveys and Questionnaires | 2021 |
Procaspase-Activating Compound-1 Synergizes with TRAIL to Induce Apoptosis in Established Granulosa Cell Tumor Cell Line (KGN) and Explanted Patient Granulosa Cell Tumor Cells In Vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzoquinones; Carboplatin; Caspase 3; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Activation; Female; Gemcitabine; Granulosa Cell Tumor; Humans; Hydrazones; In Vitro Techniques; Mathematical Concepts; Models, Biological; Ovarian Neoplasms; Piperazines; TNF-Related Apoptosis-Inducing Ligand | 2021 |
[A Rare Case of Non-small Cell Lung Carcinoma Squamous Phenotype with Epstein-Barr Virus Positivity with Prolonged Response to both Chemotherapy and Radiotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Antitubercular Agents; Carboplatin; Carcinoma, Squamous Cell; Deoxycytidine; Epstein-Barr Virus Infections; Female; Gemcitabine; Herpesvirus 4, Human; Humans; Lung Neoplasms; Lupus Erythematosus, Systemic; Middle Aged; Neck Dissection; Neoplasm Recurrence, Local; Radiotherapy; Tuberculosis, Pulmonary | 2021 |
Response to Platinum-based Chemotherapy Rechallenge for Patients With Pembrolizumab-refractory Urothelial Carcinoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Immune Checkpoint Inhibitors; Male; Middle Aged; Neutropenia; Paclitaxel; Retrospective Studies; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2021 |
Response to Pembrolizumab After Dose-Reduced Cisplatin Plus Gemcitabine Chemotherapy Is Inferior to That After Carboplatin Plus Gemcitabine Chemotherapy in Cisplatin-Unfit Patients With Advanced Urothelial Carcinoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Urinary Bladder Neoplasms | 2022 |
Platinum rechallenge treatment using gemcitabine plus carboplatin with or without bevacizumab for platinum-resistant ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Deoxycytidine; Gemcitabine; Humans; Ovarian Neoplasms; Platinum | 2022 |
Effectiveness and safety of R-GCD (rituximab, gemcitabine, carboplatin, and dexamethasone) for transplant-ineligible relapse/refractory diffuse large B-cell lymphoma and grade 3a follicular lymphoma: a retrospective analysis comparing with R-GDP (rituxima
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Dexamethasone; Gemcitabine; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Retrospective Studies; Rituximab; Salvage Therapy | 2022 |
The association of four genetic variants with myelosuppression in gemcitabine-treated Japanese is not evident in gemcitabine/carboplatin-treated Swedes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Japan; Lung Neoplasms; Neutropenia; Sweden | 2022 |
Oncological Outcomes of Neoadjuvant Gemcitabine plus Carboplatin versus Gemcitabine plus Cisplatin in Locally Advanced Bladder Cancer: A Retrospective Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cystectomy; Gemcitabine; Humans; Neoadjuvant Therapy; Retrospective Studies; Urinary Bladder Neoplasms | 2022 |
Retrospective Analysis of the Efficacy and Tolerability of Gemcitabine-Based Chemotherapy in Relapsed/Refractory Lymphoma Patients Not Eligible for Stem Cell Transplant.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Dexamethasone; Gemcitabine; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Retrospective Studies; Rituximab; Stem Cell Transplantation | 2022 |
The efficacy and safety of first-line treatment in cisplatin-ineligible advanced upper tract urothelial carcinoma patients: a comparison of PD-1 inhibitor and carboplatin plus gemcitabine chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Immune Checkpoint Inhibitors; Retrospective Studies; Urinary Bladder Neoplasms | 2022 |
Multicenter evaluation of neoadjuvant and induction gemcitabine-carboplatin versus gemcitabine-cisplatin followed by radical cystectomy for muscle-invasive bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cystectomy; Gemcitabine; Humans; Muscles; Neoadjuvant Therapy; Retrospective Studies; Urinary Bladder Neoplasms | 2022 |
Survival Analysis and Clinical Outcomes between Paclitaxel and Carboplatin Versus Carboplatin and Gemcitabine in Patients with Advanced-stage Non-small-cell Lung Cancer: A Single-center Cohort Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Female; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Retrospective Studies; Survival Analysis | 2022 |
Comparison of full-dose gemcitabine/cisplatin, dose-reduced gemcitabine/cisplatin, and gemcitabine/carboplatin in real-world patients with advanced urothelial carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Gemcitabine; Humans; Retrospective Studies; Urinary Bladder Neoplasms | 2022 |
Efficacy and Safety of First-line Carboplatin-paclitaxel and Carboplatin-gemcitabine in Patients With Advanced Triple-negative Breast Cancer: A Monocentric, Retrospective Comparison.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Retrospective Studies; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms | 2023 |
Kidney and Cancer Outcomes with Standard Versus Alternative Chemotherapy Regimens for First-Line Treatment of Metastatic Urothelial Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Female; Gemcitabine; Humans; Kidney; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2023 |
Comparison of the effectiveness of liposomal doxorubicin and gemcitabine in patients with platinum-sensitive recurrent ovarian cancer receiving third-line chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Doxorubicin; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Polyethylene Glycols; Quality of Life; Reproducibility of Results; Retrospective Studies | 2023 |
Efficacy and Safety of Combined Chemotherapy Regimens with Bevacizumab in Platinum-sensitive Ovarian Cancers.
Topics: Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms | 2023 |
Peripheral Blasts in a Patient Receiving Chemotherapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Leukopoiesis; Urinary Bladder Neoplasms | 2023 |
[A Case of Non-Hodgkin Lymphoma with Liver Involvement and Severe Jaundice That Benefited from Therapy with Gemcitabine, Carboplatin, Dexamethasone(GCD)Therapy with Rituximab].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Dexamethasone; Doxorubicin; Gemcitabine; Humans; Hyperbilirubinemia; Jaundice; Liver Diseases; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Rituximab; Treatment Outcome; Vincristine | 2023 |